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Abstract 
 
The present thesis is focused on the molecular characterization of two eukaryotic membrane 
glycoproteins that are promising candidates for new therapeutic approaches to human diseases.  
The first glycoprotein is the human Receptor for the Advanced Glycation End products (hRAGE), a 
member of the immunoglobulin superfamily. RAGE is a type I transmembrane glycoprotein that is 
beneficial in normal physiological conditions but it is also a key player in the etiology and 
progression of several chronic pathologies such as neurodegenerative disorders (Alzheimer), 
atherosclerosis, cancer and complications of metabolic diseases such as diabetes, by exacerbating 
the inflammatory response. A variety of ligands sharing an acidic charge, as the advanced glycation 
End products (AGEs), S100 proteins, HMGB1, Aβ-amyloids, bind to the extracellular V or VC1 
domains of RAGE. These domains are N-glycosylated and stabilized by disulphide bonds. To 
overcome the tendency to aggregate of the V and VC1 domains expressed in bacteria, in this work 
V and VC1 domains were expressed as secreted proteins in the methylotrophic yeast Pichia 
pastoris. While VC1 was secreted into the culture medium and was functional, the V domain was 
retained intracellularly, providing the first in vivo indication that V requires C1 to fold into a 
structurally stable domain. The glycosylation pattern of VC1 reflects the glycosylation of RAGE 
isolated from mammalian sources. A simple procedure for the purification to homogeneity of VC1 
from the medium was generated and the folded state of the purified protein was assessed by thermal 
shift assays. The protein showed a remarkable improved thermal stability compared to VC1 
expressed in bacteria. The stability and full solubility of glycosylated VC1 may be beneficial for in 
vitro studies aimed at the identification of new ligands or inhibitors of RAGE.  
The second object of this thesis was the Phr family of Candida albicans, a dimorphic fungal 
pathogen responsible of life-threatening invasive infections. These glycoproteins are anchored to 
the plasma membrane through a GPI. Phr proteins belong to family GH72 of cell wall glucan 
remodelling enzymes that are unique to fungi and essential for morphogenesis, cell wall integrity 
and virulence. For these reasons, these enzymes are targets for inhibitors of the cell wall formation 
to be used in therapy, similarly to what penicillins have been for bacteria. The catalytic properties of 
Phr proteins were studied using a new fluorescent assay. Phr1p and Phr2p are specific for β-1,3-
glucan, the pH optimum was 5.8 for Phr1p and 3 for Phr2p and the temperature optimum was 30°C. 
Pga4p was inactive suggesting that it turned out into a structural cell wall protein. Finally, we 
studied the transcriptome of cells lacking β-1,3-glucan remodelling (phr1Δ cells) after induction of 
growth as hypha, the invasive form of this pathogen. About 310 genes were modulated and genetic 
analysis showed that chitin synthesis by the Chs3p isoform is essential for viability of phr1Δ cells. 
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Introduction 
 
In pharmaceutical research, the identification and validation of a target involved in a particular 
pathology are the first steps in the process of target-based drug discovery. When the identified 
target is a protein, its recombinant production is mandatory for the entire process of drug 
development. The majority of the drugs are inhibitors that block the action of target proteins. The 
isolation of the protein is required to perform structural and biochemical studies providing results 
that could drive the design of the drug and the set-up of in vitro assays. Moreover, the recombinant 
protein could be used also for preliminary screenings to identify inhibitors from libraries of 
different compounds.  
The potential candidates as targets for therapy are often glycoproteins and namely hormones, 
growth factors, membrane-bound receptors, extracellular enzymes and antibodies. It has been 
estimated that about 30% of the human proteins are directed to the secretory pathway and the 
majority of them are glycosylated, often contain disulphide bonds and are endowed of complex 
folding [2]. Protein glycosylation has multiple functions in the cell. For instance, in the endoplasmic 
reticulum glycosylation is used to monitor protein folding, acting as a quality control system that 
guarantees only properly folded proteins to translocate to the Golgi apparatus. Moreover, the sugar 
added to soluble proteins can be recognized by specific receptors in the Golgi promoting their 
transport to the final destination. Since sugars are hydrophilic, glycans improve the solubility of the 
proteins and their steric hindrance protects proteins from the attack by extracellular proteases and 
also confers resistance to denaturation [3, 4].  
The most common host cell for the expression of recombinant proteins is Escherichia coli. 
However, bacteria are unable to carry out post-translational modifications and also proteins with 
complex folding are difficult to express in this microorganism. The aim of the present thesis has 
been the molecular characterization of two types of eukaryotic membrane-bound glycoproteins that 
are promising candidates for new therapeutic approaches of human diseases. In order to obtain 
soluble and glycosylated versions of these proteins and of their domains for the intended 
biochemical studies, we aimed at the heterologous expression in the eukaryotic methylotrophic 
yeast Pichia pastoris. 
The first glycoprotein that is object of this thesis is the human Receptor for the Advanced Glycation 
End products, hRAGE. This trans-membrane glycoprotein is a multi-ligand receptor with a modular 
organization of its domains. hRAGE plays a crucial role in several aspects of human physiology but 
it is also involved in the establishment and progression of several diseases like neurodegenerative 
disorders, chronic inflammation, and also complications deriving from metabolic diseases. At this 
regard, hRAGE contributes to the complications of diabetes especially to the chronic pathologies 
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affecting the microvascular system such as retinopathy. Studies of the interaction of hRAGE with 
its ligands can prove useful for future identification of antagonists. Therefore, this thesis focused on 
the ligand-binding domains of the receptor.  
The second subject of this work has been the family of Phr glycoproteins that are anchored to the 
plasma membrane of Candida albicans through a GPI (glycosyl phosphatidyl inositol). This 
microorganism is a common commensal of human mucosae that can turn into a pathogen and cause 
life-threatening invasive infections in immunocompromised patients. Phr proteins are 
transglycosylases belonging to family GH72. The work of this thesis focused on these enzymes 
because they are unique to fungi and are essential for cell wall assembly, morphogenesis, virulence 
and cell viability and therefore represent promising target for new drugs directed against the fungal 
cell wall. Since the armamentarium of antifungal agents is still limited, studies on the GH72 
enzymes can contribute to the identification of new inhibitors of cell wall formation, which could 
have an impact similarly to penicillins antibacterial treatment.  
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RAGE: from gene to protein 
The human RAGE gene (also termed AGER) is located on the chromosome 6, in the major 
histocompatibility complex (MHC) class III region [12]. AGER is composed of 11 exons and 10 
short introns, a 5’flanking region that regulates its transcription and overlaps the 3’-UTR of PBX2 
(pre-B-cell leukaemia homeobox 2) gene, and a 3’-UTR (Figure 2) [12].  
 
 
 
Figure 2. Structure of AGER gene. The gene is composed of a 5’-flanking region that overlaps 
with the PBX2 gene 3’-UTR, 11 exons (red boxes) and a 3’-UTR. Arrows indicate the identified 
polymorphisms, the best known being -429T/C, Gly82Ser and +1704G/T [13]. 
 
 
Approximatly 30 single nucleotide polymorphisms (SNP) were identified in AGER resulting in 
changes in the amino acid sequence or non coding changes in exons or changes in introns and in the 
5’-flanking region. The polymorphisms -429 T/C, Gly82Ser (resulting in the amino acid 
substitution of glycine with serine at position 82) and +1704 G/T are the most interesting because 
they proved to be rather common and associated with diseases [14].  
The Gly82Ser polymorphism was one of the first identified polymorphisms of AGER and occurs in 
the ligand binding V domain of RAGE. This is the only frequent coding-change polymorphism in 
the AGER. The association between Gly82Ser polymorphism and the N-glycosylation of Asn81 will 
be discussed below (section “RAGE is a glycoprotein”).  
The expression of AGER is tightly controlled at multiple levels in different cell type, both in 
physiological and pathological conditions. Different transcription factor binding sites, as well as 
silencing/enhancing regulatory mechanisms, were discovered [6]. The nuclear factor-κB (NF-κB), 
specificity protein 1 (SP-1), activator proteins 1 and 2 (AP-1 and AP-2), E-twenty-six 1 factor (Ets-
1), Hypoxia-inducible factor-1 (HIF-1), Early growth response transcription factor 1 (Egr-1) and 
Thyroid transcription factor-1 (TFF-1) putatively regulate the transcription of AGER, since the 
binding sites of these factors were found in the regulatory 5’-flanking region. An epigenetic 
regulation of AGER expression also occurs via methylation of cytosines in the AP-2 and SP-1 
binding elements of the AGER promoter [6, 15]. Further, the 3’-UTR of the AGER mRNA is 
differentially polyadenylated to regulate the stability of the mRNA and the 3’UTR has also a target 
site for mir-30 miRNA, able to affect the AGER mRNA stability when necessary [15]. 
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Alternative splicing extensively modulate the AGER transcript, resulting in different translation 
products [12].  
The most abundant protein form encoded by the AGER is the full-length RAGE (fl-RAGE). It 
consists of 404 amino acids, including the signal peptide (amino acids 1-23) that is removed during 
the co-translational translocation of RAGE precursor into the ER membrane, the full ectodomain, 
the transmembrane domain (TMD, amino acids 340-361) and a cytoplasmic tail (amino acids 362-
404) as reported in scheme of Figure 1 and Figure 3 [16].  
Besides the fl-RAGE, 19 naturally occurring splicing variants were described in humans, but only a 
minor fraction is translated into proteins [17]. It has been estimated that about 50% of the 
alternative splicing products in humans are targeted to the nonsense-mediated mRNA decay (NMD) 
degradation pathway, resulting in the reduction of the total number of functional RAGE transcripts 
[12, 17]. The major splicing products of RAGE pre-mRNA are represented in Figure 3. 
RAGE with the deletion of the V domain is unable to interact with its ligands and is unresponsive to 
any stimulus, whereas RAGE without the cytoplasmic tail functions as a “decoy” receptor with 
dominant negative effects (called dominant negative RAGE, DN-RAGE). It competes with the 
endogenous fl-RAGE for ligand binding, but is unable to transmit signal transduction activated by 
RAGE [17, 18]. Another splicing variant is the soluble form of RAGE (sRAGE) which lacks the 
TMD and the C-terminal tail. sRAGE is secreted into the extracellular space and there it can act as 
scavenger preventing ligands to interact with fl-RAGE or with other cell surface receptors. Another 
mechanism to generate sRAGE is by proteolytic cleavage of fl-RAGE through the action of the 
metalloproteinases ADAM10 and MMP9. sRAGE is the most studied isoform of RAGE, since the 
decrease of the circulating levels of sRAGE was reported in several RAGE-associated pathological 
disorders [17].  
All these isoforms are thought to be possible regulators of the fl-RAGE, either by the competition 
for ligand binding or by replacing the full-length receptor in the membrane [19].  
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Figure 3. Schematic representation of RAGE variants produced by alternative splicing of AGER 
pre-mRNA or proteolytic cleavage.  
 
 
Protein structure and surface properties 
The structure of the RAGE appears to be a very interesting topic considering the number of protein 
resolved structures deposited on the Protein Data Bank (PDB, 
http://www.rcsb.org/pdb/home/home.do) during the last years (18 structures of RAGE on April 
2015). The V, C1 and C2 domains form an elongated structure [16]. Since the isolated V or C1 
domains produced in bacteria have an intrinsic instability and a highly dynamic conformation 
compared to the VC1 domain, it has been proposed that V and C1 form a single integrated domain 
[16]. The VC1 domain and the C2 domain are connected by a segment of several amino acid 
residues with no apparent secondary structure forming a flexible linker. NMR studies show that 
VC1 moves as a single unit with respect to the C2 domain [1, 16]. The boundaries of the domains 
were defined: V (residue 23-119), C1 domain (residue 120-233) and C2 domain (residue 234-325). 
Since the tandem VC1 domain is involved in the ligand binding, it was subjected to different 
structural studies, as demonstrated by two papers appeared in 2010 reporting the crystal structure of 
VC1, solved at 1.85 Å and 1.5 Å respectively [20, 21].  
VC1 forms an elongated structure with an angle of 145° between the two Ig-like domains [20]. A 
specific interface between the domains is observed and includes several interdomain hydrogen 
bonds and hydrophobic interactions [20].  
Although, on the basis of sequence alignments, the V domain had been assigned to the Variable 
domain (V-set) of immunoglobulins, once the structure was determined it revealed features typical 
of Intermediate topology (I-set) which is characteristic of cell adhesion molecules or muscle 
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proteins. Even if more correctly classified as an I-domain, V nomenclature remains in the literature 
[1].  
The V domain is composed of eight β-strands (A, C, C0, F, G, B, D, E) connected by seven loops to 
form two β-sheets. A, C, C0, F, and G form one β-sheet, while strands B, D, and E form the second 
β-sheet. The two β-sheets are oriented in opposite manner (Figure 4). β-strands B and F are 
connected by a conserved disulphide bond (Cys38-Cys99). A short 310 helix exists in the structure 
of the V domain (between strands E and F). The loops are well structured through extensive 
intramolecular hydrogen bonds [20, 21].  
The C1 domain fits with the C1-set of Ig molecules, with strands A, B, D, and E forming the back 
β-sheet and strands C, C0, F, and G forming the front sheet of the β-sandwich. RAGE C1 domain 
has a unique topology distinct from other Ig fold sets: it contains two additional β-strands, A0 and 
G0, which form a small parallel β-sheet. This additional β-sheet stabilizes the C-terminus of the 
domain. Moreover, a hydrogen bond between Arg198 (in a loop in C1 domain) and Pro232 (in the 
linker between C1 and C2) stabilizes the C-terminus of C1 domain (Figure 4) [20, 21]. A 
disulphide bond connects Cys144 with Cys208. 
In the high-resolution structure, an extension of 10 well-ordered residues was observed at the C- 
terminal of C1 (Glu231-Leu240) and this segment constitutes the linker to the C2 domain [16]. The 
C1-C2 linker confers a high degree of mobility to the C2 domain (in the isolated protein) relatively 
to the VC1 rigid block, allowing free rotation of the C2 domain around the VC1 domain [20, 21].  
The C2 domain adopts an Ig folds that belongs to the S-type and its structure is depicted in Figure 
5. C2 domain is composed of 8 β-strands, connected by unstructured loops. Beyond the hydrogen 
bonds, there is an internal disulphide bond between Cys259 (in strand B) and Cys301 (in strand F) 
that stabilizes the C2 domain [22]. 
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Figure 4. Structure of VC1 Domains of hRAGE. A. Ribbon diagram of the VC1 structure with V 
in green and C1 in magenta. B. Topology diagram of VC1 with the β-strands coloured as in the 
upper panel [20]. 
 
 
 
 
Figure 5. Structure of C2 domain of RAGE. A. Ribbon diagram of C2 structure. B. Topology 
diagram of C2 domain [22] 
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The charge properties of the extracellular portion of RAGE clearly define the separation of the 
ectodomain into VC1 and C2 domains. The V domain has an unusually high content of arginine and 
lysine residues, which carry a positive charge at neutral pH (pI=10.5). A patch of positively charged 
electrostatic surface was also identified on C1 [1, 20]. Thus, the entire V and the majority of C1, 
form a large area of positive surface that fits well to the acidic (negative) charge of the diverse 
RAGE ligands. In contrast to the VC1 domain, the C2 domain has mainly acidic residues on its 
surface and is negatively charged (Figure 6) [20]. This subdivision of the RAGE ectodomain into 
VC1 and C2 domains is fully reflected in the ligand binding properties of the different domains [1, 
20]. 
RAGE is able to recognize ligands that have different size, fold or symmetry. The structure and in 
particular the surface properties of the ligand binding domain (VC1) suggest that the receptor is an 
electrostatic trap for negatively charged ligands (Figure 7) [1, 20]. Moreover, the area is very 
shallow and the binding could involve several low affinity binding sites whose pattern is recognized 
by the ligand. 
 
 
 
 
Figure 6. Surface representation of the ectodomain of RAGE with the electrostatic potential 
mapped on the surface. Blue represents positively charged areas and red represents negative 
charge [1]. 
 
 
.   
Figure 7. Surface analysis of VC1. In blue are shown the positive electrostatic isopotential 
surfaces at 0.8 kT/e [20]. 
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RAGE is a glycoprotein 
RAGE has two sites for N-glycosylation at Asn25 and Asn81, respectively. Both the glycosylation 
sites are in the V module but their occupancy is different. While the Asn25 is fully occupied, the 
Asn81 is only partially glycosylated in WT RAGE and further unglycosylated Asn81 undergoes 
spontaneous deamidation [23]. Asn25 is located in a β-strand, whereas Asn81 is in a loop. The 
particular microenvironment and the local structure are probably responsible for the different 
efficiency oligosaccharyltranferases (OST1 and OST2) have for these two sites. 
A naturally occurring polymorphism (occurs with a prevalence of 5%, becoming 20% in Asian 
population) has been identified and results in a glycine to serine substitution in amino acid 82. 
Gly82Ser polymorphism influences RAGE glycosylation pattern since the replacements of glycine 
in position 82 with a serine residue promotes the glycosylation of Asn81 [23]. Modification of the 
glycosylation pattern has been proposed to affect ligand binding and signaling. Some ligands have 
increased affinity for a recombinant version of the receptor produced in bacteria that lacks of 
glycans, while other ligands were shown to bind prevalently to glycosylated RAGE [24]. 
In Chinese population, the genotype G/G, G/S with respect to S/S, is correlated with an increase of 
the risk of diabetic retinopathy (DR) and increased levels of circulating sRAGE [25].  
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RAGE oligomerization 
 
In the absence of the ligands, RAGE has been proposed to exist in a dynamic equilibrium among 
monomer, dimers and multimers. The multimers include at least four RAGE molecules [26, 27]. 
The binding of multimeric ligands stabilizes the RAGE multimers and shifts the equilibrium toward 
the formation of oligomers. The advantage of receptor preassembly is that the affinity for ligands 
increases and receptor signaling is more effective [28]. Indeed, the formation of large ligand-
receptor complexes probably results into conformational changes in the cytoplasmic tail, triggering 
the activation of signaling pathways mediated by RAGE (Figure 8 A). This process leads to the 
expression of RAGE itself, increasing the number of receptor molecules that assemble in the plasma 
membrane and, upon ligand binding, activate signal transduction [29]. Thus, a positive feedback 
loop amplifies and perpetuates the original signal, manifesting a chronic state of inflammation [29]. 
The receptor assembly is stabilized by the high concentration of RAGE on plasma membrane and 
by the binding to multimeric ligands. Several mechanisms control the surface concentration of 
RAGE. A mechanism to down-regulate the signaling consists in the internalization of the active 
receptor/ligand complex in vesicular or granular structures [29, 30]. On the contrary, to increase 
immediately the surface concentration of RAGE, vesicles containing the recycled receptor are fused 
with the cytoplasmic membrane [29]. Receptor endocytosis and recycling are described for a 
number of other receptors and are tightly regulated processes. Deregulation of these processes can 
result in different disorders, including cancer [31]. Another way to modulate RAGE signaling is the 
formation of heterocomplexes with the full-length RAGE and sRAGE and/or DN-RAGE 
(paragraph “RAGE: from gene to protein”, Figure 3). These heterocomplexes result in assemblies 
that are able to bind ligands, but are not signaling-competent (Figure 8 B and C) [1, 29].  
Different molecular mechanisms for promoting oligomerization of RAGE molecules were 
proposed. The interaction could take place prevalently though V-V domain contacts with parallel 
side-by-side arrangements (like in Figure 8) [29]. Other homodimerization modes are represented 
in Figure 9 [22]. RAGE self-association may occur through C1-C1 or C2-C2 domain contacts or 
TMD helix dimerization [22]. Moreover, it has been recently shown that RAGE forms stable 
hexamers in the presence of heparan sulphate [32]. All the proposed modes of interaction between 
RAGE molecules may indicate a multiple oligomerization strategy [22]. Association between 
RAGE molecules by the formation of a C2-C2 disulphide bond is still controversial [22, 33]. All 
these homodimerization strategies were demonstrated singularly, but it is not known if all of them 
can exist at a single time [22]. 
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Figure 8. Models of RAGE inhibition by sRAGE and DN-RAGE. A. homodimerization of 
molecule of fl-RAGE, upon ligand binding, can activate signaling pathway. B and C. sRAGE and 
DN-RAGE can form heterocomplexes with fl-RAGE, but even if ligand binding can occur, the 
signaling pathway is not activated.   
 
 
 
Figure 9. Schematic representation of multimodal oligomerization strategy of RAGE. In this 
scheme are reported the different oligomerization modes, undelaying the domains that are involved 
in different oligomerization: V-V contacts, C1-C1 contacts, C2-C2 contacts, TMD dimerization and 
hexamerization in the presence of heparan sulphate (out of plane oligomerization) [22]. 
 
RAGE ligands  
 
The first identified RAGE ligands were AGEs, Advanced Glycation End products, but in a short 
time it became evident that a number of other ligands also interact with the receptor. Table 1 
summarizes a list of ligands with their related disease once they activate RAGE. It is still not clear 
the reason why RAGE binds so many different ligands and which common features they share. In 
order to provide an overview of the different ligands, a brief description of the different groups is 
reported below. 
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Advanced Glycation End products 
The Advanced Glycation End products (AGEs) are a heterogeneous group of covalently in vivo 
modified proteins, generated by the non-enzymatic reaction of sugars, or of their degradation 
products, with proteins [35]. The non-enzymatic reaction between the free amino groups of protein 
and the aldehyde groups of reducing sugars is known as Maillard reaction. The Maillard reaction 
comprises several steps, starting with the sugar that reacts with a free amino group of biological 
amines to form an unstable compound, the Schiff base. The Schiff base undergoes a rearrangement 
to a more stable Amadori product that is degraded to a variety of reactive dicarbonyl compounds 
(for example glyoxal and methylglyoxal) (Figure 10).  
 
 
 
Figure 10. Schematic representation of the formation of Advanced Glycation End products [1].  
 
Although the precise mechanism of AGE formation (also called glycation), is unclear, it involves 
reactions with compounds derived from the Amadori products [35, 49]. In vivo, these protein 
adducts occur during ageing and in conditions of hyperglycaemia contributing to the worsening of 
the symptoms of various diseases and also negatively affecting the functionality of hormones, 
cytokines, intracellular proteins and long-lived protein of the extracellular matrix. For example, the 
glycation of collagen induces vascular thickening with severe consequences including decreased 
vascular elasticity, hypertension and endothelial dysfunctions. Moreover, AGE formation 
accelerates the course of disorders such as atherosclerosis, nephropathy, and retinal pathologies. 
The glycation can also affect short-lived peptides causing changes in their biological functions as 
demonstrated by the accumulation of glycated insulin in the pancreatic β-cells of diabetic animal 
models [35]. Glycation results in modifications of the structure and function of proteins, it induces 
tissue stiffening by crosslinking of the modified proteins and it reduces their susceptibility to 
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catabolism. AGEs deposits were found in atherosclerotic plaques and myocardium of patients with 
diabetes [50-52]. 
AGEs can trigger a persisting inflammatory response by activating AGE receptors. The most 
important AGE receptor is RAGE, but other receptors were identified, such as P60/OST-48 protein 
(AGE-Rl), 80 K-H phosphoprotein (AGE-R2) and galectin (AGE-R3). AGEs-RAGE binding could 
result in fibrosis, impaired calcium metabolism, vasoconstriction in the cardiovascular system, an 
increase in oxidative stress (which is also associated to decline in organ function in aging) and 
aggravation in diabetic complications [34]. 
Despite the fact that the interaction of AGEs with RAGE has been studied for more than 20 years, 
the mechanism of AGE-RAGE complexes formation is unclear, prevalently due to the 
heterogeneity of AGEs: it is known that the negative charge of AGEs is critical for the binding to 
the positively charged V domain [53].  
AGE-modified proteins are found under normal physiology, however, their concentration is low and 
individual proteins have at most only a single modified amino acid residue. The binding of a protein 
with a single modification to the V domain is weak, resulting in the impossibility to activate RAGE 
signaling. Under cellular stress caused by different pathologies, the concentration of modified-
proteins increases and, in particular, the number of modification on a single protein increases [34]. 
This results in a stronger binding to the RAGE oligomer, triggering the RAGE-dependent response 
[53]. Therapeutic strategies are directed to inhibit AGE formation or accelerate their degradation or 
inhibit binding to the receptors [54].  
 
 
Figure 11 Human Serum Albumin (HSA) modified with sugar (glucose) is an example of AGE. 
The lysine after modification is carboxymethylated. The solvent accessible surface of AGE-
modified HSA is depicted where the acidic residues are in red and the basic residues are in blue [1]. 
 
High mobility group protein B1  
The High Mobility Group Box-1 protein (HMGB1 or Amphoterin) plays different roles depending 
on the type of cell and environment. It is an abundant non-histone DNA-binding protein that 
normally localizes to the nucleus. In inflammatory cells, such as monocytes and macrophages, it 
can be actively secreted through a vesicle-mediated secretory pathway. During tissue injury, 
necrotic cells (but not apoptotic cells) release HMGB1. Therefore HMGB1 is a damage-associated 
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molecular pattern protein (DAMP) [45]. The extracellular HMGB1 is associated with heparan 
sulphate-rich proteoglycans (HSPGs) in the extracellular matrix [55] and acts as proinflammatory 
activator in many types of cells, including monocytes, macrophages, neutrophils, dendritic cells, 
astrocytes and endothelial cells, and also induces cell migration [45]. When HMGB1 is released 
(via the secretory pathway or after necrosis, alone or associated with DNA) it can interact with 
RAGE [56]. The inflammatory response or migration of target cells mediated by the binding of 
HMGB1 to RAGE, involve activation of MAPKs, in particular Erk1/2 and p38, resulting in NF-κB 
nuclear translocation (see below, “RAGE dependent signaling pathways”). HMGB1 is composed of 
two positively charged N-terminal DNA binding domains and a C-terminal domain, rich of acidic 
amino acids, that is involved in RAGE binding (Figure 12). DNA-bound HMGB1 can bind to 
RAGE, to Toll-like Receptor 9 (TLR9) and form a complex with the two receptors. The complex 
HMGB1-RAGE-TLR9 activates autoreactive B cells [1]. 
 
 
Figure 12. Schematic representation of HMGB1. In red is represented the acidic C-terminal 
portion [1]. 
 
S100 protein family 
The S100 protein family comprises more than 25 acidic proteins characterized by two different 
calcium-binding EF-hand domains [1, 7]. Even if the S100 proteins constitute a young 
evolutionarily group present only in vertebrates, they may be divided into several sub-groups 
characterized by different functions, expression patterns and localization in the cell. S100 proteins 
are predominately intracellular calcium sensor proteins, however, some members of the family are 
found in the extracellular space where they exhibit cytokine-like properties. Moreover, some S100 
proteins exhibit both intracellular calcium signaling functions and cytokine-like properties once 
they are secreted [1, 55]. The S100 proteins change their conformation upon calcium binding, 
resulting in different distribution of surface charges and accessibility of hydrophobic residues. In 
the extracellular space, where calcium concentrations are high, the S100 proteins are permanently 
loaded with calcium, which is a prerequisite for binding to RAGE [1].  
Most S100 proteins form homodimers, but some are able to form also heterodimers and oligomers 
(from tetramers to octamers) and in particular the oligomeric complexes of extracellular S100 
proteins are thought to be crucial for their cytokine function. Several members of the family have 
been shown to interact with RAGE in vitro or in cell-based assays: S100B, S100P, S100A1, 
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S100A2, S100A4, S100A5, S100A6, S100A7, S100A8/A9, S100A12 and S100A13 [7]. The S100 
proteins are divided in sub-groups that bind to different domains of RAGE: S100B binds to the V 
domain, S100A6 can interact with the V and C2 domain while S100A12 bind to the V and C1 
domain. S100B, S100A4, S100A8/A9 and S100A12 in the dimeric and oligomeric state, interact 
with RAGE. The interaction of several S100 proteins with RAGE was determined using different in 
vitro binding assays, in particular the Surface Plasmon Resonance (SPR). In Figure 13 a summary 
of the interaction and the dissociation constant (Kd) determined for different S100 protein and 
different version of RAGE is reported [7]. 
The S100 proteins can induce different cellular responses. S100B promotes neuronal survival and 
axon growth, S100A7, S100A8/A9 and S100A12 act as proinflammatory molecules, S100A2 and 
S100A4 are associated with differentiation and cell growth, S100A5, S100A6 and S100P can 
promote tumor growth [1]. 
 
 
 
Figure 13. Interaction of S100 proteins with RAGE. The interactions were determined using 
SPR. The numbers indicated in parenthesis correspond to the S100 population that was calculated to 
bind to RAGE with a two independent binding sites model [7]. 
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β-amyloid 
Alzheimer’s disease is characterized by extracellular deposition of insoluble aggregates of the 
amyloid β peptides that originate from the proteolytic cleavage of the amyloid precursor protein. 
The two major amyloid β peptides are composed of 40 or 42 amino acid residues and are called 
respectively Aβ (1-40) and Aβ (1-42). Both Aβ (1-40) and Aβ (1-42) contain acidic (Figure 14) as 
well hydrophobic residues and have the tendency to aggregate in amyloid fibrils, resulting in 
amyloid plaques in the brain of AD patients [1].  
The finding that RAGE binds amyloid β peptides, provides a link between RAGE and degenerative 
disorders like Alzheimer’s disease (AD) and amyloidosis [8, 57]. RAGE binds free Aβ peptides and 
triggers cellular responses that include transport of circulating plasma Aβ across the blood-brain 
barrier (BBB) into the central nervous system, oxidative stress, reduction in the cerebral blood flow 
and increases level of proinflammatory cytokines [8].  
Recently an inhibitor (FPS-ZM1) that blocked Aβ binding to the V domain of RAGE has been 
identified. FPS-ZM1 interacts with high affinity with RAGE and blocks the binding of Aβ-40 and 
Aβ-42 in RAGE-expressing cells in vitro and in the mouse brain in vivo. FPS-ZM1 is non-toxic to 
mice and can cross the BBB [58]. FPS-ZM1 bound exclusively to RAGE in brain, resulting in the 
inhibition of β-secretase activity and Aβ production. Moreover, it suppresses microglia activation 
and the neuroinflammatory response. The results in using this inhibitor are the reduction of Aβ-40 
and Aβ-42 levels in brain and the normalization of cognitive performance and cerebral blood flow 
responses in aged model mice for Alzheimer’s disease [58].  
It has been demonstrated that RAGE is able to bind also amyloid fibrils [59].  
 
 
Figure 14. Surface representation of Amyloid β peptide (1-40) (A) and Amyloid β fibrils (B). The 
peptide displays a net negative charge (red), whereas the fibril displays a pattern of negative charge 
(red) [1].  
 
Mac-1  
Macrophage-1 antigen (Mac-1 or integrin αMβ2) is a heterodimeric Complement Receptor of type 3 
(CR3) composed by the subunit CD11b (integrin αM) and the subunit CD18 (integrin β2). Mac-1 is 
present primarily on the surface of leukocytes and involved in leukocyte adhesion and migration. 
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RAGE has been identified as a counter-receptor of Mac-1. RAGE present on the surface of 
endothelial cell attracts leukocytes by interaction with Mac-1. The RAGE-Mac-1 interaction is 
amplified by S100-proteins (S100B, S100A9) and HMGB1 [60]. The interaction of RAGE with 
Mac-1 defines a novel pathway for the leukocyte recruitment that is relevant in inflammatory 
disorders associated with increased RAGE expression, such as diabetes complications [60]. 
 
LPS 
Septic shock is a response, involving all the systems, to severe bacterial infection. LPS is the major 
component of the cell surface of Gram-negative bacteria. The septic shock caused by LPS is often 
associated with high mortality. LPS can induce massive production of cytokines by immune and 
non-immune cells, resulting in inflammatory tissue injuries and multi-organ failure. Several 
receptors were identified as LPS receptor, such as the Toll Like Receptor 4 (TLR4 member of 
pathogen recognition receptors PRRs), Toll Like Receptor 2 (TLR2), heat shock proteins 70 and 90, 
CXCR4 and growth differentiation factor 5 cluster, RP105-MD-1 complex, CD11c, CD55, L-
selectin (CD62L), P-selectin and scavenger receptor class A. Recently, it has been reported that also 
RAGE recognizes LPS (in a LPS shock model), resulting in NF-κB activation and TNF-α (Tumor 
Necrosis Factor α) secretion [37]. RAGE signaling activated by LPS accelerates acute inflammatory 
reactions resulting in tissue damage. This leads to the release of HMGB1, resulting in RAGE-
dependent lethality in septic shock.  
In a recent report [38] where an infection model with alive E. coli was used instead of the LPS 
shock model, RAGE signaling was demonstrated to contribute to an effective antibacterial defence 
such as inhibition of bacterial outgrowth and dissemination. RAGE deficiency results in enhanced 
organ injuries such as liver necrosis. In general, the innate immune response to severe bacterial 
infection can act in a double way, protecting the host against invading pathogens or potentially 
destroying cells and tissues. Even though the LPS shock model is an extreme exaggerated 
inflammation model, RAGE can participate in sensing pathogens and controlling a delicate balance 
between clearance of invading pathogens and exaggerated inflammation [37].  
 
Transthyretin 
Transthyretin (TTR) is a plasma homotetrameric protein of 55 kDa that functions as a transporter 
for thyroxine (T4) and retinol (vitamin A) by formation of a 1:1 molar complex with retinol-binding 
protein (RBP) [39]. The name Transthyretin is derived by its function (transports thyroxine retinol). 
A number of studies have shown that glycation induces the formation of the β-sheet structures in 
protein such as Transthyretin. Transthyretin fibrils are associated with the pathology of familial 
amyloidotic polyneuropathy (FAP), in which extracellular amyloid deposits lead to degeneration of 
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cells and tissues, in particular neurons of the peripheral nerve [39]. RAGE acts as a selective cell 
surface receptor for both soluble and fibrillar Transthyretin, leading the activation of the 
transcription factor NF-κB and the progression of neurodegenerative diseases [40]. 
 
Phosphatidylserine 
Rapid removal of apoptotic cells by phagocytes is crucial for preventing inflammation and 
autoimmune responses against intracellular antigens released from the dying cells. 
Phosphatidylserine (PS) acts as a particular signal (called “eat me-signal”) since it is recognized by 
phagocytes via specific receptors. Several classes of receptors have been implicated in the 
recognition of apoptotic cells, via direct binding to PS, such as brain-specific angiogenesis inhibitor 
1 (BAI1), T-cell immunoglobulin and mucin domains-containing protein 4 (Tim4) and stabilin-2, or 
indirect binding through bridging molecules as milk fat globule-EGF factor 8 protein (MFG-E8) 
and growth arrest-specific 6 (Gas6) [41].  
RAGE is included in the class of receptors that recognise apoptotic cell via direct binding with PS. 
RAGE binds to PS and activates signalling cascades in phagocytes that lead cytoskeletal 
reorganization to allow corpse internalization. Deficiencies of the receptors that participate in the 
recognition of PS on the surface of apoptotic cells lead to a failure to maintain self-tolerance and the 
development of autoimmunity [41].  
 
Nucleic acids  
Recognition of DNA and RNA derived from pathogens or self-antigen is a way mammalian 
immune system senses infection and tissue damages. Activation of immune signaling receptors by 
nucleic acids is controlled by limiting the access of DNA and RNA to intracellular receptors. RAGE 
binds directly to DNA and RNA and promotes their uptake into the cells, lowering the immune 
recognition threshold for the activation of Toll like receptor 9 (TLR9), the principal DNA-
recognizing transmembrane signaling receptor [42]. RAGE binds the charged sugar phosphate 
backbones of nucleic acids in a sequence-independent manner. RAGE binds various forms of 
nucleic acids, such as ds or ss DNA and RNA of about 15 nucleotides in length. Structural analysis 
of RAGE-DNA complexes indicate that DNA interacts with VC1 domain of RAGE and could 
induce formation of higher-order receptor complexes (Figure 15) [42]. No conformational changes 
were observed in the VC1 domain between the DNA-bound structures and those of the non-DNA 
bound forms. This is consistent with the observation that the linkage between the V and C1 domains 
is rigid and is not modified by the binding to DNA [42]. 
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Figure 15. Electrostatic charge surface of VC1 (blue +10 kT/e, red -10 kT/e) in different 
orientation. The bound dsDNA is represented in orange. DNA interacts with a region of positive 
charges at the VC1 dimer interface [42]. 
 
AOPPs 
Advanced oxidation protein products (AOPPs) are a family of oxidized di-tyrosine-containing and 
crosslinked protein products formed during oxidative stress by reaction of plasma protein with 
chlorinated oxidants. AOPPs are often carried by albumin in vivo. Accumulation of plasma AOPPs 
was first found in patients undergoing dialysis and subsequently demonstrated in patients with 
diabetes and metabolic syndrome. The accumulation of AOPPs results in a cascade of signaling 
events coupled with intracellular oxidative stress. AOPPs were found to be colocalized and interact 
with RAGE, which was the first receptor identified to transduce AOPPs signal [43]. 
 
Chondrointin Sulphate and Heparan Sulphate 
Chondroitin Sulphate (CS) and Heparan Sulphate (HS) are sulphated glycosaminoglycans (GAGs) 
that are covalently attached to extracellular matrix proteins to form proteoglycans (CS- and HS-
PGs, respectively). They are ubiquitous in the extracellular matrix and at cell surface in various 
tissues. CS/HS-PGs regulate various physiological events such as cytokinesis, morphogenesis, viral 
and bacterial infections, tumor growth, and tumor metastasis [44]. CS-PGs facilitate tumor invasion 
at the tumor cell surface and in the extracellular matrix by enhancing integrin-mediated cell 
adhesion, motility and intracellular signaling. HS-PGs play an important role in tumor proliferation, 
metastasis, invasion, adhesion and angiogenesis. During proteomic searches for CS and HS ligands, 
RAGE was identified as a receptor for these sulphated glycosaminoglycans [44, 45]. It was shown 
that HS binds HMGB1 and RAGE. HMGB1 is a HS dependent signaling factor, but for the 
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activation of signaling pathway the requirement for HS is manifested at the level of the receptor 
RAGE rather than HMGB1. RAGE and HS form a complex [45]. In vitro, the binding between 
RAGE and a dodecasaccharide derived from a highly sulphate form of HS, induces hexamerization 
of the receptor extracellular domain (VC1). The hexamers consist of a trimer of dimers, with a 
stoichiometry of 2:1 RAGE:dodecasaccharide [32]. This result was not seen, so far, for CS. 
 
C1q and C3a 
The complement protein C1q is a protein that binds and labels immune complexes or microbial 
surfaces to initiate complement activation. In addition to its role in the classical pathway of 
complement activation, C1q is involved in other immune functions, including the clearance of 
apoptotic cells and the modulation of adaptive immune response. This biological process is 
important both in homeostasis than during pathological process. For example in the nervous system 
the synapses and distal axons are selectively eliminated during development, but also during 
pathologic responses through mechanisms sharing features with apoptotic cell removal. Several C1q 
functions may be mediated by C1q receptors present on the effector cell surface. RAGE is a C1q 
receptor that enhances C1q mediated phagocytosis and the complex plays roles in adaptive 
immunity. RAGE-C1q complex can weakly activate the complement system, but RAGE activated 
by the binding with C1q-tagged material (as bacteria or apoptotic cellular debris) enhances 
phagocytic clearance. Moreover, Mac-1-RAGE complex may be formed to further enhance such 
phagocytic function [46].  
Many complement components have been recently screened in searching for new RAGE ligands 
and among them, C3a was found to bind RAGE [47].  
 
LPA 
Endogenous phospholipids, as Lysophosphatidic Acid (LPA), regulate fundamental cellular 
processes such as proliferation, survival, motility and invasion, and are implicated in vascular 
signaling, tumorigenesis and neuropathic diseases. LPA regulates cellular signal transduction 
cascades implicated both in homeostatic and pathological conditions. LPA exerts homeostatic 
effects in development, but in adult organisms during pathological conditions in stressed tissues 
LPA signaling is activated resulting in neointimal expansion, tumor growth and metastasis. LPA 
exerts its effects through RAGE. LPA physically interacts with RAGE, in particular with V domain. 
In vitro, RAGE was required for LPA-mediated signal transduction in vascular smooth muscle cells 
and C6 glioma cells, as well as proliferation and migration. In vivo, the administration of sRAGE or 
the genetic deletion of RAGE mitigated the activation of Protein Kinase B (PKB, see below) by 
LPA [48].  
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Mediators for the activation of intracellular signaling 
 
Since the cytoplasmic tail of RAGE (ctRAGE) is devoid of intrinsic tyrosine protein kinase activity 
typical of many receptors, intense studies have been carried out in order to understand how RAGE 
activates intracellular signalling. Its activation resembles that of integrin, a receptor also devoid of 
enzymatic activity and having a short cytoplasmic tail. The mammalian Diaphanous related formin 
1 (mDia1) was identified as binding partner of ctRAGE and a key mediator of RAGE-dependent 
intracellular signalling events [61, 62]. mDia1 belongs to the formin protein family of actin and 
microtubule polymerization factors, which controls cell migration and division. It contains two 
proline-rich formin homology domains (named FH1 and FH2) that are essential for the association 
with ctRAGE. mDia1 protein levels are positively regulated by increased RAGE expression. It has 
been shown that mDia1 has a key role in mediating RAGE ligand stimulated signaling (see below) 
[61].  
Other studies reported that ctRAGE may also bind to Src, MyD88 and to TIRAP. The activation of 
Src is responsible for many RAGE dependent downstream signal events, including the activation of 
MAPK signaling pathway (Erk1/2, p38 and JNK) and JAK/STAT signaling pathway [18]. TIRAP 
and MyD88 are adaptor proteins for Toll like receptors 2 and 4 [63, 64]. Their function was 
associated with RAGE signal events, but so far the direct interaction of MyD88 and TIRAP with 
ctRAGE was not demonstrated. Whether RAGE ligand binding recruits other adaptors proteins, in 
particular in a cell-specific manner, remains to be determined.  
 
RAGE-dependent signaling pathways  
 
RAGE signaling is influenced by a multitude of different factors. The cellular response induced 
upon ligand binding is not only dependent on the identity of the ligand, but also on the cell type, the 
concentration of the ligand, the presence of other ligands, the surface concentration of RAGE, the 
presence of coreceptors, different adaptor molecules mediating the signal and signaling pathways 
established in the cell. A brief description of the most important signaling pathways activated by 
RAGE is reported in Figure 16.  
The stimulation of RAGE by ligands and subsequent induction of oxidative stress activates the 
mitogen-activated protein kinase (MAPK) signaling cascades, resulting in release and activation of 
NF-κB:  
One of the first protein kinase involved in RAGE-dependent signalling is Src (proto-oncogene 
tyrosine protein kinase) that activates RAS. RAS activates the extracellular signal regulated kinases 
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(Erk1, also called p44 and Erk2 also called p42), and, in turn, Erk1/2 stimulate NK-kB [18]. Erk are 
also able to stimulate the transcription factor CREB (cAMP response element-binding protein). In 
addition, ctRAGE contains a putative Erk binding domain (Leu-362 to Ala-375) and may thereby 
promote directly Erk activation as effectors. Another MAPK, p38, is required for the induction of 
NF-κB activation. Different studies report that p38 is stimulated upon activation of cdc42-Rac-1 
pathway [65], while others suggest that p38 is directly activated by Src-RAS [66]. The apparent 
discrepancy regarding the activation of p38-NF-κB cascade can be explained by the fact that 
different doses of RAGE ligands, duration of stimulation and cell type were used among these 
studies. This underlines that functional specificity of the cells and therefore distinct signaling 
pathways are operating in response to each of the RAGE ligands in different cell types [18]. 
Another well-characterized signaling mechanism by which RAGE induces inflammation is the third 
MAPK pathway, JNK. The activation of JNK leads to increases in the transcriptional activity of 
activator protein 1 (AP-1), which together with NF-κB, up-regulates the transcription of 
proinflammatory genes. The stimulation of JNK by RAGE ligands is dependent upon cdc42 and 
Rac-1 [67] and may also be activated by PKCβII (Protein Kinase c βII). PKCβII is also able to 
activate the pathway that leads to the activation of GSK3β (Glycogen Synthase Kinase 3β) resulting 
in microtubule stabilization [18]. Another signaling mechanism induced by RAGE ligands which 
activate NF-κB is the PI3K-PKB pathway (PI3K phosphatidylinositol 3-kinase, PKB Protein 
Kinase B, also known as Akt). There is no direct evidence of the activation of P13K-PKB pathway 
by RAGE, and also some RAGE ligands activate this pathway via other receptors (for example 
HMGB1 via Toll like receptors), but part of the increase in PKB activity induced by AGEs is 
mediated by RAGE [68].  
Another pathway activated by RAGE is the JAK-STAT pathway (JAK Janus Kinase, STAT Signal 
Transducer and Activator of Transcription), whose activation leads to the activation of the 
transcription factor STAT3. 
Other signaling pathways activated by RAGE culminate in the activation of the transcription factors 
CREB, miogenin, AP-1 and Egr-1, which mediate alterations in cell fate, migration and production 
of inflammatory and pro-fibrotic mediators.  
RAGE is expressed on multiple cell types and, as reported above, specific signaling pathways 
activated by RAGE ligands are greatly dependent on the ligand, duration of ligand stimuli and the 
specific functions of each cell type. Figure 17 reports a schematic description of the pathways 
activated by RAGE in different cell type and upon binding to specific ligands [29]. 
 
28 
 
 
Figure 16. Schematic representation of cellular signaling pathways controlled by RAGE activation. 
RAGE controls different cellular process though many intracellular signaling pathway, such as 
MAPK pathway (involving Erk1/2, p38 and JNK), JAK/STAT pathway, PI3K/PKB pathway. The 
stimulation of these pathways leads to the activation of the signal transductions STAT3, CREB, NF-
κB, myogenin, AP1 and Egr-1, and cellular process like microtubule stabilization, cell motility, 
autophagy and apoptosis.  
 
 
Figure 17. Schematic representation of the different signaling pathways activated by RAGE on 
different cell type upon binding with specific ligands [29]. 
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Physiological role of RAGE 
 
Despite extensive studies on RAGE signaling have associated this receptor with several diseases, 
RAGE also play beneficial roles for human biology. RAGE, that is currently described both as a 
receptor and as an adhesion molecule, is involved in the fine regulation of the delicate balance 
between pathological and physiological states [69]. As reported above, the signaling pathway 
activated by RAGE depends mostly on the identity and concentration of the ligands, the surface 
concentration of RAGE and the cell type. The widespread expression of RAGE during 
development, in contrast with the low expression of RAGE in the vast majority of cell types in the 
adult, reflects the important, but still undisclosed role of this receptor during embryonic life. 
Besides RAGE signaling has been proposed to contribute to the resolution of inflammation and to 
tissue regeneration, especially in injured tissues where re-expression of RAGE occurs [69]. Low 
concentrations of RAGE ligands activate a short-term RAGE dependent-signaling that may 
stimulate tissue homeostasis and repair by promoting cell proliferation and differentiation. Long-
term RAGE signaling triggered by high concentrations of ligands may be deleterious, amplifying 
and perpetuating the inflammatory response, excessively stimulating cell survival, proliferation and 
migration or causing a lethal accumulation of ROS [64]. The different expression pattern of RAGE 
during development (from the embryonic to adult stages) and the ability of the ligands to up-
regulate RAGE expression, are factors that appear to play a fundamental role in the equilibrium 
from pathological and physiological function of the receptor. The majority of the studies on the 
beneficial role of RAGE where performed using RAGE-knockout mice (KO). Here the major 
processes associated with a beneficial role of RAGE are reported [69].  
 
Lung homeostasis 
In adult cells in physiological conditions, RAGE is expressed at low level except in the lung, where 
its expression is high [29]. Even if the RAGE-KO mice do not exhibit severe pulmonary alterations, 
they manifest significant increase in dynamic lung compliance and a decrease in the maximal 
expiratory airflow [69]. Blockade of RAGE has been reported to result also in disturbed cell-matrix 
contacts in lung cells [70]. 
 
Bone metabolism 
RAGE was proposed to have a role in osteoclast maturation and bone remodelling [71, 72]. Under 
physiological condition RAGE is expressed in both osteoclasts and osteoblasts. RAGE appears to 
be up-regulated in primary cultured bone marrow macrophages (BMM) during osteoclast 
differentiation. BMMs differentiated from RAGE-KO mice bone marrow cultures appear smaller in 
size compared with cells from WT mice cultures. This suggests a morphologic defect in in vitro 
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differentiated osteoclasts of RAGE-KO mice. Moreover in these mice both bone mineral density 
and bone biomechanical strength are increased and decreased number of osteoclasts and an 
osteoporosis-like phenotype was reported [72]. So, it was proposed that RAGE serves as a positive 
factor to regulate the osteoclast formation. Further, bone remodelling is altered in RAGE-KO mice 
due to decreased bone resorption by osteoclasts [69, 72]. 
 
Immune system 
Different studies indicate a role for RAGE in immune and inflammatory responses, suggested by its 
ability to bind proinflammatory cytokines [73]. Blockage of RAGE causes a retarded inflammatory 
response by arresting signaling pathways involve in inflammation [11, 74]. As reported above, 
RAGE was found to be a counter-receptor for Mac-1, resulting directly involved in leukocyte 
recruitment. The interaction of RAGE with leukocytes results in activation of sustained NF-κB-
dependent gene expression [75]. Recently, RAGE has been identified to form in vitro a complex 
with Toll-like receptor 9 (TLR9), the principal DNA-recognizing receptor. RAGE lowers the 
threshold of DNA concentration that is needed for the activation of TLR9 and promotes DNA 
uptake into endosomes. The RAGE-TLR9 complex is able to detect DNA from pathogens [42, 76]. 
This molecular mechanism is supported by in vivo experiments indicating that RAGE-/- mice are 
unable to support a typical inflammatory response to DNA in the lung [42].  
 
Neuronal system 
RAGE-KO mice exhibit hyperactivity and increased sensitivity to auditory stimuli suggesting that it 
is required in neuronal signaling in the brain [77]. In the peripheral nervous system, RAGE appears 
beneficial in neurite outgrowth required for regeneration after injury. The blockade of the receptor 
decreases regeneration after crush injury to the peripheral nerve (sciatic nerve) and the number of 
infiltrating phagocytes decreases [78, 79]. The equilibrium between physiological and pathological 
role of RAGE in the central nervous system seems mediated by ligands.  
Ligands for RAGE in the central nervous system are HMGB1, S100B, AGEs, and amyloid-β fibrils. 
The interaction of RAGE with AGEs or amyloid-β fibrils leads to inflammation and oxidative stress 
and is involved in the pathogenesis of some neurological disorders (for example Alzheimer’s 
disease), whereas HMGB1 and S100B are known to be involved in numerous neuronal functions, 
including neurite out growth, migration, differentiation and survival. Moreover, the concentration of 
ligands and the cell type seem to be important factors in predicting the effect of RAGE in the 
neuronal system. Low concentrations lead to more beneficial processes (neurite out growth), while 
high concentrations result in deleterious events (inflammatory signaling). Moreover, the binding of 
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HMGB1 results in neurite out growth in neurons, while in microglia HMGB1 induces potentially 
deleterious inflammatory signaling [69].   
 
 
 
 
Figure 18. Physiological role of RAGE. RAGE-mediated changes in physiology of lung 
homeostasis, bone metabolism, immune system and neuronal system [69]. 
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Aim of the Project 
 
RAGE has been demonstrated to have a key role in the establishment and progression of oxidative 
and inflammatory based pathologies, like diabetic vascular complications, atherosclerosis, 
neurodegenerative disorders and cancer. Despite several ligands have been identified, a complete 
characterization of RAGE binding properties is still missing.  
The aim of this project was the expression and purification of recombinant forms of human RAGE 
to set-up different biophysical methods to study the non-covalent interactions between RAGE and 
its ligands. We focused on the extracellular domains of RAGE that are responsible of ligand 
binding.  
Since RAGE forms oligomers on the plasma membrane of mammalian cells, a version of VC1 
suitable for immobilization on resin or matrix was designed in order to mimic the oligomeric state 
of the receptor.  
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Main Results 
 
1. Expression and purification of His-tagged VC1 in Escherichia coli  
The VC1 portion (amino acid 23-243) of the extracellular domain of human RAGE was produced in 
E. coli as an intracellular protein fused to an N-Terminal His-Tag and a Thrombin Cleavage site. 
The protein was purified using Nickel affinity chromatography and the His-Tag was removed 
through Thrombin digestion. During the purification VC1 showed a marked tendency to aggregate 
and precipitate resulting in low yield of soluble protein. Even if the protocol for the purification of 
VC1 was improved, only 10% of the purified His-tagged protein remained soluble after Thrombin 
digestion.  
The identity of the purified VC1 was confirmed by trypsin digestion of the gel-purified protein, 
separation of the resulting peptides by reversed phase capillary column and identification of the 
sequence by MS/MS analyses. The primary structure of the protein corresponded to that deduced 
from the nucleotide sequence of VC1 with coverage higher than 85%.  
 
2. Analysis of protein-ligand binding by native Mass Spectrometry (MS) 
In order to better understand the ligand-binding properties of RAGE, a native MS method was used 
to study the non-covalent interactions between ligands and recombinant VC1 produced in E. coli. 
The advantages of native MS over other methods are (i) no labelling of the target or ligands, (ii) 
high sensitivity and low sample consumption, (iii) quick and automatable analysis and (iv) 
screening of the ligands as a mixture. The binding reactions consisted in maintaining constant the 
concentration of VC1 and increasing the ligand concentration. Even if we were able to detect 
binding between low molecular weight AGEs (peptide DEFKADE and FKDLGEE with the lysine 
residue modified as carboxymethyl lysine or carboxyethyl lysine) and VC1, the tendency of VC1 to 
adhere to the glass tubes of the spectrometer, even after silanization and conversion to 
microcapillary (static injection), resulted in poorly reproducible data. We concluded that this 
approach is not suitable for VC1.  
 
3. VC1 expressed and purified from Pichia pastoris is glycosylated, functional and stable  
We expressed secretory forms of the ligand binding domains of hRAGE in the lower eukaryote 
Pichia pastoris. The rational of this approach was that expression in a eukaryotic host and targeting 
to the secretory pathway could in principle improve the folding and solubility of the proteins, 
promote glycosylation and formation of disulphide bonds and reduce the stickiness of the proteins 
to the glass.  
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Since the fusion to a tag could facilitate protein purification, first the expression of His-tagged 
proteins was attempted but unsatisfactory results were obtained as described below (see paragraphs 
4 and 5). Therefore untagged versions of the hRAGE domains were also attempted. We obtained P. 
pastoris strains expressing and secreting VC1 domain and we tested different growth conditions to 
optimize the expression whereas the V domain was expressed but retained intracellularly (see 
paragraph 5).  
By Western Blotting analysis using a polyclonal anti-RAGE Ab, VC1 was detected in the medium 
as a doublet of two polypeptides of 34 and 36 kDa (called p34 and p36). The appearance of a 
unique band of about 29 kDa after treatment of VC1 with PNGase F (an amidase that catalyses the 
cleavage of N-linked oligosaccharides in glycoproteins) provided evidence that VC1 is 
heterogeneously N-glycosylated in P. pastoris. The degree of occupancy for Asn25 and partial for 
Asn81 that was also highly susceptible to spontaneous deamidation, in agreement with the data of 
the literature concerning hRAGE expressed in mammalian cells.  
VC1 was then purified from the medium using a one-step elution cation-exchange chromatography 
as the capture step, exploiting the high charge of the protein (pI = 9.9) and a gel-filtration polishing 
step. We estimated a production of about 6 mg of VC1 per Liter of medium. We tested the 
functionality of VC1 (p34 + p36) by a filter binding assay using AGE-BSA, a well-known RAGE 
ligand and BSA as negative control. VC1 bound AGE-BSA, but not BSA, indicating that VC1 
produced in Pichia pastoris is functional.  
Furthermore, we developed a procedure for the optimization and scale-up purification of VC1, 
based on an ionic-strength linear gradient high resolution cation-exchange chromatography. With 
this improved procedure p34 and p36 separated in two partially overlapped peaks, allowing their 
isolation in homogeneous form.  
We performed a thermal denaturation analysis (ThermoFluor) of p36, p34 and of the unmodified 
form produced in E. coli at different NaCl concentration. The two glycoforms of VC1produced in 
P. pastoris had similar melting temperatures (Tm) in 150 and 300 mM NaCl whereas in the absence 
of NaCl p36 appears to be more stable than p34. In addition, the Tm of the two glycoforms is higher 
than that of VC1 produced in E. coli. In particular in the absence of NaCl, this protein is highly 
unstable, its Tm being 22.6 °C. Thus, VC1 forms produced in P. pastoris displayed a remarkable 
improved stability in comparison with the unmodified VC1. These observations are consistent with 
the fact that VC1 glycoforms obtained from P. pastoris are highly soluble and display no tendency 
to aggregation.  
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4. Fusion of VC1 to a removable histidine tag reveals proteolytic activities in the medium  
We expressed in Pichia pastoris also VC1 fused to a C- terminal His-Tag and a Thrombin cleavage 
site (VC1-His) in order to remove the tag if necessary. As for VC1, VC1-His was detected using 
Western blot analysis with anti-RAGE Ab in the medium as p34 and p36. Surprisingly, the two 
polypeptides were not recognized by anti-poly His mAb. In the cellular extracts the two 
polypeptides were recognized by both antibodies. This result indicates that VC1-His is expressed 
and glycosylated, but during secretion or in the culture medium the His-Tag is cleaved. The site of 
cleavage was identified by MS and corresponds to the cleavage site of Thrombin indicating that a 
secreted serine protease of P. pastoris could be responsible of the cleavage. A candidate was Sub2p, 
an endogenous subtilisin-like protease that is secreted in the medium in the presence of methanol 
(inducing condition). To verify if the His-tagged VC1 was a substrate of Sub2p, we transformed the 
deleted sub2 strain and monitored the production of the tagged form of VC1. The cleavage occurred 
also in this strain, suggesting that another protease is secreted in P. pastoris medium. 
 
5. Expression and purification of V module in E. coli and P. pastoris  
It is still unclear the role of the V domain in the binding with AGEs, although a paper published in 
2011 proposed that the only V domain is necessary to specifically bind AGEs. This prompted us to 
express this soluble truncated form in order to study the binding properties of V to low molecular 
weight AGEs.  
The V domain was expressed in the E. coli strain as an intracellular recombinant protein with an N-
Terminal His-Tag and a Thrombin Cleavage site. The protein was purified using Nickel affinity 
chromatography. The expression level of this recombinant protein was lower in comparison with 
the expression level of His-Tag-VC1 and most of the protein was found in the insoluble fraction. 
Furthermore, His-Tag-V aggregates and precipitates dramatically during the purification 
procedures, resulting in the impossibility to treat the protein with Thrombin in order to remove the 
His-Tag.  
Therefore, we attempted to express the V domain in P. pastoris. We obtained P. pastoris cells 
expressing V and we tested different induction conditions. In all the conditions tested, no bands 
were detected in the media using Western Blotting analysis with polyclonal anti-RAGE Ab. In the 
cell extracts three bands were recognized by polyclonal anti-RAGE Ab. We observed that the V 
polypeptide was glycosylated, as the detected polypeptides were susceptible to PNGase F treatment. 
These results strongly indicate that V is expressed intracellularly and modified in the ER but it is 
not transported to the extracellular space probably as a consequence of protein folding. From the 
results of expression and purification obtained from E. coli and Pichia pastoris, the V module 
appeared to be unstable, probably due to the absence of C1 domain, indicating that VC1 is a single 
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folding unit. Our results, based on an in vivo approach, extend previous in vitro biochemical studies 
indicating that V and C1 constitute a single integrated unit of the ectodomain of RAGE.  
 
6. Expression of VC1-StrepTag 
To identify new RAGE ligands and enrich AGEs from biological samples (for example fluids from 
diabetic patients), we set up a pull down assay. This technique requires an immobilized form of 
RAGE. The rational was to purify a recombinant VC1 with a C-terminal StrepTag that binds with 
high affinity to streptavidin-resin. The tag was placed at the C-terminal and to let VC1 interact 
freely with the AGE ligands and to our knowledge this is the first construct of VC1 immobilized 
through the C-terminal end. The resin with VC1-Strep immobilized was named RAGE-column. 
We developed different strategies: (i). VC1-StrepTag expressed in E. coli and directly immobilized 
on streptavidin resin from the soluble fraction of E. coli, (ii). HisTag-VC1-StrepTag expressed in E. 
coli, purified by Nickel affinity chromatography and then treated with thrombin to remove the His-
Tag; immobilization the purified protein on the streptavidin resin, (iii). VC1-Strep expressed and 
secreted in P. pastoris, purified and immobilized on the streptavidin-resin. 
Using the protein produced in E. coli (i, ii), the RAGE-column was able to capture ligands such as 
purified species of AGEs (BSA-ribose, BSA-glucose), S100B and S100A12. BSA-ribose was also 
specifically identified from a complex matrix like milk. With this pull down assay we also captured 
proteins from sera from diabetic patients. MS analyses are in progress to reveal the identity of the 
polypeptides identify.  
VC1-Strep Pichia pastoris medium (iii) was successfully immobilized on streptavidin resin and the 
system was set for future experiments. 
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Conclusions and Future Prospects 
 
The activation of RAGE upon ligand binding, modulates different signal transduction pathways, 
culminating in the expression of genes involved in the inflammatory response. Therefore, in the 
context of hyperglycaemia and/or oxidative stress-based diseases, RAGE activation can establish a 
sustained inflammation crucial for the progression of nephropathies or atherosclerosis. Moreover, 
inflammation increases oxidative stress, reinforcing the expression of RAGE and RAGE signaling 
pathway by a vicious cycle. The characterization of RAGE binding properties is crucial to develop 
antagonists able to reduce the effects of RAGE activation. For this purpose we focused in obtaining 
recombinant and soluble form of the receptor in order to perform ligand binding experiments. 
During my PhD project, different recombinant forms of the human Receptor for the Advanced 
Glycation End products were produced in different heterologous expression systems. 
V and VC1 were expressed as intracellular proteins in E. coli, but the tendency to aggregate and 
precipitate of the purified proteins resulted in low yield of VC1 and greater loss of V. A native MS 
method was used to study the non-covalent interactions between ligands and the recombinant VC1 
produced in E. coli, but the tendency of VC1 to adhere to the glass tubes of the spectrometer, even 
after silanization, resulted in poorly reproducible data. We concluded that this approach is not 
suitable for VC1.  
Since RAGE has disulphide bonds and is also glycosylated, we expressed V and VC1 as secreted 
protein in the methylotrophic yeast Pichia pastoris. VC1 produced in Pichia pastoris was purified 
from the culture supernatant with no relevant loss of the protein during the purification steps. VC1 
was glycosylated and displayed to mimic the glycosylation pattern observed in human cells. 
Moreover the protein did not show tendency to aggregate and precipitate. By measuring the melting 
temperature of VC1 produced in E. coli and in Pichia pastoris, the protein from P. pastoris proved 
to be more thermal stable, indicating that the addition of N-linked glycans is important for proper 
folding, protein stability and solubility. Unfortunately, the presence of the oligosaccharide chains 
hampers the use of native MS to study the non-covalent interactions of RAGE with ligands, but 
other techniques, such as Microscale Thermophoresis or SPR, will be used.  
In contrast with VC1, the V domain was retained intracellularly in Pichia pastoris, suggesting that 
it did not acquire the proper folding. This result obtained with an in vivo approach, indicates that V 
and C1 form a single folding unit and that V is not a domain but rather a module of RAGE and also 
reinforce the conclusion derived from previously published in vitro biophysical studies indicating 
that V and C1 form a single integrated domain  
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Another approach for the study of the binding properties of RAGE and the discovery of new ligands 
is currently under development. The method consists in the setup and implementation of an 
innovative approach that combines affinity chromatography and MS to capture and characterize 
RAGE ligands from biological samples, such as serum obtained from patients with hyperglycemia 
and oxidative stress (nephropathic diabetic patients). VC1 was expressed as a recombinant protein 
with a C-terminal StrepTag in E. coli and in P. pastoris. Then VC1-Strep was immobilized on a 
streptavidin resin to create the solid phase of a chromatography column (called RAGE-column). 
The RAGE-column was tested and proved to be able to capture well known RAGE ligands.  
Using this RAGE-column, endogenous RAGE ligands will be captured from biological samples, 
such as serum obtained from patients in conditions that mimic the physiological ones.  
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Candida albicans 
 
Candida albicans is a eukaryotic microorganism and is the most common human pathogen among 
the Candida species. C. albicans infections occur predominantly on mucosal surfaces, including 
oral mucosal, gut, vaginal mucosa and skin. The mucosal infections, that cause morbidity and 
reduce the quality of life for infected individuals, are extremely common and occur in healthy 
individuals. However, when the fungus penetrates through the epithelial barrier, enters the 
bloodstream and invades organs like kidney or liver, infections can become life threatening [80]. 
These types of infections are called systemic/invasive candidiasis and can be acute or chronic. 
Invasive candidiasis is reported to be the fourth most common cause of bloodstream infections in 
the United States [81].  
Under normal circumstances, C. albicans is a commensal of the human mucosae and skin 
predominantly found in the gastrointestinal tract, where the microbial flora, epithelial barriers and 
the innate immune system control its invasiveness. Antibiotic treatments, surgery trauma, catheters 
and neutropenia are considered major risk factors for invasive candidiasis [82]. Even if the 
commensal stage is frequently described as “harmless” for the host, this stage is highly regulated 
and the fungus interacts continuously and transiently with the host immune system [82, 83]. 
Candida albicans is often classified as an opportunistic pathogen, but infections are not strictly 
limited to individuals with compromised immunity. In fact, C. albicans can cause superficial 
mucosal infections in healthy hosts that suffer of disturbances in normal flora due to antibiotic use 
or vaginal infection caused by hormonal changes [80].  
The success of C. albicans as a pathogen depends on its morphological plasticity. C. albicans is a 
polymorphic fungus and the most frequently observed morphological forms are the yeast and the 
filamentous forms (pseudo-hyphae and hyphae) (Figure 19). C. albicans yeast cells resemble the 
budding yeast Saccharomyces cerevisiae. Filamentous growth results in the production of elongated 
cells that differ for their size shape: hyphal cells are narrower then pseudo-hyphae and have parallel 
walls with no constriction at the site of septation, while pseudo-hyphae are wider and form 
constriction between elongated buds [84]. Yeast form is the preferred morphology for dissemination 
within the blood flow while the switch to hyphal growth allows an efficient penetration of C. 
albicans through the tissues [85]. Complex and interconnected signaling cascades regulate 
morphogenesis in C. albicans, in particular elevated CO2, serum, 37° C, nutrient and phosphate 
limitation and alkaline pH promote yeast-to-hyphae transition. These morphological states also 
enable the formation of biofilm (Figure 19), complex surface-associated (usually on medical 
devices) communities composed of a mixed population of yeast cells, pseudo-hyphae and hyphae. 
Biofilm is usually resistant to antifungal drugs [86].  
41 
 
The morphological plasticity of C. albicans is an important virulence factor, as mutants that are 
unable to undergo morphogenesis are usually attenuated in virulence [84].  
 
 
Figure 19. Images of the different morphological states of C. albicans (Yeast, Pseudo-hyphae, 
hyphae and biofilm). Yeast cells are shown under differential interference contrast (DIC) 
microscopy (upper panel) and scanning electron microscopy (SEM, lower panel). The filaments in 
this figure (DIC) were induced by different conditions: medium at pH 6 at 35°C (Pseudo-hyphae) 
and 10% serum at 37°C (Hyphae). The biofilm image is a SEM image of a mature 48 h-biofilm 
composed of yeast and filamentous cells. The bars indicate 10 μm [84]. 
 
Candida albicans cell wall 
 
In the establishment and progression of pathogenesis, C. albicans cell wall plays an important role. 
The cell wall is the first structure that interacts with the host cells, it carries important antigens and 
it is responsible for the adherence of the pathogen [87]. As in fungi in general, the cell wall of 
Candida albicans is an articulate and ordered structure, made by arrangement of its different 
components. Some of these are linked by covalent bonds, whereas others are retained in the wall by 
hydrogen bonds, salt-type, hydrophilic or hydrophobic interactions. The cell wall provides 
protection to the cell against physical, chemical and biological aggression and is responsible for its 
morphogenesis [87].  
C. albicans cell wall represents about 15-30% of the dry weight of the cell and is composed of 
polysaccharides and proteins, as major components, and lipids present as minor component [87]. 
The cell wall has a layer organization, where the structural polysaccharides accumulate in the inner 
layer while mannoproteins are enriched in the outer layer and are essential for adhesion, virulence 
and biofilm formation (Figure 20).  
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The polysaccharides are present in three major forms: β-glucans, chitin and mannans of 
mannoproteins. β-glucans are the unique and most abundant polysaccharide (C. albicans cell wall 
does not contain α-glucans) and are polymers of glucose joined by β-1,3 and/or β-1,6 glycosidic 
linkages (β-1,3 glucan and β-1,6 glucan) [82, 87]. Chitin is a linear polysaccharide made of more 
than 2000 units of N-acetylglucosamine joined by β-1,4 linkages. Chitin chains are associated in an 
antiparallel mode through hydrogen bonds to form microfibrils composed of about 20-400 chains. 
The linkages of chitin to β-1,3 glucan form a scaffold to which mannoproteins are covalently 
associated. The last types of polysaccharide present in C. albicans cell wall are mannans, O-linked 
and N-linked to the mannoproteins. Mannans are the post-translational modification of cell wall 
proteins [82, 87].  
The cell wall proteins (CWPs), that are covalently attached to the scaffold of structural fibrillar 
polysaccharide, are divided in two classes. The first and the most abundant class of CWPs is linked 
to β-1,6-glucan through a glycosyl phosphatidyl inositol (GPI) remnant, and are called GPI-CWPs. 
The second class of proteins, termed Pir (proteins with internal repeats), are linked directly to the β-
1,3-glucan. An additional class of CWPs does not utilize a covalent attachment for retention in the 
cell wall. These proteins have substrates in the cell wall and remain predominantly cell associated 
[88]. In conclusion, β-glucan and chitin are structural polysaccharides of the inner layer and ensure 
strength and shape to the cell wall. In contrast, mannoproteins form a fibrillar outer layer and the 
mannans, less structured and with low permeability and porosity, prevent the permeability of the 
host attacking molecules and antifungal drugs, but does not influence cells shape (Figure 20) [82].  
The cell wall of C. albicans contributes to the activation of the immune response by the host. It 
contains pathogen-associated molecular patterns (PAMPs) that are recognized, via pattern 
recognition receptors, by the innate immune system as non-self-molecules, triggering a cascade of 
molecular events that will end with a protective response against the fungus [89]. In particular, the 
constituents of the cell wall are highly immunogenic and engage a variety of pattern recognition 
receptors (PRRs) as represented in Figure 21. For example, O-linked mannans are recognized by 
Toll like receptor 4 (TLR4), N-linked mannan by the Mannose Receptor (MR), Galectin-3 and DC-
SIGN. β-1,3-glucan is the major pro-inflammatory mediator and its main PRR is C-type lectin 
Dectin-1, which can collaborate with TLR2. The damage of the mannan layer, with consequential 
exposure of β-1,3-glucan, enhances the strength of the proinflammatory signal [82]. Chitin also 
participates in immune recognition, but the chitin binding receptor was not identified so far [82, 89].  
 
43 
 
 
Figure 20. Structure of Candida albicans cell wall. On the left, section of the C. albicans cell wall 
(Transmission electron micrograph, TEM). On the right scheme showing the architecture of the 
major components of the cell wall [82]. 
 
 
 
 
Figure 21. The cell wall of C. albicans plays a central role in the activation of host immune 
cells. Cell wall components are pathogen-associated molecular patterns (PAMPS) that interact with 
several pattern recognition receptors (PRRs) present on immune cells (for example monocytes, 
macrophages and dendritic cells). This results in the stimulation and production of anti- and pro-
inflammatory cytokines [89]. 
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The Phr family of glucan remodelling enzymes 
 
Cell wall biogenesis of fungi requires three groups of enzymes involved in synthesis, assembly and 
remodelling, namely: synthases, transglycosidases and glycosylhydrolases. The PHR family of C. 
albicans encodes for β-1,3-glucanosyltransferases and is one of the best characterized families of 
glucan remodelling enzymes. The PHR family has high homology with the GEL and GAS families 
of Aspergillus fumigatus and Saccharomyces cerevisiae and together form the GH72 family of the 
Carbohydrate Active Enzyme database (http://www.cazy.org/ [90]). GH72 is a family of enzymes 
unique to fungi [91]. GH72 enzymes in vitro cleave internally a β-1,3-glucan and transfer the newly 
generated reducing end to the non-reducing end of another β-1,3-glucan molecule, forming a β-1,3-
linkage. This results in the elongation of the β-1,3-glucan chains [92-94]. From in vivo analyses of 
several mutants with reduced GH72 activity, it has been proposed that these enzymes contribute to 
the formation of the long and branched β-1,3-glucan that constitutes the scaffold of the fungal wall 
[95]. The crucial role of β-1,3-glucanosyltransferases in the assembly of the cell wall core has been 
recently demonstrated in vivo in S. cerevisiae where the absence of this activity caused the 
conversion of the high molecular weight β-1,3-glucan into a highly polydisperse polymer [93, 96].  
The GH72 enzymes have similar structural characteristics: (i) a signal peptide necessary for the 
targeting of the protein in the secretory pathway, (ii) an N-terminal domain (GH72) with two 
conserved glutamic acid residues essential for enzyme activity and cysteine residues essential for 
the formation of the disulphide bonds, (iii) a linker that connects GH72 domain with the other 
portion of the protein and contains a conserved cysteine in a region usually not conserved, (iv) a 
region with 8 cysteine residues, called Cys-box or X8, present only in a subfamily of GH72 
enzymes, called GH72+ (the subfamily without the Cys-box is called GH72-) [97], (v) a disorder 
region with a cluster of serine residues (PolySer), site for O-mannosylation, (vi) a C-terminal signal 
sequence for GPI attachment.  
In all fungal species so far analysed, the GH72 family of β-1,3-glucanosyltransferases consist of 
four to seven members [91]. The biological significance of this redundancy has been deeply 
investigated in S. cerevisiae that presents five GH72 members (ScGAS1-5). It has been shown that 
different paralogs are expressed at specific stages of the yeast cycle. ScGAS1 and ScGAS5 are 
expressed during vegetative growth and are required for cell wall assembly, whereas ScGAS2 and 
ScGAS4 are repressed during vegetative growth and transcribed in the middle of meiosis where 
they are essential for spore wall formation [93, 97, 98]. Among GH72 family some members have 
been demonstrated to be essential genes, for example AfGEL4 of Aspergillus fumigatus and 
Spgas1+ of Schizosaccharomyces pombe [99, 100].  
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C. albicans PHR family consists of five genes, PHR1, PHR2, PHR3, PGA4 and PGA5. PHR1 and 
PHR2 were the first identified pH-responsive genes in C. albicans [101, 102]. PHR1 expression is 
triggered at pH values higher than 6 whereas PHR2 has the reverse expression pattern. Ambient pH 
is an important parameter that affects the ability of this major fungal pathogen to survive and grow 
within the human body where pH can be slightly alkaline, such as in the bloodstream (pH 7.3), 
close to neutrality such as in organs like kidney, liver and duodenum or acidic as in the stomach 
(pH 2) and vagina (pH 4.5) [93]. Loss of PHR1 induces morphological defects at neutral-alkaline 
ambient pH, the mutant exhibits a round morphology and the inability to support hyphal growth, to 
adhere and invade human epithelia. Moreover, PHR1 null mutants are avirulent in mouse models of 
systemic infection (pH 7.3) and in the model of experimental keratomycosis (pH 7.5) [103, 104]. At 
acidic pH, PHR2 null mutant has the growth and morphological defects of PHR1 mutant at its 
restrictive pH [101, 102] and it is avirulent in the rat model of vaginitis (pH 4.5) [103].  
PGA4 mRNA was detected independently of ambient pH and was upregulated upon in vitro model 
of infection and transiently increased upon yeast-to-hyphal switch [105] PGA4 null mutant does not 
exhibit a defective phenotype: growth rate and sensitivity of the strain to stress inducing and cell 
wall perturbing agents are not affected, indicating that the cell wall is not damaged. Moreover, the 
virulence of the mutant was unchanged with respect to the wild type strain [105]. PHR3 and PGA5 
transcripts are absent or hardly detectable with microarray or Northern hybridization analysis. The 
null mutant of PHR3 does not result in a distinct phenotype, while phenotype of PGA5 null mutant 
was never published [105].  
In Figure 22 a scheme of the domain organization of Phr protein is reported. 
 
 
Figure 22. A. domain organization of the Phr protein family of Candida albicans. The asterisk 
indicates the conserved glutamic acid residues.  B. Percentage of amino acid identity between the 
indicated portion of the N-terminal and C-terminal parts of the proteins. Blast2n was used with the 
filter option for LC region. The values in bold indicate the highest percentage of amino acid 
identity. NS: no similarity. The asterisk indicates the presence of PolyAsn and PolyGlu in Pga5p.  
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Aim of the Project 
 
The Phr family of Candida albicans is a family of five GPI-anchored glycoproteins with 
glucanosyltransferase activity. They catalyse the elongation of β-1,3-glucan and of its branches in 
the fungal cell wall. These enzymes are essential for formation of the core glucan network, for the 
morphological plasticity and adaptability of this pathogen to different ambient pHs. 
The first aim was the investigation of the biochemical properties of three GPI-anchored β-1,3-
glucanosyltransferases of C. albicans, Phr1p, Phr2p and Pga4p. A fluorescent assay for β-1,3-
glucanosyltransferases activity was used to study the catalytic properties of recombinant Phr 
proteins produced in Pichia pastoris.  
The second part of this project was focused on the study of the transcriptional profile of C. albicans 
cells lacking β-1,3-glucanosyltransferase activity. The transcriptional profile of phr1Δ cells during 
induction of hyphal growth was analysed. Despite the defective phenotype of phr1Δ in these 
conditions, the cells maintain their integrity because a complex adaptive response.  
These studies could provide useful information for the development of new therapeutic strategies 
aimed to combine the inhibition of cell wall target together with the compensatory pathways.  
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Main Results 
 
1. Production of soluble and glycosylated forms of Phr proteins 
In order to study the biochemical properties of Phr proteins of C. albicans, they were produced and 
purified as secreted proteins in Pichia pastoris. Since PHR3 and PGA5 genes are weakly or not 
expressed in C. albicans and their products were never detected, we focused only on the study of 
Phr1p, Phr2p and Pga4p. P. pastoris is a suitable host for the expression of proteins that are 
abundantly glycosylated and rich of disulfide bonds as Phr proteins. Moreover, this eukaryotic 
microorganism secretes very few proteins and at a very low level. Thus, the recombinant protein is 
the major product present in the medium and can be easily purified by affinity chromatography on 
Nickel resins, provided that a 6xHis tag is fused to the protein.  
PHR1, PHR2 and PGA4 were cloned into the pHIL-S1 vector for P. pastoris. In order to obtain 
secreted proteins, in each gene the sequences encoding the original N-terminal signal peptide was 
replaced with a signal sequence from P. pastoris. Moreover, the C-terminal signal for GPI 
attachment was substituted by the His-Tag. After sequencing to check the absence of mutations in 
the nucleotide sequence and the proper gene fusion, the recombinant plasmids were used to 
transform P. pastoris strain GS115. The production and secretion of the soluble proteins were 
induced and major bands of 90, 96 and a doublet of 60-66 kDa were detected in the SDS-PAGE 
with the medium of the cells expressing Phr1p, Phr2p and Pga4 respectively. At 48 h of induction 
the protein production was 10 mg for Phr1p, 55 mg for Phr2p and 40 mg for Pga4p for Liter of 
culture. The recombinant proteins were purified from the culture supernatants by Nickel affinity 
chromatography. 
The purified proteins were analysed on SDS-PAGE before and after treatment with PNGase F, an 
amidase that catalyses the cleavage of N-linked oligosaccharides chain. The apparent molecular 
mass of Phr1p, Phr2p and Pga4p upon treatment with PNGase F decreases from about 90, 96 and a 
doublet of 60-66 kDa respectively to about 70, 78 and a single band of about 46 kDa. This result 
indicates that the Phr proteins produced in Pichia pastoris are N-glycosylated. This is in agreement 
with the presence of 3 potential N-glycosylation sites in Phr1p, 4 in Phr2p and 3 in Pga4p. 
However, the predicted molecular weight for the His-tagged polypeptides is 54875 for Phr1p and 
54359 for Phr2p suggesting that the serine-rich region present in these proteins might be target of 
O-mannosylation. On the contrary, the predicted molecular weight of Pga4p is 45164 that is very 
close to the apparent molecular weight of the deglycosylated band, suggesting that the protein is not 
heavily O-glycosylated, in agreement with the lack of a PolySer tract. Moreover, after PNGase F 
treatment, Pga4p doublet migrated as a single polypeptide suggesting that the heterogeneity in the 
apparent molecular weight is due to the N-glycan moiety. 
48 
 
2. Characterization of the catalytic properties of Phr1p, Phr2p and Pga4p 
To analyse the catalytic properties of the recombinant Phr proteins, we used a new fluorescent 
method that is based on the β-1,3-glucanosyltarnsferasis activity of this protein. This activity 
consists of the (i) internal cleavage of the donor substrate, a linear and water-soluble β-1,3-glucan 
(laminarin), (ii) release of the reducing end product, and then (iii) transfer of the remaining portion 
to the non-reducing end of another β-1,3-glucan molecule that functions as an acceptor. In the 
absence of a suitable acceptor, the polysaccharide residue may be transferred to a water molecule 
(hydrolysis). The new fluorescent assay is based on the use of laminarin as substrate and linear 
laminarioligosaccharide of 5 or 6 glucose residues (L5 or L6) as acceptors. The acceptor is 
fluorescently labelled by conjugation of the reducing end to sulforhodamine (L5-SR or L6-SR).  
The reaction mixture was in solution and contained the Phr enzyme, laminarin as donor and L5-SR 
or L6-SR as acceptors. The elongated products resulting from the transferase reaction are 
fluorescent and insoluble in 66% ethanol, whereas the L5-SR or L6-SR molecules are readily 
soluble. After the removal of unreacted L5-SR or L6-SR with 66% ethanol, the fluorescence of the 
elongated products is measured. 
The fluorescent assay was used to test the effect of different pH on the transglycosylating activity of 
the Phr proteins in buffers of different pH but constant ionic strength. The pH-dependent activity 
curves showed their maximum at different pH values. Phr1p was most active at pH about 5.8 with a 
sharp decrease of activity at pH higher than 6.5, while the highest activity of Phr2p was at pH 3. 
The partial overlap of the two curves indicated that both enzymes have activity also between 4 and 
5.5. Regarding the temperature optimum, Phr1p and Phr2p activity had similar curve and an 
optimum of temperature at 30°C. This assay was used to determine the acceptor and donor substrate 
specificity on a panel of polysaccharides and laminarioligosaccharides of increasing length. Phr1p 
and Phr2p used exclusively β-1,3-glucan or cell wall glucan as donor and laminarin-derived 
oligosaccharides as acceptor.  
Unexpectedly, Pga4p was inactive in all the condition tested with the fluorescent assay, suggesting 
that Pga4p is an inactive member of the Phr family and it probably turned into a structural 
mannoprotein.  
 
3. Stress response to Phr1p deficiency  
PHR1 is expressed at neutral-alkaline pH in C. albicans in both yeast and hyphal forms. In the 
transition from yeast to hyphae at 37°C, pH 7.5, the wild type cells emit germ tubes that elongate 
and form thin hyphae whereas phr1Δ cells exhibit short and large germ tubes, aberrant septa and 
never elongate to form hyphae. These effects clearly indicate a defect in the polarized growth and 
cell wall formation. β-1,3-glucan decreases and chitin level increases indicating the presence of a 
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wall stress response. We exploited the pH-conditional nature of a PHR1 null mutant to analyse the 
genome-wide transcriptional changes (DNA microarray analysis) in response to absence of β-1,3-
glucan remodelling during the transition from yeast to hyphae.  
Two classes of differentially modulated genes were identified: (i) Class 1: genes whose transcript 
levels were more abundant in the mutant in comparison with the wild type, (ii) Class 2: genes 
whose transcript levels were less abundant in the mutant in comparison with the wild type. 
Among Class 1, the functional category of genes related to the cell wall was the largest. We found 
in phr1Δ cells increase of transcript level for 19 proteins included in the functional category cell 
wall/surfaces. Among this we can find a cross-linking enzyme (CRH11), two chitin synthases 
(CHS2 and CHS8), a β-1,3-glucanase (XOG1) and several GPI anchored proteins (for example 
PGA23, PGA13, PGA6 and PGA54). In the mutant the chitin level increased, as the level of 
transcript for CHS2 and CHS8. To evaluate the role of chitin synthases in the adaptive response of 
the phr1Δ mutant, a PHR1 homozygous null mutation was introduced into strains lacking CHS2, 
CHS8, CHS2 and CHS8 or CHS3. During the induction of hyphal growth, the double mutant CHS3-
PHR1 presented a defective phenotype, resulting in lethality in particular conditions. Thus, CHS3-
mediated chitin synthesis is essential for phr1Δ viability.  
PHR2 was repressed during induction of hyphal growth and none of the other three members of the 
PHR family was up-regulated indicating that no transcriptional-mediated cross compensatory 
mechanism exists for the paralogs.  
Up-regulation of DNA replication genes was seen in phr1Δ mutant especially in the first time points 
during hyphal indication. We analyzed by flow cytometry the DNA distribution profile of wild type 
and phr1Δ mutant strains undergoing the transition from yeast to hyphae. These experiments 
confirmed that the mutant enters early in into S-phase in comparison with wild type and also the 
mutant presented an enrichment of cells at G2/M.  
β-1,3-glucan remodelling is important to sustain the hyphal development and its absence activates 
an adaptive response to preserve cell integrity. Phr1p and Chs3p are potential targets for combined 
treatments of C. albicans infections. 
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Conclusions and Future Prospects 
 
The synthesis, assembly and hydrolysis of the fungal wall require three groups of enzymes: 
synthases, transglycosylases and glycosylhydrolases. The function of these enzymes is tightly 
regulated by the machinery controlling polarized growth and in turn affects the morphological 
development of fungi. Transglycosylases are responsible for the formation of a branched β-1,3-
glucan structure on which other components are linked in a layered organization. The structure and 
architecture of the fungal wall undergo dynamic changes during the fungi life cycle, in response to 
environmental signals and damages that may affect cell integrity. Moreover, in fungal pathogens, 
the cell wall is the primary interface with the host. Surface properties are crucial for the 
establishment and progression of an infection and also for the interaction with the immune cells. 
Thus, the cell wall is rich of ideal targets for new antifungal agents, candidates for vaccines or 
immune modulators.  
Phr family is a component of the family 72 of Glycosyl hydrolases (GH), which is unique to fungi. 
These enzymes, in vitro, catalyse the internal cleavage of a β-1,3-glucan, the transfer of the new 
reducing end to the non-reducing end of another β-1,3-glucan (acceptor) with the formation of a 
new β-1,3-glycosidic linkage. This reaction results in the elongation of the acceptor. In vivo this 
activity is required for morphogenesis and virulence and in some fungal species is essential for 
viability 
This work was focused on the study of the catalytic properties of some members of the Phr family 
of Candida albicans, Phr1p, Phr2p and Pga4p. The three Phr proteins were expressed and purified 
as soluble proteins in the eukaryotic system Pichia pastoris. A sensitive fluorescent assay for β-1,3-
glucanosyltransferase activity was applied on the recombinant proteins. A panel of different 
possible donor and acceptor were tested. The strict substrate specificity of Phr proteins indicates 
that they are typical homotransglycosylases specialized in cleaving and re-joining molecules of β-
1,3-glucan. The optimal reaction temperature was 30°C for both enzymes, while the pH optimum 
was 5.8 for Phr1p and 3 for Phr2p. The overlap of the pH dependent curves shows that two enzymes 
have relevant activity also between 4 and 5.5, suggesting that they can buffer reciprocally their 
function during pH transition. The presence of different enzymes with same activity at different pH 
enable Candida albicans to growth over the whole spectrum of physiological pH of the host niches 
of the human body that vary from acidic (stomach, vagina) to neutral (kidney, duodenum) or 
slightly alkaline (blood).  
Surprisingly, Pga4p showed no transglycosylases activity in all the conditions tested, consequently 
we proposed that Pga4p turned into a structural cell wall protein. The absence of any relevant 
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phenotype in pga4Δ null mutant suggests that the potential structural function of Pga4p in not 
fundamental for Candida albicans. 
In the second part of the project, a transcriptional profile of phr1Δ mutant in the transition from 
yeast to hyphae was analysed, resulting in the identification of genes involved in the response of 
cell wall stress induced by the absence of β-1,3-glucanosyltransferase activity. We produced a 
series of double mutants for chitin synthases (CHS) genes and PHR1, finding the existence of 
synthetic lethality between PHR1 and CHS3. 
Since cell wall components are highly immunogenic, essential for fungi life and absent in humans, 
the cell wall represents a target of great scientific and biomedical interest for the development of 
new agents for therapy and prophylaxis. Therapies of candidiasis rely on the use of a still limited 
armamentarium of drugs that target ergosterol (amphotericin B and azoles) or the synthesis of β-
1,3-glucan (echinocandins). However, a compensatory response can generates tolerance to these 
drugs.  
The results from these two projects provide new insights in C. albicans glycobiology This 
knowledge can be used in the future for applications such as the search of β-1,3-
glucanosyltransferase inhibitors to be used alone or in combination with inhibitors of the 
compensatory pathway activated by cell wall stress. 
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Abstract 35 
 36 
The receptor for the advanced glycation end products (RAGE) is a type I transmembrane 37 
glycoprotein belonging to the immunoglobulin superfamily and binds a variety of unrelated ligands 38 
sharing a negative charge. Most ligands bind to the extracellular V or VC1 domains of the receptor. 39 
In this work, V and VC1 of human RAGE were produced in the methylotrophic yeast Pichia 40 
pastoris and directed to the secretory pathway. Fusions to a removable C-terminal His-tag 41 
evidenced proteolytic processing of the tag by extracellular proteases and also intracellular 42 
degradation of the N-terminal portion of V-His. Expression of untagged forms was attempted. 43 
While native VC1 was secreted into the culture medium and was functionally active in binding 44 
AGEs, the V domain was retained intracellularly. The glycosylation state of VC1 was analyzed by 45 
mass spectrometry and peptide-N-glycosidase F digestion. Like RAGE isolated from mammalian 46 
sources, the degree of occupancy of the N-glycosylation sites in VC1 was full at Asn25 and partial 47 
at Asn81 which was also subjected to non-enzymatic deamidation. A simple procedure for the 48 
purification to homogeneity of VC1 from the medium was developed. The folded state of the 49 
purified protein was assessed by thermal shift assays. Recombinant VC1 showed a remarkably high 50 
thermal stability as compared to the protein expressed in bacteria. Our in vivo approach indicates 51 
that the V and C1 domains constitute a single folding unit. The stability and solubility of 52 
glycosylated VC1 may be beneficial for future in vitro studies aimed to identify new ligands or 53 
inhibitors of RAGE. 54 
 55 
Keywords: Receptors - RAGE - Immunoglobulin superfamily – Pichia pastoris – protein N-56 
glycosylation – deamidation 57 
 58 
 59 
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Introduction 61 
The receptor for the advanced glycation end products (RAGE) is a protein unique to mammals. In 62 
humans, it is expressed at low levels in many cell types, in particular leukocytes, dendritic cells, 63 
endothelial cells, smooth muscle cells, neurons and microglia and is  abundant in the lung [1]. This 64 
receptor is important for human biology. It promotes neurite outgrowth, differentiation and 65 
migration in the nervous system, and is involved in bone metabolism and lung homeostasis [1]. It 66 
contributes to the inflammatory response [2] and participates to innate and adaptive immunity, 67 
where the activation of human RAGE (hRAGE) leads to the production of reactive oxygen species 68 
(ROS). Furthermore, hRAGE is involved in the pathogenesis of several diseases. Thus, hRAGE 69 
plays two opposing roles, one beneficial for human biology and one that promotes the disease 70 
establishment and progression.  71 
High levels of hRAGE and its ligands lead to several dysfunctions through the sustained activation 72 
of different signal transduction pathways depending on cell type, context and ligand. The signaling 73 
pathways include (i) the p21ras/mitogen-activated cascade of protein kinases (MAPKs) such as 74 
ERK1/2 and the stress-activated kinases (JNK and p38) and  (ii) the JAK/STAT pathway, resulting 75 
in the nuclear translocation of NF-B and activation of transcription of inflammatory genes, of 76 
RAGE gene itself and of the interferon-stimulated response, (iii) the cdc42/rac pathway that is 77 
involved in cell growth and migration, and (iv) the NADPH oxidase pathway that leads to ROS 78 
formation [1, 2]. Sustained activation of RAGE signaling can result in cell damage as in 79 
complications of diabetes such as cardiovascular disorders, atherosclerosis, nephropathies and 80 
chronic inflammation. For these reasons, various studies indicate that antagonizing RAGE 81 
activation, by use of inhibitors or through binding to soluble ectodomain (sRAGE), has potential 82 
therapeutic effects in several inflammatory-based diseases including Alzheimer disease [3, 4]. 83 
Small molecules acting as RAGE antagonists have been recently reported and a Pfizer compound 84 
(PF-04494700) has reached a phase II clinical trial [3-5]. 85 
hRAGE is a type I transmembrane glycoprotein of 404 amino acids, a member of the  86 
immunoglobulin (Ig) superfamily and functionally and structurally similar to cell adhesion 87 
molecules [6, 7]. hRAGE contains a 22 residue signal peptide and an extracellular portion that 88 
comprises a variable (V) and two constant (C1 and C2) Ig-like domains. A single transmembrane 89 
domain connects the V-C1-C2 segment to a short C-terminal tail that is responsible for intracellular 90 
signaling. hRAGE binds a wide spectrum of ligands [8], the majority of which are: AGEs, i.e. 91 
products generated by the non-enzymatic glycation and subsequent oxidation of proteins, amyloid-92 
-peptide and -sheet fibrils and members of the S100/calgranulin protein family [9]. Additional 93 
ligands include: extracellular matrix proteins, such as collagens I and IV, Mac-1 (member of the 2-94 
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integrin family), the High Mobility Group protein Box-1 (HMGB-1 or amphoterin) which is a 95 
prototypic Damaged-Associated Molecular Pattern (DAMP) [6], the lipopolysaccharide of bacterial 96 
walls (LPS), the complement component C1q [10], chondroitin sulfate and heparan sulfate [11, 12] 97 
and nucleic acids [13]. hRAGE ligands do not share sequence or structural similarity but all display 98 
a highly negative charge at neutral pH and the tendency to oligomerize [14]. The 3D-structure of 99 
the RAGE extracellular portion (V-C1-C2), of VC1 and V, has been determined, providing an 100 
insight into the molecular mechanism of RAGE activation [14]. Most hRAGE ligands bind to the 101 
highly basic V domain through electrostatic and hydrophobic interactions. Due to its peculiar 102 
binding properties, RAGE is also defined as a pattern-recognition receptor. A model of RAGE 103 
activation proposes that RAGE molecules preassemble in the plane of the membrane and this 104 
potentiates signaling after the binding of the ligand to the V domain [2]. Moreover, two RAGE 105 
molecules are also able to associate in head-to-head fashion possibly mediating the interaction 106 
between cells similarly to adhesion proteins (homophilic adhesion).  107 
We are interested in studying the binding of hRAGE to AGEs, since the RAGE-AGE axis is crucial 108 
in the etiology of many diseases. Indeed, the formation of AGEs is accelerated in the presence of 109 
hyperglycemia and oxidative stress (for a review, see [15]). In this work, we probed the expression 110 
of V and VC1 in the lower eukaryote Pichia pastoris. This microorganism has an efficient 111 
apparatus of protein glycosylation, folding and secretion that may be beneficial for the expression 112 
of naturally secreted glycoproteins. In addition, glycosylation, together with the formation of 113 
disulfide bonds, confers stability to proteins and also improves their solubility, properties that may 114 
favor in vitro studies on the protein biophysical properties. To our knowledge, the expression of the 115 
isolated V and VC1 domains in a eukaryotic system has not been attempted to date, although P. 116 
pastoris proved to be an appropriate host for the expression of the full ectodomain [16]. Here, we 117 
report the expression/secretion of VC1 and V domains of hRAGE in P. pastoris. A protocol for 118 
VC1 purification to homogeneity from the culture medium, the analysis of its glycosylation profile, 119 
the improved quality of the protein in comparison to the form produced in bacteria and the proof of 120 
its functionality are presented.   121 
 122 
Materials and methods 123 
 124 
Strains and growth conditions 125 
 126 
The E. coli DH5 strain was used for DNA manipulation. P. pastoris GS115 strain (his4) 127 
(Invitrogen) was used for the heterologous expression of hRAGE domains. The GS115-sub2 strain, 128 
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inactivated in the gene encoding the major secreted subtilisin-like protease, was kindly provided by 129 
Dr. Michel Monod (Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland). P. pastoris 130 
cells were routinely propagated on plates of YPDA (1% yeast extract, 2% peptone, 2% glucose and 131 
2% agar) at 30 °C.  To induce the expression of recombinant proteins, His+ Muts cells were shifted 132 
from Buffered Glycerol-complex Medium (BMGY) (1% yeast extract, 2% peptone, 1% glycerol, 133 
1.34% YNB, 4x10-5% biotin, 0.1 M potassium phosphate, pH 6.0) to Buffered Methanol-complex 134 
Medium (BMMY) (1% yeast extract, 2% peptone, 0.5% methanol, 1.34% YNB, 4x10-5% biotin, 0.1 135 
M potassium phosphate, pH 6.0) according to the manufacturer’s instructions. Alternatively, MGY 136 
and MMY media, having the same composition as above but without potassium phosphate buffer, 137 
were used. Cells were routinely grown in flasks at 28 °C under strong agitation and growth was 138 
monitored through the increase in optical density at 600 nm (OD600). 139 
 140 
Construction of the expression plasmids 141 
 142 
Recombinant plasmids for integrative recombination in P. pastoris were obtained by cloning XhoI -143 
digested PCR fragments into the XhoI site of pHIL-S1 (Invitrogen), to generate in-frame fusions 144 
with the secretion signal of P. pastoris PHO1, encoding an extracellular acid phosphatase. PCR was 145 
carried out using as a template pET-15b-VC1243 [17], harboring the cDNA encoding a portion of 146 
hRAGE (residues 23-243), high-fidelity Fusion DNA polymerase (NEB) and appropriate primers 147 
(Table 1). The DNA fragments encoding VC1233 and VC1233-His were obtained using VC-148 
For/VC233-Rev and VC-For /VC233His-Rev oligonucleotide pairs, respectively. Similarly, the 149 
DNA encoding V121 and V121-His were obtained using the primer pairs VC-For/V121-Rev and VC-150 
For/ V121His-Rev. Both PCR products and the digested vector were gel-purified before ligation. 151 
Screening of the transformants was performed by colony PCR using 5’-AOX1/VC233-Rev and 152 
VC-For/3’AOX1 for VC1233, 5’-AOX1/VC233His-Rev and VC-For/3’AOX1 for VC1233-His, 5’-153 
AOX1/V121-Rev and VC-For/3’AOX1 for V121, 5’-AOX1/V121HIS-Rev and VC-For/3’AOX1 for 154 
V121-His (Table 1). Recombinant plasmid DNA, named pHIL-S1- VC1233, pHIL-S1- VC1233-His, 155 
pHIL-S1-V121 and pHIL-S1-V121-His, were purified from positive clones. The correct orientation, 156 
the in-frame fusion, and the absence of random mutations in the inserts were verified by DNA 157 
sequencing (BMR Genomics, Padova, Italy).  158 
 159 
Transformation of P. pastoris and expression of recombinant forms  160 
 161 
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Plasmids, linearized with BglII, were transformed into P. pastoris cells using the “EasyComp” 162 
chemical transformation method (Invitrogen). Selection of His+ transformants and screening for 163 
Muts phenotype were performed as previously described [18]. To induce the expression of the 164 
recombinant proteins, the positive clones were grown overnight at 28 °C in 10 ml of glycerol-165 
containing medium (BMGY or MGY) under strong agitation and at a ratio between volume of 166 
culture and capacity of the flask of 1:10. Then, appropriate amount of cells were collected and 167 
transferred in methanol-containing medium (BMMY or MMY) in order to obtain an initial OD600 of 168 
1. Growth was monitored by increase of OD600. Fresh methanol was added daily to 0.5% (v/v) final 169 
concentration. To monitor protein expression, supernatants from 1ml-aliquots of culture, withdrawn 170 
at intervals after induction, were obtained by centrifugation, flash-frozen and stored at –20 °C until 171 
analysis by SDS-PAGE. Total protein extracts from flash-frozen cell pellets were prepared as 172 
previously described [19]. At least three clones were analyzed per construct. 173 
 174 
Purification of recombinant VC1 175 
 176 
For protein small-scale purification, 80 ml-culture of induced P. pastoris cells was centrifuged at 177 
4,000 × g for 10 min and the supernatant was filtered through cellulose nitrate filters (1.2 m pore 178 
size, Sartorius) to remove residual cells and debris. After dialysis (Spectra/Por membranes, cut-off 179 
6-8,000) at 4 °C for 16 h against 10 mM Na-acetate pH 5.0, the sample was applied to a cation-180 
exchange RESOURCE S column (1.6 x 15 cm; GE Healthcare) connected to an ÄKTA-FPLC 181 
system (GE Healthcare) and equilibrated with 10 mM Na-acetate pH 5.0. The column was washed 182 
with the same buffer until the A280 reached the baseline. The protein was then eluted with 10 mM 183 
Na-acetate pH 5.0 containing 1M NaCl. The fractions containing the recombinant protein, as judged 184 
by SDS-PAGE, were pooled and chromatographed on a Superdex 75 (10/30) gel filtration column 185 
(GE Healthcare) equilibrated with 10 mM Na-acetate, pH 5.0, 1M NaCl. Fractions were added with 186 
trichloroacetic acid and precipitated proteins were analysed by SDS-PAGE. To estimate the 187 
molecular weight of VC1, standard proteins (BSA dimer, 132 kDa; BSA monomer, 66 kDa; 188 
carbonic anhydrase, 29 kDa; cytochrome c, 12.3 kDa) were separated under the same conditions.  189 
For a large-scale purification, the supernatant from 400 ml-culture was obtained as described above. 190 
After concentration to ~ 30 ml by ultrafiltration using a 30,000 cut-off membrane and dialysis 191 
against 10 mM Na-acetate, pH 5.0, for 16 hours at 4°C, the solution was applied to a cation-192 
exchange Mono S HR5/5 column (GE Healthcare) equilibrated with 10 mM Na-acetate, pH 5.0 and 193 
connected to an ÄKTA-FPLC system (GE Healthcare). After column washing with the same buffer, 194 
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elution was performed with a 0 -1 M NaCl gradient in the same buffer. Fractions were analyzed by 195 
SDS-PAGE.  196 
 197 
Electrophoresis and immunoblotting procedures 198 
 199 
P. pastoris culture supernatants and chromatographic fractions were denatured by boiling for 3 min 200 
in SDS sample buffer [0.0625 M Tris-HCl, pH 6.8, 2.3% (w/v) SDS, 5% (v/v) -mercaptoethanol, 201 
10% (w/v) glycerol and 0.01% Bromophenol blue]. SDS-PAGE was performed on 13% or 16% 202 
polyacrylamide gels (14 ×16 cm or 8 × 10 cm). Proteins bands were stained by Coomassie Blue 203 
Biosafe (Bio-Rad, USA). After Western blotting, immunodecoration was carried out using a 204 
1:1,000 dilution of an affinity-purified goat polyclonal antibody raised against an N-terminal 205 
peptide of hRAGE (N-16, Santa Cruz Biotechnology) or a 1:10,000 dilution of a monoclonal anti-206 
poly(His) antibody (mAb) (Novagen) in combination with the appropriate peroxidase-conjugated 207 
anti-goat (Sigma) or anti-mouse secondary antibodies (Jackson Laboratories). Bound antibodies 208 
were revealed by the LiteAblot®PLUS Western blotting detection reagent (Euroclone, Italy). 209 
Quantification of the intensity of VC1 bands on immunoblot was performed using a ChemiDoc MP 210 
system (Bio-Rad). The level of VC1 accumulated in the medium was determined by comparison to 211 
a calibration curve obtained using known amounts of VC1 overproduced in E. coli (60-240 212 
ng/lane). VC1 purification from E. coli was previously described [20]. 213 
 214 
Treatment with peptide N-glycosidase F 215 
 216 
N-peptide glycosidase F (PNGase F) treatment was performed on either concentrated culture 217 
supernatant or purified proteins. In order to remove the N-linked oligosaccharide chains, 0.5-1 g of 218 
protein (5 l) were denatured at 95 °C for 3 min in the presence of 0.2% SDS. Then, samples were 219 
diluted to 50 l and their composition was adjusted to 0.02 % SDS, 1% Triton X-100, 10 mM 220 
EDTA, 1 mM phenylmethansufonyl fluoride (PMSF), 50 mM Na-acetate, pH 5.5. Each sample was 221 
halved and one aliquot was used as a control while the other was added with 0.3 U of PNGase F 222 
(Roche). The samples were incubated at 37 °C under gentle agitation for 16 h before SDS-PAGE 223 
analysis. 224 
 225 
VC1 digestion  226 
 227 
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Bands excised from gels were digested accordingly to an established procedure [21]. Briefly, after 228 
destaining with 50% acetonitrile, 25 mM ammonium bicarbonate, gel pieces were incubated at 56 229 
°C for 60 min with 10 mM dithiothreitol in 50 mM ammonium bicarbonate for reduction of 230 
disulfide bonds and then treated with 55 mM iodoacetamide in 50 mM ammonium bicarbonate at 231 
room temperature for 45 min, in the dark, to alkylate cysteine residues. Gel pieces were then rinsed 232 
with 50 mM ammonium bicarbonate and incubated in 100% acetonitrile for dehydration. About 1 233 
μg sequencing-grade trypsin (Roche Diagnostics S.p.A, Monza, Italy) dissolved in 50 mM 234 
ammonium bicarbonate was added to each gel fragment. After overnight digestion at 37 °C, the 235 
liquid phase was withdrawn and gel pieces were washed first with 30% acetonitrile, 3% 236 
trifluoroacetic acid for 10 min, and then with 100% acetonitrile for 10 min. The three solutions were 237 
pooled and dried on a vacuum concentrator. Tryptic peptide mixtures were then suspended in 15 μl 238 
0.1% formic acid for mass spectrometry analysis. 239 
 240 
Mass spectrometry analyses 241 
 242 
Peptides (5 µl) were injected on a reverse phase C18 HALO PicoFrit column (75 µm × 10 cm, 2.7 243 
µm particle size, 100 Å pore size, New Objective, USA) using an UltiMate 3000 RSLCnano liquid 244 
chromatographic system online with an LTQ-Orbitrap mass spectrometer (Thermo Scientific, 245 
USA). Peptide separation was performed by a 35% acetonitrile linear gradient in 0.1% formic acid 246 
over 40 min, at flow rate of 300 nl/min. Eluting peptides were electrosprayed using a nanoESI 247 
source (Thermo Scientific, USA). The instrument operated in data-dependent mode to acquire both 248 
full MS and MS/MS spectra. Full MS spectra were acquired in profile mode by the FT analyzer in a 249 
scan range 300–1500 m/z, using capillary temperature of 220 °C, AGC 5 × 105 and resolution 250 
100,000 FWHM at m/z 400. Tandem mass spectra were acquired by the linear ion trap (LTQ) for 251 
the 3 most intense ions. MS/MS spectra acquisition was set as follows: centroid mode, resolution 252 
15,000, precursorions isolation width of 2.5 m/z, AGC target 1 × 104 and normalized collision 253 
energy 30 eV. Dynamic exclusion was enabled to reduce redundant spectra acquisition: two repeat 254 
counts, 30 s repeat duration, 45 s exclusion duration. Monoisotopic precursor selection was enabled; 255 
singly and unassigned charged ions were not fragmented. Instrument control and spectra analysis 256 
were operated by the software Xcalibur 2.0.7 and Chromeleon Xpress 6.80. 257 
 258 
Peptide identification 259 
 260 
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The software Proteome Discoverer (v 1.3, Thermo Scientific) was used to extract peaks from 261 
spectra and to match them to a dedicate protein database containing: (i) the sequences of VC1 and 262 
VC1-His preproteins obtained from the translation of the cDNA cloned in P. pastoris  263 
(Supplementary file 1) and (ii) P. pastoris proteome (8073 entries downloaded from UniProt 264 
database on 27.06.2014). Trypsin was selected as the cleaving protease, admitting a maximum of 265 
two missed cleavage sites. Peptide and fragment ions tolerance were set to 5 ppm and 0.3 Da, 266 
respectively. Cysteine carbamidomethylation was set as fixed modification and methionine 267 
oxidation was allowed as variable modifications. In PNGase F-treated samples, Asn-Asp 268 
conversion was also allowed as additional variable modification (monoisotopic delta mass equal to 269 
0.984 Da). Low-confidence identifications were filtered out by selecting peptide confidence < 0.05 270 
and at least 2 peptides/protein. Regarding the analysis of glycosylated peptides, the extracted ion 271 
chromatograms (XICs) of selected m/z values, corresponding to peptides of interest, were manually 272 
obtained from Quan Browser (Xcalibur software version 2.0.7) using tolerance 5 ppm and mass 273 
precision 5 decimals. 274 
 275 
Filter binding assay 276 
 277 
AGE-bovine serum albumin (AGE-BSA) was produced as described previously [22]. Serial 278 
dilutions of solutions of BSA, and AGE-BSA (BSA modified with ribose, also named BSA-R) were 279 
spotted on a nitrocellulose membrane. After saturation with 5% (w/v) dried milk powder in TBS-T 280 
(10 mM Tris-HCl, pH 7.4, 166 mM NaCl, 0.05 %  Tween-20), the membrane was incubated over 281 
night at 4 °C with purified VC1 (5 g/ml) in 20 mM HEPES, pH 7.1, 100 mM NaCl. The 282 
membrane was then washed twice with TBS-T for 10 min. To identify bound VC1, the membrane 283 
was incubated with a 1:1000 dilution of anti-RAGE antibody in TBS-T-BSA (5% BSA in TBS-T). 284 
After washing the membrane four times with TBS-T for 10 min and incubation with a 1: 80,000 285 
dilution of secondary peroxidase-conjugated anti-goat IgG in TBS-T, immunocomplexes were 286 
detected as described above. 287 
 288 
Thermal stability analysis 289 
 290 
0.5 mg/ml purified proteins were added with the fluorescent dye SYPRO Orange (Sigma-Aldrich), 291 
according to the manufacturer’s instructions in 10 mM Na-acetate, pH 5.0 containing no salt, 150 or 292 
300 mM NaCl. 25 µl-aliquots were loaded in a multi-well plate (MJ white, Bio-Rad) and subjected 293 
to a 15 °-99 °C temperature ramp at a rate of 2 °C/min using the real time PCR apparatus 294 
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MiniOpticon MJ Mini (Bio-Rad). The intensity of fluorescence emission in the range 540-700 nm 295 
was recorded after each 0.2 °C increment. Each protein under each ionic strength condition was 296 
analyzed in triplicate. Melting temperature of the proteins (Tm) was identified as the inflection point 297 
of the plot of the fluorescence emission as a function of temperature and was determined as the 298 
maximum of the first derivative of such a function. 299 
 300 
Results 301 
 302 
Expression of His-tagged VC1 fragment of hRAGE reveals proteolytic activities in the medium and 303 
inside P. pastoris cells  304 
 305 
To produce and secrete the VC1 and V domains in P. pastoris, the human N-terminal signal peptide 306 
was replaced by the signal sequence of P. pastoris PHO1 encoding the extracellular acid 307 
phosphatase Pho1p (see scheme in Fig. 1). Expression was driven by the strong methanol-inducible 308 
promoter AOX1. VC1 and V domains were tagged with a thrombin cleavable hexa-His sequence at 309 
the C-terminus to facilitate purification and allow the removal of the tag to avoid interference in 310 
binding studies (see Fig. 1). Two bands of about 34 and 36 kDa were detected by immunoblot with 311 
anti-RAGE antibody in the medium of P. pastoris cells expressing VC1-His, but these polypeptides 312 
did not react with anti-poly(His) mAb, indicating that the tag was removed (Fig. 2A). To ascertain 313 
whether the tag was cleaved inside the cell or after secretion, we analyzed cell extracts. Both anti-314 
RAGE antibody and anti-poly(His) mAb recognized the two bands, indicating that the tag was 315 
removed outside the cell (Fig. 2A). Interestingly, in the cell extracts an additional band of about 30 316 
kDa was detected exclusively by anti-poly(His) antibody suggesting that this protein is devoid of 317 
the N-terminal epitope recognized by the anti-RAGE antibody (Fig. 2A). This N-terminal truncated 318 
form likely represents an intermediate of VC1 degradation that probably occurs at the level of the 319 
ER.  320 
MS analysis of the secreted VC1 protein did not detect the C-terminal His-tag (data not shown) 321 
(Supplementary file 1). These results are consistent with the hypothesis that the His-tag is 322 
proteolytically cleaved by an extracellular protease. To verify if the tagged VC1 forms were 323 
substrates of Sub2p, the major secreted subtilisin-like protease of P. pastoris [23], we analyzed the 324 
production of the tagged VC1 in a sub2-deficient strain (Fig. 2B). VC1-His forms were detected in 325 
cell extracts but only the forms devoid of the tag were present in the medium suggesting that a 326 
secreted protease other than Sub2p is responsible of the proteolytic cleavage of the tag.  327 
 328 
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The histidine tagged V domain of hRAGE does not properly fold when expressed in P. pastoris 329 
 330 
Fusion of the V domain to the His-tag (see Fig. 1), resulted in the accumulation in P. pastoris cells 331 
of polypeptides of about 20, 21 and 16 kDa recognized by the anti-poly(His) mAb (Fig. 3, left 332 
panel). Treatment with PNGase F indicated that such recombinant products represent different 333 
glycosylated forms of the V protein (data not shown). These proteins reached a maximal level after 334 
48 h induction (Fig. 3, left panel). None of these polypeptides reacted with the anti-RAGE antibody 335 
(Fig. 3, right panel), indicating that the N-terminal epitope was removed, as described above for the 336 
30 kDa form of VC1.  Moreover, no V-His forms were detected in the culture supernatant (data not 337 
shown). Despite several attempts to overcome the block of secretion by employing a mixed 338 
induction regimen or lowering the growth temperature, no secretion of V-His was observed. 339 
These results strongly indicate that the isolated V-His domain is incorrectly folded in P. pastoris 340 
and likely undergoes degradation in the ER and/or in the vacuole.   341 
 342 
Expression and secretion of the VC1 domain of hRAGE in P. pastoris 343 
 344 
VC1 and V domains were subsequently expressed in P. pastoris without a tag (see scheme in Fig. 345 
1). No specific bands of the V domain were detected in the culture supernatant even after 30-fold 346 
medium concentration, by SDS-PAGE and Coomassie staining or by immunoblotting (data not 347 
shown). No further attempts to secrete this protein were performed and the focus was placed on 348 
untagged VC1. The growth kinetics of cells expressing VC1 is shown in Fig 4A. After the shift to 349 
methanol containing medium (time zero), cells grew exponentially for about 24 h and then the 350 
growth rate progressively decreased. Two bands of ~34 and ~36 kDa were detected by SDS-PAGE  351 
analysis in the culture medium at 24, 48 and 72 h after induction but not in the medium of non-352 
induced cells (Fig. 4B) and cross-reacted with anti-RAGE antibody (Fig. 4C). The two recombinant 353 
VC1 forms were named p34 and p36. Mass spectrometry (MS) analysis confirmed the identity of 354 
the two bands as proteins forms with the expected human VC1 sequence, as reported in 355 
Supplementary File 1, with coverage of 77.36% for p36 and 81.60% for p34. Moreover, the 356 
identification of the RAQNITAR peptide as the N-terminal end indicated that the cleavage of the 357 
Pho1p signal peptide occurs at the expected site. 358 
VC1 levels in the medium were quantified, as described in the Materials and Methods.  The highest 359 
level, about 6 mg of total VC1 per liter culture medium, was reached after 72 h of induction, a time 360 
concomitant with the growth arrest (Fig. 4A). Protein production was highly reproducible among 361 
different recombinant clones. No substantial improvement in protein production was obtained by 362 
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lowering the growth temperature to 23 °C or using unbuffered media (MMY instead of BMMY). 363 
Therefore, buffered rich medium (BMMY) and 28 °C were chosen as standard growth conditions.  364 
 365 
VC1 is N-glycosylated in P. pastoris and the site occupancy mimics the human one  366 
  367 
p34 and p36 polypeptides displayed a lower electrophoretic mobility compared to VC1expressed in 368 
E. coli (p32Ec), a sign of the presence of post-translational modifications. Since two potential N-369 
glycosylation sites are located in the V domain, VC1 was subjected to treatment with PNGase F, an 370 
enzyme that removes the N-linked oligosaccharide chains and concomitantly converts the 371 
asparagine residue (Asn) into an aspartic acid (Asp). Upon deglycosylation, p36 and p34 were no 372 
longer detected and a polypeptide of ~32 kDa appeared. This indicates that VC1 is N-glycosylated 373 
in P. pastoris and that the observed mobility differences are due to heterogeneity of the glycan 374 
moiety (Fig. 5). These results are compatible with the presence of 1 and 2 “core” type N-linked 375 
oligosaccharide chains in p34 and p36, respectively.  376 
hRAGE contains two potential N-glycosylation sites, or “sequons” [consensus sequence: NX(S/T) 377 
where X≠P], namely Asn25 (NIT) and Asn81 (NGS) where the numbering refers to the precursor 378 
protein. Asn25 is reported to be fully occupied in native hRAGE whereas Asn81 is only partially N-379 
glycosylated and is susceptible to deamidation that converts it into an aspartic acid [24]. The two 380 
sites correspond to Asn26 and Asn82 in the recombinant precursor forms s but for the sake of 381 
clarity here they will be referred to the numbers adopted for the human pre-protein. 382 
To address the question whether such sites are N-glycosylated in P. pastoris, we mapped the Asp 383 
residues generated by the enzymatic removal of N-linked chains by MS analysis. Tryptic digests of 384 
gel-purified VC1 were analyzed by nano LC-MS/MS. Peptides were identified by database 385 
matching and the intensity of the peaks corresponding to the tryptic peptides containing the 386 
deamidated Asn25 and Asn81 were quantified relative to their unmodified form. The extent of p34 387 
and p36 glycosylation was evaluated on the tryptic peptides RAQN25ITAR and 388 
VLPN81GSLFLPAVGIQDEGIFR. Their natural, non-glycosylated forms were expected to appear 389 
in MS spectra at theoretical m/z values of 465.26740 and 1121.61512, respectively, for the double 390 
charged ions. In the presence of Asn to Asp conversion, RAQD25ITAR and 391 
VLPD81GSLFLPAVGIQDEGIFR were expected to display the increased m/z values of 465.75940 392 
and 1122.10712. The high resolution of LTQ-Orbitrap XL and fragmentation spectra 393 
unambiguously discriminated the natural peptides from their deamidated variants. 394 
The peptide RAQN25ITAR was not identified in the untreated VC1 sample (p34 and p36 bands), 395 
suggesting that this peptide is fully glycosylated in P. pastoris. Consistently with this hypothesis, its 396 
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variant RAQD25ITAR was identified in the deglycosylated p32. This observation was confirmed by 397 
the manual extraction of the chromatogram for the peaks corresponding to the two peptide variants; 398 
peaks at m/z 465.26740 were barely visible in p34 and p36, while an intense peak at m/z 465.75940 399 
was indeed visible in the deglycosylated sample (about 3 orders of magnitude). This indicates that 400 
chemical deamidation is negligible and thus Asn25 is fully occupied in VC1. Supplementary Fig. 401 
1A reports the extracted ion chromatograms. In contrast with RAQN25ITAR, the peptide 402 
VLPN81GSLFLPAVGIQDEGIFR was detected in the untreated VC1 sample, indicating that Asn81 403 
is present both in glycosylated and unglycosylated state (Supplementary Fig. 1B).Consistently, its 404 
deamidated variant was identified upon enzymatic deglycosylation (p32 band). Moreover, the 405 
peptide VLPD81GSLFLPAVGIQDEGIFR was also detected in the untreated VC1 sample indicating 406 
that chemical deamidation occurs at Asn81 as already reported for hRAGE expressed in human cell 407 
lines [24]. Following PNGase F treatment, the ratio of peak intensities of deamidated versus 408 
unmodified peptide increased, confirming that a subpopulation of Asn81 is glycosylated, as reported 409 
also by Srikrishna G. et al. [25]. 410 
Overall, our analyses suggest that Asn25 is fully occupied whereas only a subpopulation of Asn81 411 
is glycosylated as occurs in human cells. 412 
Finally, the difference between p34 and p36 electrophoretic mobilities suggests that the N-linked 413 
chains are of the “core” type, consistently with the notion that hypermannosylation of the N-linked 414 
oligosaccharide chains is rare in P. pastoris in contrast to Saccharomyces cerevisiae. 415 
 416 
VC1 is a monomer and is functional  417 
 418 
VC1 was purified from the culture supernatant by cation-exchange chromatography as the capture 419 
step, exploiting the high charge of the protein (pI = 9.9) and a final gel filtration polishing step. As 420 
shown in the SDS-PAGE of Fig. 6A, the one-step elution from the cation-exchange column yielded 421 
highly enriched p34 and p36 forms contaminated by a small amount of a lower mobility protein and 422 
abundant heterogeneous low Mr components of the growth medium. Gel filtration studies yielded 423 
pure VC1 that eluted in a single sharp peak corresponding to monomeric VC1 forms. The low Mr 424 
contaminants eluted as a broad peak at higher elution volume (Fig. 6B). It was well expected that 425 
glycosylated VC1 is monomeric under the chosen acidic and high salt buffer conditions, as 426 
previously observed for un-glycosylated VC1 expressed in E. coli [14].  427 
The functionality of purified VC1 was tested by nitrocellulose filter-binding assay (Fig. 6D). 428 
Different amounts of BSA and AGE-BSA were absorbed onto nitrocellulose in dot-blot format. 429 
Following incubation of the membrane with purified VC1, bound protein was detected by anti-430 
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RAGE antibody as described under Materials and Methods. VC1 binding to AGE-BSA but not to 431 
BSA indicated that the protein is functional (Fig. 6D). 432 
 433 
Analysis of the thermal stability of VC1 glycosylated forms 434 
 435 
During the optimization and scale-up of the VC1 purification protocol, we developed a procedure 436 
based on an ionic-strength linear gradient for the fractionation of the concentrated culture 437 
supernatant by high resolution cation-exchange chromatography. Such an improved procedure 438 
yielded the two individual glycosylated species of VC1 in homogeneous form. Indeed, p34 and p36 439 
separated in two partially overlapped peaks, allowing their isolation in homogeneous form at the 440 
expenses of a loss in recovery (Fig. 7). Since the pI of the two glycoforms is expected to be the 441 
same, the separation likely reflects the different steric hindrance caused by the presence of one or 442 
two glycans which affects the affinity of the glycoprotein for the resin. Indeed, p36 with two 443 
glycans eluted before p34, which contains just one glycan. As shown in Fig. 7, VC1 glycoforms 444 
were well separated from low Mr components of the growth medium that eluted during the first part 445 
of the salt gradient. The immunoblot shown in Fig. 7 also indicates that no relevant protein 446 
degradation occurred during purification. Overall, this procedure of purification provided pure VC1 447 
with a minimum loss of the target protein. Table 2 summarizes the progress of the purification 448 
attained from 1 l-culture. 449 
Recently, ThermoFluor emerged as a powerful technique to evaluate the conformational stability of 450 
recombinant proteins [26]. Therefore, thermal denaturation analysis of p36, p34 and of the 451 
unmodified form produced in bacteria (p32Ec) was performed at different ionic strengths. Melting 452 
temperatures (Tm) obtained for the various proteins are reported in Table 3.  The two glycoforms of 453 
VC1produced in P. pastoris are equally stable in 150 or 300 mM NaCl whereas, in the absence of 454 
NaCl, p36 appears to be more stable than p34. In addition, the two glycoforms are more stable than 455 
p32Ec. In particular, in the absence of NaCl, p32Ec is highly unstable (Tm = 22.6 °C). Thus, VC1 456 
forms produced in P. pastoris displayed a remarkable improved stability in comparison with the 457 
unmodified p32Ec. These observations are consistent with the fact that VC1 glycoforms obtained 458 
from P. pastoris are highly soluble and display no tendency to aggregation that is, in contrast, a 459 
typical feature of p32Ec (data not shown).   460 
 461 
 462 
Discussion 463 
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We here demonstrated that the VC1 tandem domain of hRAGE can be produced in secretory form 464 
in P. pastoris. Recombinant VC1 forms can be purified to homogeneity from the concentrated 465 
culture supernatant by cation-exchange chromatography with no relevant protein loss during the 466 
purification step. Moreover, no other highly basic proteins appear to be secreted by P. pastoris. The 467 
level of VC1 forms produced by flask cultivation reached about 6 mg/l after 72 h of induction but 468 
by using fermentation-based technologies this level is expected to increase as higher cell density 469 
can be reached.  470 
The VC1 protein forms are of good quality since they show no tendency to aggregate/precipitate. 471 
Compared to VC1 produced intracellularly in E. coli (p32Ec), the secreted proteins are remarkably 472 
more thermally stable as demonstrated by thermal shift assays. Most importantly, the VC1 forms 473 
produced in P. pastoris proved to be functional, as verified by binding to AGE-BSA.  474 
In contrast with these findings, the V module of hRAGE was retained intracellularly in P. pastoris. 475 
The ER harbors an ER protein quality control (ERQC) that ensures only properly folded and 476 
assembled proteins traffic to the Golgi apparatus. Proteins that do not pass ERQC are diverted by 477 
retro-translocation back to the cytosol for degradation by the 26S proteasome in a process termed 478 
ER-associated degradation (ERAD). Moreover, a previous work in P. pastoris suggested that 479 
misfolded proteins can also be transported from the Golgi to the vacuole for degradation [27].  480 
Previous studies indicated that the isolated V, and to a lower extent also VC1 domain, produced in 481 
E. coli possess a highly dynamic conformation and that V requires C1 association to fold properly 482 
[17, 28]. Thus, our finding that V does not acquire the proper folding in P. pastoris is consistent 483 
with, and also extends, previous biophysical in vitro studies [17]. Molecular models based on X-ray 484 
crystallography and NMR, support the notion that V and C1 domains physically interact through 485 
surfaces exposing hydrophobic amino acids [14]. Our results obtained using an in vivo approach, 486 
support such observations and strongly indicate that V and C1 domains form a single folding unit. 487 
Consequently, the V unit should be described as a protein module rather than a domain. Our study 488 
also provides evidence of a cellular protease that removes the N-terminal portion of the V module. 489 
This protease likely is a component of the ERQC of P. pastoris.  490 
This work also showed the full occupancy of Asn25 and the partial occupancy of Asn81 in the VC1 491 
forms produced in P. pastoris. This glycosylation pattern mimics that observed in human cells [24] 492 
indicating that it is driven by intrinsic features of VC1, such as the target sequences, its location in 493 
the three-dimensional structure of the protein and the microenvironment. Moreover, we have shown 494 
here that Asn81 undergoes partial deamidation. Interestingly, as previously reported for Asn81 of 495 
hRAGE from mammalian sources and also for different types of antibodies, specific asparagine 496 
residues can undergo non-enzymatic deamidation [16, 24]. The susceptibility to deamidation 497 
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markedly increases if a glycine residue is immediately after the asparagine [29]. In this case, 498 
deamidation occurs via cyclization of asparagine by the -aspartyl shift mechanism in which the 499 
main chain peptide nitrogen of the glycine residue acts as a nucleophile on the Asn side chain amide 500 
group forming a succinimide intermediate that breaks down in - or -isomeric aspartate products  501 
[29]. Interestingly, Asn81 is located in the sequon N-Gly-S providing an explanation of the marked 502 
propensity to deamidation of this site in hRAGE.  503 
In fact, a polymorphism, consisting in a single nucleotide change, occurs at the Asn81 sequon in 504 
humans and   results in a Gly to Ser replacement that leads G/S or S/S genotypes, often associated 505 
with diseases. G/S (heterozygous) individuals are more prone to undergo diabetic retinopathy with 506 
respect to G/G (homozygous) patients in the Chinese population [30, 31]. An association of the S 507 
allele with microvascular complications in diabetic patients has been reported and theS/S genotype 508 
has been correlated to low levels of circulating sRAGE [30]. Notably, the G82S replacement 509 
increases the occupancy of Asn81 and this could affect AGE-RAGE binding [24]. 510 
Finally, glycosylation was proposed to affect RAGE ligand binding specificity. For example, the 511 
lack of glycans in bacterial recombinant proteins is accompanied by increased affinity for some 512 
ligands, while others have been shown to bind more tightly to glycosylated RAGE [25, 32]. Thus, 513 
the availability of glycosylated VC1 forms from a eukaryotic microorganism can prove useful in 514 
future studies. It is important to note that P. pastoris was also engineered to produce humanized N-515 
glycan chains, an important accomplishment in the perspective to produce biotherapeutic products 516 
in this yeast [33]. However, irrespective of the role of specific glycan requirements for ligand 517 
binding, the VC1 forms produced in P.pastoris proved to be more stable and soluble than the non-518 
glycosylated VC1 produced in bacteria, suggesting that the oligosaccharide chains promote the 519 
proper folding and are important for protein stabilization and solubility. These features are expected 520 
to be beneficial for the in vitro studies of the properties of RAGE ligand binding domain and for the 521 
set-up of high throughput screening methods for the identification of RAGE antagonists. 522 
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 633 
Legends 634 
 635 
Figure 1. Schematic representation of the constructs used in this work. The upper scheme shows the 636 
domain structure and the N-glycosylation sites of the full-length hRAGE. After the N-terminal signal 637 
peptide, three immunoglobulin-like domains (V, C1 and C2) are present, followed by the trans-membrane 638 
domain and a short cytoplasmic tail. The numbers indicate the amino acid sequence positions at the domain 639 
borders. The truncated proteins are shown in the lower part. The sequence of the thrombin recognition site 640 
(T), present in the constructs carrying a C-terminal 6 x His Tag (H), is LVPRGS (with cleavage between R 641 
and G).   642 
 643 
Figure2. Immunoblot analysis of culture supernatant and extracts of cell expressing VC1-His. Culture 644 
medium and cell extracts of GS115 (A) and GS115-sub2 (B) expressing VC1-His were analyzed by 645 
immunoblotting using anti-poly(His) mAb or anti-RAGE antibody as indicated. VC1-His expressed in E. 646 
coli was used as positive control. Culture supernatants (110 µl) of the indicated time points were denatured 647 
and loaded on SDS-slab gels. Cell extracts were obtained as described in Material and methods. Cell extracts 648 
immunostained with anti-Poly(His) mAb contain an extra band of ~ 33 kDa  ascribable to a VC1 proteolytic 649 
product lacking the N-terminal RAGE epitope. 650 
 651 
Figure 3. Immunoblot analysis of cell extracts of cells expressing V-His. Total extracts of GS115 cells 652 
expressing V-His harvested after the indicated induction times were analyzed by immunoblotting using anti-653 
poly(His) mAb or anti-RAGE antibody as indicated. V-His expressed in E. coli was used as positive control. 654 
The cell extracts were obtained as described in Material and methods. The lack of reactivity with the anti-655 
RAGE antibody is ascribable to a proteolytic cleavage occurred intracellularly at the N-terminus as shown in 656 
Fig. 2 for VC1. 657 
 658 
Figure 4. Kinetics of accumulation of recombinant VC1 in P. pastoris culture medium. A. Growth 659 
kinetics at 28 °C of a representative culture of P. pastoris cells transformed with pHIL-S1-VC1233 plasmid 660 
(solid line). Time zero indicates the moment of the shift from BMGY to the inducing medium, BMMY. The 661 
arrows indicate the time points of the withdrawal of culture aliquots for analysis. The recombinant protein 662 
level (dashed line) in the culture supernatant was estimated by densitometry as reported in Material and 663 
methods using immunoblot with anti-RAGE antibody and recombinant VC1 isolated from E. coli as a 664 
calibrator. B. SDS-PAGE of culture supernatant (160 μl) collected at the indicated induction times. Protein 665 
bands were stained by Coomassie blue. C. Immunoblot analysis of the same samples of panel B.  Culture 666 
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supernatant volumes loaded on the gel were 112 μl for 0 and 24 h, and100 μl for 48 and 72 h. Recombinant 667 
VC1 produced in E. coli was used as a control.  668 
 669 
Figure 5. Analysis of the recombinant VC1 glycosylation. 670 
Immunoblot analysis using anti-RAGE antibody of culture supernatant harvested after 72 h of induction and 671 
incubated in the absence (-) or presence (+) of PNGase  F. Purified recombinant VC1 produced in E. coli was 672 
used as a control.  673 
 674 
Figure 6. Purification of VC1 from the culture supernatant and filter binding assay.  675 
A. Result of separation by cation-exchange chromatography and one-step elution of the culture supernatant 676 
at 72 h of induction. The Coomassie stained gel is shown. The arrows indicate p36 and p34; * indicates low 677 
Mr components of the medium. B. Profile of gel filtration chromatography on a Superdex 75 column of the 678 
partially purified VC1 forms. The peak eluted at 10 ml corresponds to VC1 forms, while those eluted 679 
between 13 and 18 ml correspond to the low Mr components of the medium (predominantly peptones *). 680 
Standard proteins were chromatographed under the same conditions to obtain the calibration curve shown in 681 
the inset (inset). C. SDS-PAGE and Coomassie staining of the fractions corresponding to the VC1 peak. 682 
Proteins were precipitated by 10% TCA. D. Filter binding assay.  2 l of a concentrated solution of BSA or 683 
BSA-R (2mg/ml) (1) and 1:2 serial dilutions (from 2 to 6) were spotted on nitrocellulose filter that was 684 
incubated with purified VC1 as described in Materials and methods. VC1 specifically recognizes BSA-R 685 
indicating that the protein expressed and purified from P. pastoris is functional.  686 
 687 
Figure 7. Large-scale purification and separation of p34 and p36 glycoforms of VC1 by cation-688 
exchange chromatography. A. Cation-exchange chromatography on a Mono S column of 400-ml culture 689 
supernatant collected after 72 h of induction and 13 × concentrated by ultrafiltration (membrane cut-off 690 
30,000). The fractions eluted using a linear ionic-strength gradient were analyzed by SDS-PAGE and 691 
proteins were stained by Coomassie blue B. Immunoblot with anti-RAGE antibody indicates that fractions 5 692 
to 6 contain only p36, fractions 7 and 8 contain both forms and 9-10 contain only p34. The 66-kDa 693 
polypeptide visible in panel A (lane 1) is a contaminating endogenous protein. VC1 purified from E. coli 694 
(p32Ec) was used as a control (C).  695 
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Table 1 
Oligonucleotides used in this worka 
 a XhoI site is underlined and CDS of VC1 or V is in bold. Stop codon is in italic 
Primer Sequence 5’-3’ 
VC-For AGCATATTCGACTGACTCGAGCTCAAAACATCACAGCCCG 
VC233-Rev ATCGTCGGGCTCACTCGAGCTACACAGGCTCCCAGACACG 
VC233His-Rev 
ATCGTCGGGCTCACTCGAGCTAGTGATGGTGATGGTGATGGCTGCTGCCGCTGCCGCG
CGGCACCAGATGGCTGCTGCCGCTGCCGCGCGGCACCAGATGCACAGGCTCCCAGA
CACG 
V121-Rev ATCGTCGGGCTCACTCGAGCTAAGGAATCTGGTAGACACGGA 
V121His-Rev 
ATCGTCGGGCTCACTCGAGCTAGTGATGGTGATGGTGATGGCTGCTGCCGCTGCCGCG
CGGCACCAGATGGCTGCTGCCGCTGCCGCGCGGCACCAGATGAGGAATCTGGTAGA
CACGGA 
5’-AOX1 GACTGGTTCCAATTGACAAGC 
3’-AOX1 GCAAATGGCATTCTGACATCC 
84
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Table 2 
Large-scale purification of VC1 from P. pastoris mediuma 
aThe starting material was the supernatant from a yeast 1-liter culture harvested after 72 h 
induction at the OD600 of 13. 
bData refer to total VC1, i.e. the sum of the two p36 p34 glycoforms. 
cDetermined by densitometry, since the high concentration of peptides in the medium precluded 
the determination of the actual total protein concentration.  
dPurified VC1 not separated into its individual glycoforms. 
Purification step VC1 protein 
(mg) 
Yield 
(%) 
Culture supernatantb  6.00c 100% 
Concentrationb 5.88 98% 
Cation exchange chromatographyb 5.21 86% 
p36 form  1.45  24% 
p34 form  1.52  25% 
Cross-contaminated p34 p36 formsd  2.24  37% 
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Summary  
 
During the yeast to hypha (Y-H) transition, Candida albicans acquires attributes essential for 
adhesion and penetration into the tissues, two important processes for the establishment of 
invasive infections in immunocompromised patients. Cell wall (1,3)-glucan remodeling 
catalyzed by Phr1p is required for hypha elongation, adhesion and virulence. We exploited 
the pH-conditional nature of a PHR1 null mutant to analyze the genome-wide transcriptional 
response to the absence of (1,3)-glucan remodeling during the Y-H transition. The changes 
include increase of transcript levels for 10 mannoproteins, a cell wall cross-linking enzyme 
(CRH11), two chitin synthases (CHS2 and CHS8), a chaperone of ER-export of Chs3p 
(CHS7) and reduction of adhesins, indicating adjustments in hyphal wall structure. 
Additionally, up-regulation of DNA replication and cell-cycle control genes was associated 
with premature entry into S-phase. Chitin level increased in the mutant and the deletion of 
CHS3 was synthetically lethal with deletion of PHR1 whereas CHS2 and CHS8 were 
dispensable in M199 pH 7.5. Interestingly, the synthetic lethal phenotype of the chs3 phr1 
mutant on solid medium is affected by the filamentation conditions and a physiological 
adaptation of the double mutant occurred at pH 7.5 on the less demanding Spider medium.  
 
Introduction 
 
C. albicans is a medically important fungal pathogen that exhibits various morphological 
forms: yeast, hypha, pseudohypha and chlamydospore. The transition from yeast cell to 
hyphal form (Y-H) is one of the best-studied developmental pathways in fungi and also 
represents a major virulence attribute of this microorganism.  
As a commensal, C. albicans grows on human mucosae and is a component of the oral fungal 
microbiome (Ghannoum et al., 2010). Its extraordinary ability to inhabit diverse niches of the 
human body is reflected in its adaptability to a wide range of external pH values and to a 
range of oxygen pressures, ion concentrations, and carbon sources (Ene et al., 2012, Davis, 
2009). As an external envelope endowed with mechanical strength, the cell wall plays a 
primary role in determining cell shape and in maintaining cell integrity during morphological 
changes or osmotic shock. Additionally, the surface of the cell wall is positioned at the 
interface between the pathogen and the host cells, with which dynamic interactions crucial for 
adhesion or the immune response are established. Whereas the yeast form is suitable for 
dissemination through the blood stream, the thin filamentous shape of hyphae is specialized 
for adhesion to epithelial and endothelial barriers, and penetration and invasion of the tissues 
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below. Genomic scale expression studies of the Y-H morphological transition have identified 
a number of signature genes induced by this transition (Lane et al., 2001, Nantel et al., 2002, 
Wilson et al., 2009). 
Hypha formation requires a coupling between the polarity machinery of the cell and the 
components involved in the biogenesis of the wall in order to drive growth at the tip of the 
germ tube. The wall results from the synthesis and assembly of two glucose polymers, (1,3)-
glucan, the most abundant, and -glucan. Other major constituents are mannoproteins, 
many of which are modified by attachment to glycosylphosphatidylinositol (GPI) and are 
localized both in the plasma membrane and cell wall (reviewed in (Klis et al., 2009). Chitin, 
a (1,4)-linked polymer of N-acetylglucosamine (GlcNac), is a minor constituent but it is 
crucial for the formation of the septum and enhancement of the structural integrity of the 
wall. Fks1p, the catalytic subunit of (1,3)-glucan synthase, polymerizes linear (1,3)-glucan 
from UDP-glucose in a vectorial manner at the cell membrane, whereas mannoproteins and 
probably (1,6)-glucan are processed through the secretory pathway. In the extracellular 
compartment, a branched (1,3)glucan-chitin structure that forms the “core” of the wall is 
created (Latge, 2007). This core structure is decorated by links between chitin and -
glucan or trimmed GPI-mannoproteins, the latter forming the “brush-like” surface layer of 
the wall which functions as a permeability barrier and adhesive surface.  
Among the extracellular transglycosidases crucial for cell wall assembly, (1,3)-glucan 
transglycosidases of family GH72 play a primary role. These enzymes internally cleave a 
donor glucan chain and attach a portion of the donor to an acceptor glucan in (1,3)-linkage, 
thus lengthening one chain at the expense of the other (Mouyna et al., 2000). Multigene 
families of redundant enzymes are present in all fungal species so far analyzed (Sillo et al., 
2013). These genes are essential for viability in many fungal species, such as in the  
pathogens Aspergillus fumigatus (AfGEL4) or C. glabrata (CgGAS), and in nonpathogenic 
species such as the fission yeast Schizosaccharomyces pombe (Spgas1+) (Gastebois et al., 
Weig et al., 2001, de Medina-Redondo et al., 2010). 
C. albicans has a family of five GH72-encoding genes: PHR1, PHR2, PHR3, PGA4 and 
PGA5. Phr1p and Phr2p are highly similar to ScGas1 and play the same glucanosyltransferase 
activity in vitro. Pga4p is most similar to ScGas5 but recent evidence from our laboratory 
indicate that it is an inactive enzyme (Kovacova et al., 2015). Phr3p and Pga5p are 
homologous to the sporulation-specific gene products ScGas4p and ScGas2p, respectively. 
The significance and the role of PHR3 and PGA5 are still unknown but the transcript level of 
both is very low or undetectable (Eckert et al., 2007). Taking into account that PGA4 deletion 
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does not bring any phenotype and Pga4p likely turned into a structural mannoprotein, Phr1p 
and Phr2p appear to be the major players among the C. albicans PHR family.  
C. albicans PHR1 and PHR2 are pH-regulated genes. PHR1 is expressed when the external 
pH is higher than 6 both in yeast and hyphal growth. It is repressed in acidic conditions where 
it is replaced by PHR2 which exhibits the opposite expression pattern (Muhlschlegel & 
Fonzi, 1997, Saporito-Irwin et al., 1995b). Moreover, both PHR1 and PHR2 are repressed in 
stationary phase. PHR1 is also induced at a transcriptional level in response to heat stress, to 
treatments with the antifungal drug caspofungin (CS) and during infection (Meyer et al., 
2007, Heilmann et al., 2013, Liu et al., 2005, Brown et al., 2007). 
Consistent with it enzymatic activity, the Phr1 protein localizes to sites of new wall formation 
such the periphery of the bud, the septum, the tip of the germ tube, the hyphal apex and it also 
concentrates at the hyphal septa (Ragni et al., 2011a). Loss of Phr1p affects cell wall 
composition, with a reduction of (1,3)-glucan content and an increase of chitin, and results 
in aberrant cell morphology (Fonzi, 1999, Popolo & Vai, 1998). At the restrictive pH of 7.5 
at 25°C, phr1 cells are round and multi-budded. At 37°C they are unable to form filaments 
and arrest with short and enlarged germ tubes. A delocalized actin cytoskeleton is apparent 
under both conditions (Saporito-Irwin et al., 1995b). The phenotype is more severe if the pH 
is raised from 7.5 to 8, where greatly enlarged vacuoles and a swollen aspect are present 
(Saporito-Irwin et al., 1995b). Moreover, PHR1 null mutants are avirulent in an animal 
model of systemic infection (De Bernardis et al., 1998) and in a model of experimental 
keratomycosis (Yuan et al.). The PHR1 null mutant is unable to invade in vitro reconstituted 
epithelia and has a reduction in adhesion, two fundamental processes for the establishment of 
fungal infections  (Calderon et al., 2010). 
By exploiting the pH-conditional nature of the PHR1 null mutant, which manifests its defects 
in wall assembly only upon a shift to neutral-alkaline pH, we investigated the impact of 
defective glucan remodeling on the transcription profile during the induction of hyphal 
growth. Our results show that the activity of Phr1p is important to fully execute the genetic 
program of hyphal development. Among the different classes of functions that are involved in 
the adaptive response are genes involved in the reorganization of the cell wall but also in cell 
cycle control and morphogenesis and in DNA replication/repair and chromatin formation. 
Classes of genes involved in the cell cycle control and in morphogenesis indicate that the 
inability to accomplish the yeast-hypha transition in the phr1 mutant. Genetic analysis 
indicated that during hyphal growth CHS3 is essential for viability but on mild solid 
filamentation media it its presence is dispensable and physiological adaptation occurs. 
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Results 
 
Global transcriptional response to the lack of (1,3)-glucan remodeling upon induction of 
hyphal growth in Candida albicans 
 
To induce hyphal growth, a pH/temperature regimen was used. Blastospores of the wild type 
strain (CAI10) and phr1 mutant (CAS10) were transferred to buffered M199, pH 7.5 at 37° 
C. Despite the phenotype of the mutant was stronger at pH 8, the percentage of dead cells at 5 
h after the pH shift, measured by methylene blue staining, was about 15% compared to only 
5% at pH 7.5 and therefore the latter was the preferred condition for microarray analysis. 
The Phr1p accumulation, the kinetics of germ tube induction and the changes in morphology 
were monitored after the shift to pH 7.5. Phr1p was recognized by anti-Gas1p antibodies and 
detected in CAI10 extracts as a glycosylated 88 kDa-polypeptide (Fig. 1A). Phr1p was absent 
at time zero but upon induction of hyphal growth, was already detected at 1, and was further 
accumulated at 3 and 5h and was still present 24 h after the shift (Fig. 1B) whereas was 
absent in CAS10 at all time points as expected (data not shown). At time zero, the 
morphology of CAI10 and CAS10 (PHR1-/-) was indistinguishable (Fig. 1C) and the two 
strains had the same chitin content [8.8 ± 0.66 and 8.5 ± 0.88 g N-acetylglucosamine 
(GlcNac)/mg d.w. (dry weight) of cells, for CAI10 and CAS10, respectively] supporting the 
notion that PHR1 null deletion does not confer a detectable phenotype in non-inducing 
conditions. At 45 min, CAI10 cells started to form germ tubes and the percentage of cells 
with germ tubes steadily increased with time reaching 50% at 1 h after the shift and 80-90% 
by 3 h. CAI10 produced elongated hyphae whereas CAS10 cells produced germ tubes that 
remained short, enlarged and sometime curved culminating in a yeast-like aspect with large 
septa at 5 h from the shift (Fig.1C). These morphological defects were consistent with those 
described in previous reports (Saporito-Irwin et al., 1995b). After 5 hours, chitin level 
increased to 11.7 ± 1.07 GlcNac/mg d.w. of cells in CAI10, in agreement with stimulation of 
chitin accumulation in hyphae, and to 16.4 ± 1.5 GlcNac/mg d.w. of cells in CAS10 and this 
~ 40% extra chitin is ascribable to the presence of cell wall stress. 
We characterized the pattern of gene expression at 1, 3 and 5 h after the pH shift. Principal 
component analysis showed a clear separation between the wild type and mutant strain at 
each time point and underlined the high reproducibility of the biological replicas (Fig. 2A). 
Moreover, hierarchical clustering indicated that for both strains changes at 3 h and 5 h 
clustered tighter than at 1 h (Fig. 2B). Next, we determined how the stimulus to hyphal 
97
  6
development affects gene expression in the wild type and in the mutant. Dataset S1 shows 
genes that were up- (≥2 fold) or down–regulated (≥ 2-fold) with a False Discovery Rate 
(FDR) ≤ 0.05. This threshold was chosen to ensure that the analysis was stringent but would 
not miss significant genes. Among the 6346 probes, 537 genes were up-regulated at 1 h, 806 
at 3 h and 1020 at 5 h in the wild type whereas 701, 780 and 964 genes were up-regulated in 
the phr1 mutant. Moreover, 795, 956 and 1014 were down regulated at least 2-fold in the 
wild type and 953, 993 and 1128 in the mutant. Comparison of the data from wild type and 
mutant strains identified a common group of responsive genes (54%, 58% and 62% up-
regulated and 59%, 72% and 72% down regulated at 1 h, 3 h and 5 h, respectively), 
suggesting that phr1 mutant cells trigger the hyphal expression program in spite of their 
failure to form hyphae. 
The modulation of many genes reflects the extensive differentiation associated with induction 
of the hyphal program and, at least in the early stages, the shift from quiescence to growth 
and the change in culture conditions (media composition, pH and temperature). Up-regulated 
genes belonged to the functional categories expected for hyphal development: hyphal growth, 
pathogenesis, endoplasmic reticulum (ER)-Golgi transport, cell wall organization, Golgi-ER 
retrograde transport, ER-associated-protein degradation (ERAD) and biofilm formation. The 
typical signature up-regulated genes of hyphal growth, such as ECE1, SOD5, ALS10, ALS3 
RBT1, HWP1, HYR1 PRA1, ALS3 SAP4, SAP5, SAP6 and the typical down-regulated genes 
RHD1, TYE7, NRG1 were present (Nantel et al., 2002). PHR1 itself is typically induced 
during hyphal growth and was up-regulated 1.4 fold at 1 h and 1.6 fold at 5 h  in the wild 
type, in agreement with previous reports (Nantel et al., 2002, Wilson et al., 2009). As 
expected, PHR1 transcript was undetectable. PHR2 was repressed both in the wild type and 
in the mutant (Dataset1). 
Many genes up or down-regulated in each strain appeared to be differentially modulated. To 
extract these differences, we used a relation factor (RF) representing the ratio between the 
expression ratio of each gene in the mutant and in the control. Thus, the value of the RF 
reflects the effect of the mutation on the abundance of a transcript. We set a threshold of RF 
≥ 2 to select for transcript levels more abundant in the phr1 mutant than in the control 
(Class 1), and RF ≤ 0.5 for transcript levels reduced in the phr1 mutant compared to the 
control (Class 2). The complete list of Class 1 and Class 2 and their RF is reported in Tables 
S1 and S2 respectively.  
Table 2 summarizes the functional categories of mutation-sensitive genes. Notably, in Class 
1 many the categories “Metabolism and energy” and “Cell wall/surface”, indicates the cell’s 
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need of reorganizing the cell surface and redirecting metabolism. The categories “DNA 
replication”, “Chromatin and chromosomes” and “Cell cycle control/morphogenesis” were 
also affected, suggesting perturbation of the coordination between cell cycle events and their 
coupling to morphogenesis. Class 2 contained many genes required for RNA processing and 
ribosome biogenesis primarily at 1 h. This response is likely to be a general reaction to 
defects in morphogenesis rather than to a specific cell wall stress, since it was also present in 
farnesol-treated cells (see Discussion).  
As shown in Fig. 2C, the increase of transcripts of selected genes was confirmed by 
quantitative real time reverse transcriptase PCR (qRT-PCR). The RF values obtained from 
qRT-PCR were similar to the values obtained from the microarray analysis indicating the 
validity of the analysis.    
 
Expression profile uncovers extensive rearrangement of the cell surface in cells lacking 
(1,3)-glucan remodeling during induction of hyphal growth  
 
As shown in Table 3, the Cell wall/surface category was among the largest and comprised: 
seven cell wall structural mannoproteins (PGA23, RBR1, PGA13, PGA54, RHD3/PGA29, 
orf19.750 and orf19.675) found only in C. albicans or Candida spp., and three cell wall 
proteins (PGA6, RBT4, ECM331) that have homologs in S. cerevisiae. Other induced genes 
were CRH11, encoding a GPI-anchored transglycosidase of GH16 family which catalyzes the 
cross-links between chitin and glucans, two chitin synthase isoforms (CHS2, CHS8) and 
TOS1, EXG2, XOG1, SCW11, orf19.7214 and PLB3 that have enzymatic activity on glucans 
or lipids (PLB3). Interestingly, in the protein folding/modification category the presence of 
the ER chaperones involved in Chs3p-dependent chitin synthesis (CHS7) and in (1,6)-
glucan synthesis (ROT1) suggest their involvement in the chitin and glucan synthesis. 
Two aspects of the expression data suggested that the absence of PHR1 forces multiple 
adjustments in the cell’s chitin synthesis process together with mannoproteins. Among the 
four genes encoding isoenzymes of chitin synthase (CHS1, CHS2, CHS3 and CHS8) CHS8 
and CHS2 transcript level was higher in the phr1 mutant (Table 3). CHS2 and CHS8 are 
also up-regulated by echinocandins (EC)  (Walker et al., 2008). Moreover, the transcript of 
CHS7, encoding a chaperone for Chs3p export from ER, was also more abundant in the 
mutant. Secondly, chitin cross-linking (CRH11) was also increased in the mutant suggesting 
that cross-linking between chitin and mannoproteins may occur.  
CHS1 is an essential gene that is required for the formation of the septum and for cell wall 
integrity (Munro et al., 2001). CHS2 is preferentially expressed in the hyphal form and is 
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involved in septum formation (Walker et al., 2013, Gow et al., 1994, Lenardon et al., 2007), 
whereas CHS8 is responsible for the synthesis of a particular type of long fibrillar chitin at 
the septum (Walker et al., 2013, Lenardon et al., 2007). CHS3 contributes the majority of cell 
wall chitin, which is deposited in the septal ring and lateral walls. Moreover, CHS3 is 
responsible for the Calcofluor white/CaCl2 induced stimulation of chitin accumulation that 
protects C. albicans cells from the killing effect of echinocandin (Walker et al., 2008). CHS2, 
CHS8 and CHS3 are also responsible for the remedial septum, that is synthesized when 
Chs1p is inhibited, an indication of cross compensation (Walker et al., 2013). 
 
To evaluate the role of chitin synthases in the adaptive response of the phr1 mutant, a PHR1 
homozygous null mutation was introduced into strains lacking CHS2, CHS8, CHS2 and 
CHS8 or CHS3 (Table 4) and analyzed during the induction of hyphal growth. Two 
independent clones were used in all the analyses. The wild type strain and all chs mutants 
formed hyphae, although hyphae of the chs mutants were altered in morphology (Fig. 3A and 
3 B). Hyphae of the chs3 mutant were highly flocculant and at the microscopic level they 
were sometimes curved at the apex. As shown by CW-staining, the chs3 cells were CW-
negative except at the thin line of the septa, an observation in agreement with Chs3p being 
responsible for the deposition of the majority of chitin located in the lateral wall and chitin 
ring but not in the chitin disk of the primary septum (Sanz et al., 2005, Lenardon et al., 
2010b). Hyphae of chs2 and chs8  were also highly flocculant, were larger in diameter, 
and were curved and hyper-branched. These traits were accentuated in the double mutant 
chs2 chs8 cells. Despite these morphological differences, CW staining of these mutants 
was comparable to the wild type strain in distribution and intensity.  
The phr1 mutant formed few germ tubes, most cells exhibiting short, enlarged, outgrowths 
with wide septa. CW-fluorescence was distinctly more intense than in control all over the 
walls and septum (Fig. 3A). Deletion of PHR1 conferred the same morphological defects to 
the chs mutants, but the combined mutations did not noticeably accentuate the 
morphological aberrations of phr1 cells after 5 h incubation. Unexpectedly, the 
phr1 chs3 mutants stained with similar intensity and distribution as the phr1 mutant. 
Conversely, the absence of either CHS2 or CHS8 resulted in reduced CW staining, whereas 
the simultaneous absence of both enhanced CW staining.  
Variation in CW staining presumably reflects altered chitin content but can also be affected 
by damages to cell wall and alterations of permeability. To verify this, we measured the 
chitin content of the mutants after the induction of hyphal growth. As shown in Fig. 3C, the 
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cells while loss of either CHS2 or CHS8, alone or in combination, resulted in a small 
reduction in chitin indicating that these genes provide a minor contribution to the total chitin 
of the wild type hyphae. In contrast, the chitin increase observed in the phr1∆ mutant was 
only slightly reduced in the absence CHS3 or both CHS2 and CHS8. However, the phr1∆ 
chs2 ∆and phr1∆ chs8∆ strains were deficient in chitin accumulation suggesting that the 
combined loss of CHS2 and CHS8 is compensated by other isoenzymes in the phr1 mutant. 
In addition, chitin content of phr1 chs3 at 3 h was about half that at 5 h, suggesting that extra 
chitin is progressively accumulated as a consequence of increasing stress during germination 
(Fig 3 D).  
Microscopic examination of the phr1∆chs3 ∆mutant after 24 h incubation revealed swollen, 
lysed cells and ghosts of cells into which CW had penetrated (Fig. 3B, asterisks). This 
prompted an examination of the viability of the various mutants using methylene blue 
staining. While only a few percent of phr1∆ cells were inviable at 5h and this increased to 
around 15% at 24 hr, 20% of the phr1 ∆chs3∆ cells, or units of cells, were dead within 5 hr 
and this increased to about 82% by 24 h (Fig. 3D). When the phr1 ∆mutation was combined 
with deletions of CHS2 and/or CHS8 no relevant decline in viability was observed (Fig. 3D). 
Finally, no lysis phenotype for the hyphae of the parental strains was detected except for 
some apex of chs3 mutant. Thus, Chs3p is required for long-term viability of phr1 in liquid 
M199 alkaline pH. 
Interestingly Chs2p and Chs8p appear to contribute to the synthesis of chitin during the 
initiation phase of hyphal development. However, chitin increment per se does not provide 
cell wall integrity in the absence of Phr1p. Although at 5 h the phr1∆chs3 ∆mutant has a 
comparable increase in chitin content with respect to phr1 chs2 chs8 mutant, the chitin 
accumulated in phr1 chs3 mutant does not contribute to maintain cell integrity on a long 
temporal scale.  
We next asked which isoenzyme/s contribute to chitin synthesis  when CHS3 or CHS2 and 
CHS8 are missing. Thus, we tested the cell sensitivity of mutants RO- 09-3143, a specific 
inhibitor of Chs1p (Sudoh et al., 2000). The absence of visible growth of the 
phr1 ∆chs3 ∆mutant, precluded testing the inhibitors against this strain confirming the severe 
lytic phenotype of this mutantΙ .f phr1 chs2 chs8 mutant (remaining activities Chs1 and 
Chs3p) was more dependent on Chs1p, it would be correspondingly more sensitive to RO-09- 
3143 whereas if the mutant did not depend on Chs1p for viability, the sensitivity would be 
the same of the phr1 mutant. 
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Fig. 4A shows that the growth of the phr1 and phr1 chs2 chs8 mutants was more 
susceptible to the inhibitor with respect to the parental strains but the mutants strains 
appeared to have a similar sensitivity to the drug suggesting that Chs1p is not required for 
the growth of phr1 chs2 chs8 mutant. However, since the inhibitor causes an enlargement of 
the wild type and chs2 hyphae and the appearance of “balloons” as previously described 
whereas phr1 strains appeared as chains of septum-less cells and also swelling occurred, we 
also tested the killing effect by the XTT-reduction assay. Interestingly, the killing curves 
were similar for all the strains (Fig. 4B). These results indicate that Chs1p is not 
recruited in the triple mutant as the main compensatory chitin synthase. 
The dependence of phr1 cell integrity on Chs3p is attenuated in slow filamentation 
conditions 
Because some mutations differentially influence filamentation in broth culture versus solid 
media (Lin et al, 1994; Sharkey et al, 1999), we tested the phenotype of phr1chs mutants also 
on agar solidified media. On solid M199-pH 7.5 at 37 °C, all the strains germinated and gave 
rise to visible colonies except phr1chs3 mutant that did not produce colonies (Fig.5A). 
Upon microscopic observation of the agar surface, we concluded that phr1chs3 cells did 
not undergo germination suggesting that cell death is an early event. Inclusion of 0.8 M 
sorbitol into the plates did not suppress the lethal phenotype (Fig. 5B). The defect of 
germination of the phr1chs3 mutant was suppressed at pH 4.5 in agreement with the 
relation of the synthetic lethal phenotype to the presence of the PHR1 deletion (data not 
shown).  
We conducted a filamentation assay also on Spider medium, a less potent filamentation 
condition. At 37 °C and pH 7.5, all the strains formed colonies including phr1 chs3 mutant 
whose colonies became visible with a day of delay but progressively became bigger till the 
size of the single phr1 mutants (Fig. 5B). The inclusion of 0.8 M sorbitol in the plates 
increased the number of CFU by 50%, supporting the notion that the reduced germination of 
phr1 chs3 mutant was due to lysis at the onset of blastospore germination (data not 
shown).  
Next, we determined the effects of Spider medium buffered at pH 8. phr1 mutant gave rise 
to small colonies in agreement with the worsening of the phenotype at higher pH whereas 
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phr1chs3 mutant did not produce colonies (Fig. 5) The lethal phenotype of phr1chs3 
mutant at pH 8 was not reverted by the inclusion of sorbitol in the plates (data not shown).  
To understand the nature of the attenuation of the phenotype in Spider medium at pH 7.5, the 
four independent phr1 chs3 clones, named “adapted”, were recovered from the plates at 
pH 7.5 and filamentation assays at pH 7.5 were repeated. The adapted clones were able to 
germinate and grow in Spider medium at pH 7.5 but not on M199 at pH 7.5 as the original 
phr1 chs3 mutant (data not shown). The phenotype in liquid M199 was indistinguishable 
from that of the original strain. These results indicate that attenuation of the 
phr1 chs3 phenotype on Spider medium at pH 7.5 results from physiological adaptation. 
In conclusion, the phenotype of phr1chs3 mutant is influenced by the filamentation 
conditions used in solid medium. On solid M199-pH 7.5 and Spider-pH 8 phr1 chs3 cells die 
at the very early onset of germination. In Spider-pH 7.5 roughly 50 % of the population adapt 
after a long germination time. These results are consistent with M199 medium being a more 
demanding growth condition than Spider medium.  
 
The block of hyphae elongation up-regulates DNA replication genes and accelerates the 
progression into the DNA division cycle  
 
Next, we investigated the Class 1 genes related to “DNA replication and repair” (POL30, 
POL3, RAD51, DUT1, MSH6, RFA2, RFA1, orf19.7425, orf19.2796, POL1, CDC54, RBR1, 
EXO1, orf19.4030, CDC46, MCM6) and “Chromatin and chromosomes” (HHF22, HHF1, 
HTA1, HTA2, HTB1, IRR1, ASF1, SMC6, NAT4) (Tables S1). This transcriptional response 
occurred within 1 and 3 h and may be related to the block of filamentation, as a similar 
response was observed during the arrest of hyphal elongation by farnesol (Enjalbert & 
Whiteway, 2005). However, the actual effect of these changes on entry into S-phase has not 
been reported. Therefore, we analyzed by flow cytometry the DNA distribution profile of 
wild type and phr1 mutant strains undergoing the Y-H transition. Blastospores from 
prolonged incubation in stationary phase (1.5 days) showed a very high degree of synchrony 
in germ tube formation when inoculated into hyphal induction conditions. The percentage of 
germ tubes was about 88% both for the wild type and phr1 mutant at 1 h. By 1.5 h thin 
hyphae already appeared in the wild type whereas the germ tubes of the mutant developed a 
swollen apex. At this time, phr1 cells have already entered S-phase, earlier than control 
cells, and also an enrichment of cells at G2/M was observed (Fig. 6). These results are in 
agreement with the early induction of DNA replication genes in the mutant.    
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Discussion  
 
The present study describes the impact of the loss of cell wall assembly on the transcriptional 
program of C. albicans cells undergoing hyphal growth. To our knowledge this is the first 
report in which no inhibitor of glucan formation was used and where the impact on hyphal 
growth instead yeast growth was examined. Moreover, we performed a time-course analysis 
and obtained information both the short-term (1 h), medium-term (3h) and long-term (5h) 
exposure to hyphal wall stress. Cells lacking the glucan transferase/elongase ctivity Phr1p, 
that is fundamental for assembly and remodeling of (1,3)-glucan, were the object of our 
study. Genes that are differentially modulated compared to the wild type provided a key to 
understand the consequences of the weakening of the cell wall on the abnormal 
morphogenetic effects, on the maintenance of cell integrity and contributed to explain some 
phenotypic traits typical of the mutant such as the defect of adhesion besides providing 
evidence of new unknown functions.   
First, the results of our microarrays and genetic analyses indicated that cells deficient in 
(1,3)-glucan remodeling under hyphal growth inducing conditions initiate the hyphal 
transcriptional program. The indication that phr1 cells initiate the hyphal developmental 
program is provided not only by the ability to form germ tubes but also by the presence of 
typical hyphal-induced genes ECE1, ALS10, ALS3, RBT1 (Dataset 1). The block in hyphal 
elongation that occurs o longer time causes a reduction of the expression of ECE1, as 
expected, although this reduction did not overcome the stringent parameters that were set in 
the microarray analysis and ECE1 is not present among the modulated genes.  
Another hint regards the PHR family. None of the PHR genes (PHR2, PHR3, PGA4 and 
PGA5) was identified in our analysis indicating that no transcriptionally-mediated cross 
compensatory mechanism exists between these paralogs and PHR1. The recent finding that 
recombinant Pga4p is inactive also reinforces the unique role of PHR1 at neutral-alkaline pH.  
adaptive response is triggered to survive. 
 
A core set of 10 mannoproteins responds during time to the loss of (1,3)-glucan assembly 
 
Among the 10 genes encoding structural cell wall proteins, seven were found only in C. 
albicans or Candida spp. (PGA23, RBR1, PGA13, PGA54, RHD3/PGA29, orf19.750 and 
orf19.675) five of them are predicted to be modified by GPI (PGA23, PGA13, RBR, PGA54 
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and RHD3/PGA29) and were also partially characterized (Lotz et al., 2004, de Boer et al., 
2010, Gelis et al., 2012). We included one uncharacterized ORF, orf19.750, and one 
predicted ORF, orf19.675 that may be interesting for future studies. The first encodes a new 
mannoprotein since it has features in common with surface mannoproteins: the presence of a 
signal peptide, abundance of alanine, serine and threonine residues, a hydrophobicity plot 
similar to that of Ece1p, presence of internal repeats. Furthermore, it was also shown to be a 
substrate in vitro of the Kex2 protease (Bader et al., 2008). Orf19.675 also encodes a putative 
extracellular protein. 
Other two genes, PGA6 and ECM331, have homologs in S. cerevisiae as do the remaining six 
genes encoding non-covalently linked cell wall proteins RBT4, TOS1 and ECM331 whose 
expression is sensitive to cell wall stress. PGA6 is the ortholog of CCW12, a S. cerevisiae 
gene encoding a covalently linked cell wall mannoprotein required for cell wall integrity, and 
similarly Pga6p could be important for cell wall strength of C. albicans (Ragni et al., 2011b, 
Ragni et al., 2007).  
As many mannoproteins have a structural role, this wide response could be related to the 
reinforcement of the extracellular matrix. 
  
PGA13, ALS2 and ALS4 modulation and the defects in adhesion of phr1 mutant 
 
PGA13 was reported to influence surface properties such as hydrophobicity and its deletion 
affects cell wall organization, increases adhesion to plastic and induces ALS gene expression 
(Gelis et al., 2012). We postulate that, conversely, PGA13 transcript increase in the mutant 
may result in reduced adhesion and this could contribute, together with the down-regulation 
of ALS2 and ALS4, to the severe defect in adhesion to plastic and cell monolayers we 
previously described for phr1 cells (Calderon et al., 2010). Together with the inability to 
elongate, the adhesion defect contributes to the avirulence of the mutant in animal models of 
systemic infection and experimental keratomycosis (De Bernardis et al., 1998, Yuan et al.).  
 
CRH11 transglycosidase: the only member of the UTR2/CSF4 to respond to stress   
 
Among genes encoding cell wall enzymes, CRH11 was strongly induced. CRH11 is the only 
member of a family of genes that includes UTR2/CSF4 and CRH12, to respond to cell wall 
stress at the transcriptional level (Pardini et al., 2006). Moreover, in vegetatively growing C. 
albicans cells treated with caspofungin, CRH11 is up-regulated (Liu et al., 2005). Thus, up-
105
  14
regulation of CRH11 in the phr1 mutant during hyphal development is likely a response to 
the hyphal wall defects associated with the loss of PHR1. Interestingly, the homolog ScCRH1 
is also up-regulated in response to cell wall stress both in cell wall mutants, including a gas1 
mutant, and in cells treated with Congo red, or zymolyase (Lagorce et al., 2003, Garcia et al., 
2004, Cabib, 2009). Biochemical and genetic studies have demonstrated that Crh1p of S. 
cerevisiae functions in vitro and in vivo in the cross-linking of chitin chains to (1,3)-and 
(1,6)-glucan which in turn can be linked to GPI-CWPs yielding a more resistant wall 
(Mazan et al., Cabib et al., 2007, Cabib et al., 2008, Cabib, 2009). It is notable that in gas1 
cells an increase in the transglycosylase activity mediated by these proteins has been reported 
(Cabib et al., 2008). Assuming a functionally analogous role for C. albicans Crh11p, its 
induction in phr1 mutant, in conjunction with the observed increase in chitin would enhance 
the establishment of new cross-linkages and guarantee the robustness of the cell wall, 
protecting phr1 cells from lysis (see model in Fig. 7).  
 
Caspofungin (CS) induces cell wall stress by inhibiting -1,3-glucan synthesis and the 
response to this cellular insult might be expected to partially overlap the response to loss of 
Phr1p.  Bruno et al. (2006) defined a core set of 34 CS-responsive genes by combining their 
results and those of Liu et al. (Liu et al., 2005, Bruno et al., 2006). Of the PHR1-responsive 
genes, 9 were in common with the core CS-responsive genes. Eight of these were up-
regulated under both conditions.  These included CRH11, PGA13, ECM331, DDR48, ALS1, 
orf19.3615, orf19.909, and orf19.2846. The CS-responsive genes were defined after 1 h 
treatment with CS and the last six of these common genes were induced at 1 h in the phr1 
mutant, but their expression declined by 3 h.  In contrast to this transitory response, CRH11, 
PGA13, DDR48 showed a sustained expression in the phr1 mutant (Table 3 and S1), 
suggesting these genes may be more critical to the cell’s attempt to counteract cell wall 
damage. In addition, PGA23 and RTA4 (a putative fatty acid transporter), two additional CS-
induced genes described by Bruno et al. (2006), are persistently up-regulated also in the phr1 
mutant. Only one down-regulated gene, orf19.5267, was in common at 1 h in the phr1 
mutant and CS-treated cells. Notably, the expression of CRH11, PGA13, PGA23, ECM331 is 
governed by CAS5, encoding a zinc-finger transcription factor that plays a major role in cell 
wall damage response in vegetative growth (Bruno et al., 2006). Interestingly, CAS5 
transcript level increases in phr1 mutant after hyphal growth induction suggesting that this 
transcription factor is important also for hyphal wall stress.  
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In addition to the altered expression of mannoproteins and glucanases, the phr1 mutant 
responded with an induction of genes encoding chitin synthases and an increase in chitin 
content. Of particular note is the induction of the genes encoding Class I chitin synthases, 
CHS8 and CHS2. Similarly, CHS2 and CHS8 are up-regulated in CS-treated vegetatively 
growing C. albicans cells and these synthases constitute the major activities measured in vitro 
although the extra chitin was largely dependent on Chs3p (Walker et al., 2008). Our analysis 
of phr1 chs mutants demonstrated that CHS2 and CHS8 are not required for the maintenance 
of phr1 cell integrity during hyphal growth.  On the contrary, CHS3 is essential for the 
survival of phr1 cells. The absence of Chs3p in the phr1 mutant induces a progressive 
increase of chitin resulting from the recruitment of Chs2 and Chs8 that restore the chitin level 
of the phr1 mutant by 5 h from the induction of hyphal growth (see Results). However, chitin 
increase per se does not appear enough to remedy the cell wall stress because phr1 chs3 cells 
start to lyse (Fig. 3D).  [the structure of this chitin must differ such that it is incapable of 
incorporation into a stable structure and cells die on a longer temporal scale. ] An increase in 
chitin content is regarded as a typical response to cell wall stress (Fonzi, 1999, Popolo & Vai, 
1998, Popolo et al., 2001, Ram et al., 1998).  
These results can be reconciled by taking into account that different isoforms produce 
different fibrils of chitin that may be not equally effective in reinforcing the lateral cell wall. 
It has been shown that in C. albicans cells Chs8p is responsible for the synthesis of long 
chitin microfibrils at the septum whereas Chs3p synthesizes short chitin rodlets at both the 
septum and the rest of cell surface (Lenardon et al., 2007, Walker et al., 2013). Assuming 
that also in hyphae chitin fibrils produced by CHS8 and CHS2, have a different structure than 
those produced by Chs3p, they may probably be able to compensate better the damage caused 
by lack of Phr1p at the level of the septum than that in lateral cell wall. This is supported by 
the fact that phr1 chs3 cells usually lysed at the apex (data not shown). 
The recruitment of other CHS isoforms by hyphal wall stress represents a difference between 
C.albicans and the yeast S. cerevisiae where absence of Chs3p does not lead to deposition of 
chitin by other isoforms, namely the Class I chitin synthase Chs1, despite CHS1 is always up-
regulated by cell wall stress (Lagorce et al., 2003, Valdivieso et al., 2000).  
Regarding Chs3p, many reports suggest that Chs3p is regulated at a post-transcriptional level 
such as recruitment to the plasma membrane from the intracellular stores (chitosomes or ER) 
and regulation by phosphorylation of its localization. (Lenardon et al., 2007) (Lenardon et al., 
2010a) (Chuang & Schekman, 1996, Bulik et al., 2003). Interestingly, the level of the CHS7 
transcript in phr1 cells is higher than in the wild type suggesting that Chs3p export from ER 
is increased in the phr1 mutant Other biochemical mechanisms may contribute to increased 
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chitin synthase activity: the availability of the substrate (UDP-GlcNac), which is regarded as 
the limiting factor for chitin synthase activity, allosteric regulation by glucosamine, 
interaction with activators or protein modifications (Bulik et al., 2003). Gfa1p was proposed 
to be the major control point in the chitin biosynthetic pathway (Lagorce et al., 2002).  Gfa1p 
could play a critical role in regulating Chs3p activity also in the phr1 mutant. In C.albicans 
Gfa1p is a minor component of cytosolic proteins (0.0025%) (Milewski et al., 1999). 
However, despite the transcriptional increase of GFA1 in the mutant, we did not find any 
correlation between the absolute in vitro activity of Gfa1p and the chitin levels, suggesting 
that the activity of this enzyme is not limiting in C. albicans (data not shown). 
Overall, the results of our studies show for the first time the primary role of Chs3p in the 
response to wall stress in Candida albicans hyphae that differs in structure and composition 
from the yeast form cell wall on which most studies have concentrated. Our study also 
supports the hypothesis of a general mechanism of cellular response to wall stress. In fungi, a 
stress response is activated to counteract a weakening of the cell wall as shown in yeast 
constitutive cell wall mutants, or in cells under cell wall perturbing conditions such as 
treatment with echinocandins, Calcofluor, Congo Red, or high temperature (Liu et al., 2005, 
Heilmann et al., 2013, Popolo et al., 2001, Meyer et al., 2007).  
 
Other functions affect cell cycle regulation 
 
Finally, we demonstrated that the block in morphogenesis brings about an accelerated entry 
into S-phase and G2. In C. albicans, cells enter S-phase when germ tubes reach a critical 
length or size. Stabilization of the G1 cyclin and delayed accumulation of the mitotic cyclins 
Clb2 and Clb4 occurring during germ tube formation suggests an extended G1 phase with 
respect to yeast cells (Bensen et al., 2005, Finley & Berman, 2005, Barton & Gull, 1988). 
The mechanism regulating this seems to be altered or negated in the presence of phr1 
defects that block the hyphal morphogenic program. Moreover, in the mutant, genes involved 
in rRNA processing, maturation and transport are repressed at 1 h. We propose that 
premature entry into S-phase may bring about a temporary block in rDNA transcription and 
ribosome biogenesis. This response could be a consequence of the morphogenetic arrest as an 
early repression of ribosome biogenesis genes was also detected in the block of hyphae 
formation by farnesol (Enjalbert & Whiteway, 2005).  
Interestingly, the cyclin genes PCL1, PCL2 and CCN1, a homolog of CLB3 in S. cerevisiae, 
normally repressed in cells induced to make hyphae, are up-regulated both in phr1 and in 
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farnesol-arrested hyphae (Table S1 and (Enjalbert & Whiteway, 2005). Also, the cyclin-
dependent kinase CDC28 is up-regulated at all three time points in the phr1 mutant. Future 
studies will address the relations between the block of morphogenesis and cell cycle 
regulation under hyphal growth conditions.   
This work highlights the existence of synthetic lethality between PHR1 and CHS3, two 
fungal-specific genes. As the incidence of invasive fungal infections has been increasing, the 
current armamentarium of drugs is still limited both for therapy and for prophylaxis. The 
(1,3)-glucanosyltransferases are essential in fungi either for viability or virulence. In C. 
albicans Phr proteins could be a promising target for new cell wall specific drugs taking also 
into account that the three dimensional-structure of the homologous protein ScGas2p was 
determined and a fluorescent enzyme assay for GH72 activity is available (Hurtado-Guerrero 
et al., 2008, Mazan et al., 2011). In C. albicans Chs3p is essential for survival of the phr1 
mutant suggesting that a combination therapy might be designed to hit the primary target 
together with the compensatory pathway.  
 
The long-term adaptive response  
 
These genes are included in the model of Fig. 7.  
(TO BE COMPLETED) 
 
Experimental procedures  
 
Strains and growth conditions 
 
The strains used in this work are listed in Table 4. To induce hyphal development, stationary 
phase cells from an overnight culture in YPD (1% yeast extract, 2% peptone, 2% glucose)-
150 mM HEPES pH 6.0 incubated at 30 °C were pelleted. The pre-culture medium was 
buffered at pH 6 to limit the residual Phr2p since at this pH value, the expression of PHR2 is 
extremely low whereas the phenotype of phr1 cells is not yet manifested (Muhlschlegel & 
Fonzi, 1997).  Cells were suspended at an initial OD600 of about 0.25 in pre-warmed M199-
150 mM HEPES buffered at pH 7.5 and supplemented with 1.9% glucose, and incubated 
under agitation at 37°C. For Ura- strains, 25 g ml-1 uridine was added to the growth medium 
of the pre-culture whereas 100g ml-1 uridine was added to the M199 medium. The formation 
of hyphae was monitored every 30 min.  
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For the colony filamentation assay, M199-150 mM HEPES, supplemented with 2% agar, was 
adjusted to the desired pH and supplemented with 100 g ml-1 uridine. Stationary phase cells 
from an overnight culture in YPD-pH 6 at 30° C were diluted to 103 cells ml-1 by two serial 
1:100 dilutions in buffered liquid medium. From the last dilution, 100 and 150 l were spread 
on top of solid M199.  Plates were incubated at 37°C for 24 h. Plates were observed using a 
Leica MZ6 stereomicroscope. 
 
Mutant strain construction 
 
Strains C155 (chs2/chs2), NGY128 (chs8/chs8), Myco3 (chs3/chs3), and NGY138 
(chs2/chs2 chs8/chs8) were kindly provided by Prof. Neil Gow (Aberdeen Fungal Group, 
University of Aberdeen, UK) and transformed with HindIII and PvuII digested DNA of 
plasmid pSMS23 to delete one allele of PHR1 (Saporito-Irwin et al., 1995a, Fonzi & Irwin, 
1993, Saporito-Irwin et al., 1995b).  Cell transformation was performed essentially as 
described in (Walther & Wendland, 2003).  Ura+ transformants were selected on SD agar.  
Linkage of the transforming DNA with the PHR1 locus was verified by PCR amplification 
using primers PHR1-N7 and hisG3'P for the 5’-end and primers hisG-forward and 
PHR1rev(+1840) for the 3’-end. The primers used in this work are listed in Table S3.   
Deletion of the second allele was achieved by transformation with BtgZI and PvuII digested 
DNA of plasmid pLit-PHR1-1NAT DNA.  Plasmid pLit-PHR1-1NAT was constructed by 
cloning a 2.5 kb EcoRI-HindIII fragment from a genomic clone of PHR1 (Yesland & Fonzi, 
2000) into the like sites of pLITMUS38 (New England Biolabs).  The resulting plasmid 
pLit38PHR1-1 was digested with SacII and KpnI, which removed nucleotides +167 to +853 
of the PHR1 coding region, and ligated with a 1265 bp SacII-KpnI fragment containing the 
nourseothricin resistance gene, NAT1, isolated from plasmid pJK795 (Shen et al., 2005).  
Transformed cells were selected on SD medium containing 450 ugml-1 nourseothricin. 
Linkage to the PHR1 locus was tested with PCR primers PHR1-N7 and NAT1_5’link_rev for 
the 5’ end and NAT1-3'link_fwd and PHR1rev(+1840) for 3’-linkage. Absence of a wild type 
allele was verified with primers PHR1-N7 and PHR1-rev(+1840). Two independent phr1 null 
mutants were constructed in each chs mutant background. 
 
DNA microarray analysis    
                                                                                                                                                                               
At 0, 1, 3 and 5 hours after the shift of stationary phase blastospores to the hyphal growth 
inducing medium, cells (200 OD600) were collected by filtration on a Millipore 0.45 m filter 
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disk. The filter was removed, transferred to a tube and the cells suspended in 1 ml of ice-cold 
H2O. The washed cells were quickly frozen in liquid nitrogen and stored at -80°C until use.  
Cell samples were collected from two independent cultures. 
Total RNA was extracted using the RNeasy Midi Kit (QIAGEN).  Cell pellets were thawed 
and suspended in 600 l of RTL buffer. After addition of an equal volume of cold, sterile 
glass beads, cells were broken by 5 cycles of 1 min agitation in a BeadBeater (Biospec) at 
4°C and 1 min on ice. Total RNA was isolated from two independent experiments.  RNA 
concentration and quality were assessed by spectrophotometric measurements and denaturing 
agarose gel electrophoresis. RNA samples were processed for further analysis at the 
Microarray Facility, Washington University at St. Louis, Mo U.S.A. (currently GTAC, 
Genome Technology Access Center). 
 
DNA microarray hybridization 
 
RNA integrity and quality were validated on an Agilent 2100 Bioanalyzer and reverse 
transcribed into cDNA in the presence of Cy3/Cy5 labeled dNTPs using the 3DNA array 350 
detection system (Genisphere, Hatfield, PA)  For each strain, data from 1, 3 and 5 h were 
compared to time zero. To exclude any influence due to the type of fluorophore used, the 
labeling of the samples was also inverted (dye-swap). In total 24 hybridizations were 
performed (12 for each strain).  
DNA oligonucleotide microarrays represented 6,346 of the 6,354 predicted ORFs in the 
annotated C. albicans genome assembly 19. Probes consisted of unique ORF-specific 70-mer 
oligonucleotides, and oligonucleotide sequences were selected using an ArrayOligoSelector 
software and were obtained from Illumina (San Diego, CA). Each probe was spotted three 
times per slide, thus 19,308 spots were present on each array plus 10 specific control genes 
from Arabidopsis thaliana.  A two-step protocol was used for hybridization (3DNA array 350 
detection system). First, oligonucleotide arrays were hybridized to the cDNA probes in 2× 
formamide-based hybridization buffer overnight at 43°C and washed in 2× SSC (1× SSC is 
0.15 M NaCl plus 0.015 M sodium citrate)-0.2% sodium dodecyl sulphate (SDS) according 
to the manufacturer's protocol. Fluorescent Cy3- and Cy5-capture reagents were combined in 
hybridization buffer and added to each array, which were incubated and washed again as 
described above. Slides were scanned immediately after hybridization on a ScanArray 
express HT scanner (Perkin-Elmer) to detect Cy3 and Cy5 fluorescence. The laser power was 
kept constant, and photomultiplier tube (PMT) values were set for optimal intensity with 
minimal background. An additional scan was done for each slide with the PMT such that 
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<1% of the elements are saturated in order to characterize spots which were saturated at the 
higher PMT setting. Gridding and analysis of images was performed with ScanArray 
software express V2.0 (Perkin-Elmer). Processing of the raw data and normalization were 
carried out at the Microarray Facility, Washington University at St. Louis, Mo using the 
LOWESS normalization. The Median of Ratios was used for further analyses.   
 
Statistical analysis 
 
For each strain, each time point (1, 3, 5 h) was compared with the respective time zero 
sample, once with each dye orientation (6 hybridizations per strain). For two biological 
replicas, a total of 24 hybridizations were performed. Microarray data were deposited at GEO 
database (GSE51064). The four expression ratios per comparison for each gene (2 biological 
replicates and 2 dye-swap) were averaged (arithmetic mean) and one-sample Limma analysis 
and False Discovery Rate (FDR, using a p-value ≤ 0.05) for multiple testing correction were 
applied (Smyth, 2005, Hochberg, 1995). This statistical analysis was performed with the 
web-software Babelomics (Medina et al., 2010). Principal Component analysis was 
performed using the software Partek. Hierarchical cluster analysis was performed using 
Pearson correlation (average linkage) and the Multiple Viewer Experiment (MeV) software 
package developed by TIGR (Saeed et al., 2003). The cutoff to consider transcriptional 
induction or repression with respect to time zero was a ratio ≥ 2 and ≤0.5, respectively. For 
the comparison of the transcriptional profile mutant versus the wild type strain, we calculated 
a Relation Factor (RF, ratio of the expression ratios) that measures the dependence of the 
transcript level on the mutation. All genes with available data in at least 3 replicates and 
FDR≤ 0.05 were considered in this analysis (Dataset S2 is available upon request).  In order 
to select genes whose expression levels at different time were significantly altered in the phr1 
mutant we set a threshold of RF ≥ 2 to select transcripts at least twice more abundant in the 
phr1 mutant than in the control (Class 1), and RF ≤ 0.5 for transcript at least twice less 
abundant in the phr1 mutant compared to the control (Class 2).  
 
Verification of differential gene expression using quantitative real-time RT-PCR 
 
Gene-specific primers were designed using Primer3 software 
(http://frodo.wi.mit.edu/primer3/) and further analyzed using the tool from Integrated DNA 
technologies (http://eu.idtdna.com/analyzer/applications/oligoanalyzer/). Primer sequences 
are shown in Table 5. Total RNA was extracted at time zero, 3 and 5 hours after induction of 
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hyphal growth. On-column DNase digestion was performed according to the manufacturer’s 
instructions (QIAGEN). First strand cDNAs were synthesized from 1.6 μg of total RNA in 20 
μl final volume, using the Reverse Transcription System A3500 (Promega). As a test for 
residual genomic DNA contamination, reactions were performed also in the absence of 
reverse transcriptase. Real time quantitative PCR reactions were carried out in a Bio-Rad IQ5 
instrument. Each PCR reaction contained 5 l of diluted cDNA, 7.5 l of 
SsoFast™EvaGreen®Supermix with low ROX  (Bio-Rad), 1.5 l of oligos (final 
concentration each 0.5 M) and 1 l nuclease-free H2O. Triplicates of all reactions were 
analysed. For quantification, the abundance of each transcript during induction conditions 
was determined relative to the standard TDH3 RNA, as indicated in other reports (Fanning et 
al., 2012, Blankenship et al., 2010), for input cDNA normalization. Final data on relative 
gene expression between the two conditions (sample from time 3 or 5 h with respect to time 
zero for each strain) were calculated according to the 2-CT method (Livak & Schmittgen, 
2001).  
 
Microscopy  
 
For Calcofluor White (CW) staining, 0.5 ml of culture (about 1-2 OD600) were collected and 
the cells washed with 0.5 ml of dH2O. The pellet was suspended in 0.5 ml of CW (0.1 mgml-
1 dH2O). After 5 min, the sample was washed twice with 1 ml of dH2O and then examined by 
fluorescence microscopy. For DAPI staining, cells were collected, washed with dH2O, fixed 
in 70% ethanol and stored at 4°C until examination. The sample was washed with dH2O and 
suspended in DAPI solution (0.125 g ml-1) and incubated for 10 min in the dark. Then, the 
sample was washed twice with dH2O and examined by fluorescence microscopy. 
Fungal viability was assessed by methylene blue staining which identifies metabolically 
inactive or membrane compromised cells. Viable cells appear colorless while dead cells are 
blue. Cells were collected by centrifugation and suspended in the same volume of methylene 
blue solution (methylene blue 0.2 g/l, KH2PO4 27.2 g/l, K2HPO4 0.071 g/l, pH 4.6 stored at 
4°C) and incubated for 20 min at RT prior to examination by bright-field microscopy.  
 
Broth microdilution and XTT-reduction assay 
 
To test sensitivity to the Chs1p inhibitor RO-09-3143, a microdilution assay at an inoculum 
size of 5 x 105 was performed according to the NCCLC guidelines M27-A2 and as previously 
described (Popolo & Vai, 1998). Briefly, cells were grown to stationary phase in YPD-
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HEPES buffered at pH 6 at 25 °C. In a well of a 96-well micro titer plate, 100 l of a 
suspension containing106 cells ml-1 in M199-HEPES pH 7.5, supplemented with 100 g ml-1 
of uridine if required, was added to an equal volume of medium containing RO-09-3143 
(kindly donated by Roche) dissolved in DMSO. Two-fold serial dilutions of the inhibitor 
were made to achieve a range of concentrations from 0.012 M to 25 M. All determinations 
were made in duplicate. Control wells contained DMSO with no drug. The plates were 
incubated at 37 °C and inspected at 24 and 48 h. The effect of the treatment was evaluated 
both visually and also by reading the turbidity with a Tecan Infinite F200 PRO microtiter 
plate reader set to 5-reads of different areas per well. After centrifugation of the plate and 
removal of the medium a reduction assay of the tetrazolium salt 2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) was performed 
according to a previously published protocol (Ramage et al., 2001) except for the ZTT 
concentration that was reduced to 0.250 g/ml. 
 
Enzymatic assay of the chitin content 
 
Pellets corresponding to about 150-200 OD600 of cells were collected by centrifugation, 
suspended in 6 ml of H2O, and divided into four equal aliquots, two of which were used to 
determine the dry weight. The other two were centrifuged and the pellets stored at −20°C for 
later chitin determinations.Total cellular chitin was measured by an enzymatic method, as 
described by Bulawa et al. (Bulawa, 1992). Washed cells (about 100 mg wet weight) were 
suspended in 1 ml 6% KOH and incubated at 80°C for 90 min. After cooling, 100 µl of 
glacial acetic acid were added and samples were centrifuged for 15 min at 13,000 x g. The 
pellet, containing the alkali-insoluble material, was washed twice with 50 mM phosphate 
buffer, pH 6.3 and suspended in 1 ml of the same buffer containing 1.7 mg of Serratia 
marcescens chitinase (Sigma). After 2 h at 37° C, 400 l were transferred to a new tube and 
25 l of Helix pomatia β-glucuronidase (Roche) were added. Samples were incubated for 1 h 
at 37° C. After 1 min-incubation at 100°C, samples were centrifuged and the supernatants 
were saved. The amount of GlcNAc was determined with the Morgan-Elson reaction. To 100 
µl of sample, 150 µl of H2O were added. After 1 min-incubation at 100°C and addition of 
250 µl of 0.27 M potassium tetraborate, pH 9, samples were boiled again for 8 min. After 
cooling, 3 ml of Ehrlich-solution (stock solution 10 times concentrated was prepared by 
mixing 10 g of p-dimethylaminobenzaldehyde (Sigma) in 12.5 ml of 10 N HCl and 87.5 ml 
of glacial acetic acid) was added and the samples were incubated for 40 min at 37°C.  
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The absorbance at 585 nm was measured and compared with a standard curve ranging from   
to 1 mg of N-acetylglucosamine. The micrograms of N-acetylglucosamine were normalized 
to the milligrams of dry weight of cells. 
 
 
Flow cytometry analysis of DNA 
 
CAI10 and CAS10 cells were grown to stationary phase at 30° C (1.5 days) in YPD pH 6 and 
then shifted to M199-pH 7.5 at 37°C at an initial density of 0.25 OD600. At different time 
intervals after induction of hyphal growth, 1 OD600 of cells were mildly sonicated, collected 
by centrifugation, fixed in ice-cold 70% ethanol and stored at 4°C. The samples were 
suspended in 0.5 ml of RNase A (1 mg ml-1 in 50 mM Tris-HCl pH 7.5) and incubated at 
37°C overnight. The next day, the samples were centrifuged and suspended in 0.5 ml of 
Proteinase K (2 mg ml-1 in 50 mM Tris-HCl pH 7.5). After 2 h at 42°C, the samples were 
centrifuged, suspended in FACS buffer (200 mM Tris-HCl pH 7.5, 200 mM NaCl, 78 mM 
MgCl2) and stored at 4°C. At the time of the analysis, 100 l of sample was added to 1 ml of 
Sytox Green 1x, a nucleic acid stain (diluted 1:5000 in 50 mM Tris-HCl pH 7.5; Invitrogen), 
subjected to a brief sonication and analyzed with a FACScan flow cytofluorimeter (BD 
Biosciences, San Jose, Ca). We analyzed 104 cells for each sample. 
 
 
Accession numbers 
 
Information for the C. albicans genes can be found at the Candida genome Database (CGD) 
Web site (http://www.candidagenome.org). Microarray data seta can be found at the Gene 
Expression Omnibus Web Site (http://www.ncbi.nlm.nih.gov/geo/) under the accession 
number GSE51064. 
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Legends 
 
Figure 1. Morphological responses to the lack of (1,3)-glucan remodeling during 
induction of hyphal growth in C. albicans.  A. Specificity of the anti-Phr1p antibody in 
immunoblot analysis of total extract. B. Detection of Phr1p during hyphal growth by 
immunoblot analysis after induction of hyphal growth. C. Morphology of the indicated strains 
at different time after induction of hyphal growth by shifting blastospores to M199-150 mM 
HEPES buffered at pH 7.5 at 37°C. 
 
Figure 2. Global comparison of the transcriptional profile of wild type and phr1 cells 
during induction of hyphal growth. (A) Principal component analysis. Each of the four 
blocks for each strain represents one of the sets of hybridization results. The median of ratios 
was used. (▲), CAI 10; (■) CAS10. (B)  Hierarchical clustering analysis of gene expression. 
The top part of the complete analysis is shown. C. qRT-PCR of some selected genes. The 
mutant was refereed to wild type at time zero set equal to 1.  
 
Figure 3. Effects of deletion of CHS3, CHS2, CHS8 or CHS2 and CHS8 on the PHR1 
null mutant. (A) Strains CAI4 (wild type),  Myco3 (chs3), C155 (chs2), NGY128 (chs8) and 
NGY138 (chs2 chs8) and their respective phr1 derivatives CAS8 (phr1), FP3 (phr1 chs3), 
FP155 (phr1 chs2), FP128 (phr1 chs8) and FP138 (phr1 chs2 chs8) were induced to switch to 
hyphal growth in M199-150 mM HEPES buffered at pH 7.5 at 37°C and 5 hours later 
aliquots of culture were processed for calcofluor white (CW) staining. Pictures were taken 
using the same exposure time (2.5 s). For chs3 and phr1 chs3 the corresponding bright field 
image is also shown. (B) Same as in A but cells were collected 24 hours after induction of 
hyphal growth. Exposure time of phr1 chs3 cells was reduced to 1 s as indicated in the figure 
and the corresponding bright field image shows cell ghosts into which CW penetrated. 
Magnification, x 1,300. (C) Chitin content at 5 h. Mean values ± standard deviations (SD) are 
shown, n = 3. (D) Determination of the percentage of dead cells. Data are mean values of two 
independent experiments that gave very similar results. 
 
Figrue 4. Evaluation of the Chs1p inhibition on the viability of phr1 chs2 chs8 mutant. 
116
  25
The indicated mutants and the wild type were analyzed for sensitivity to the Chs1p inhibition 
by microdilution assay. A. profiles of the growth measured by turbidity. All data were 
referred to wild type set 100%. B. Killing effect of the inhibitor. The viability of the strains 
was evaluated by the XTT assay as described in Materials and methods.  
 
Figure 5. Synthetic lethal phenotype of CHS3 and PHR1 on solid M199-pH 7.5 and 
Spider medium pH 8.  Blastospores were plated on solid M199-150 mM HEPES medium 
buffered at pH 7.5, with the inclusion of sorbitol (right panel) or at pH 4.5 and images were 
taken after 24 h of incubation at 37 °C. Blastospores were also plated on Spider-150 mM 
HEPES medium buffered at pH 7.5 or pH 8 and images were taken afte 7 days at 37 °C.     
 
Figure 6. Cytofluorimetric analysis of DNA distribution. Cells were analyzed at the 
indicated time after induction of hyphal growth at 37°C in M199 buffered at pH 7.5. 1C and 
2C indicate the DNA content.   
 
Figure 7 Model of the long-term adaptive response to the wall stress in phr1 on 
induction of hyphal growth. 
 
In this model the core response of adaptation at 5 h from the induction of hyphal growth is 
reported. The suffix * indicates the genes that are repressed in the wild type and induced in 
the mutant (green/red) whereas ** indicates the genes that are not modulated in the wild type 
and induced in the mutant (white/red). Only up-regulated genes were examined. Genes 
encoding predicted GPI-anchored mannoproteins are underlined.  
The figure highlights genes involved in the signaling pathways, in the reshape of the surface 
(Cell wall/surface, Filamentous growth, protein folding), in the control of the cell cycle and 
morphogenesis (cell cycle) as those with the most striking difference between the mutant and 
the wild type at long term.  
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Supporting Information 
 
Dataset S1. Transcriptional profile of wild type and phr1 cells during induction of 
hyphal growth. (available UPON REQUEST OF THE COMMISION) 
Figure S1.  Progress curves of Gfa1p reaction. Crude extracts that had been gel-filtered 
through a Sephadex G25 column to remove low molecular mass molecules, were incubated 
under the conditions described in Materials and Methods. The amount of glucosamine-6P 
formed (in nmoles) is referred to the protein content (in mg) of the sample. Values are mean 
± standard deviations of three different experiments.  
Table S1. Class 1: transcripts that are more abundant in the phr1 mutant than in the 
wild type.  
Table S2. Class 2: transcripts that are less abundant in the phr1 mutant than in the 
wild type.  
Table S3. Comparison of data from microarray and qRT-PCR analyses. a and b Expression 
ratio of each gene at the indicated time compared to time zero in the same strain. c RF, Relation 
Factor, ratio of the expression ratios or fold-change MUT/WT. d and e Fold-change of the 
transcript level of each gene at the indicated time with respect to time zero. 
Table S4. Oligonucleotides used in this work 
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Table 1. Functional categories and number of 
genes in Class1 or Class 2 
Functional category 1h 3h 5h
Class  1 
Unknown function 38 11 32
Cell wall/surface 13 14 11
Metabolism and energy 11   6   4
Filamentous growth 10   3   8
DNA replication and repair 10 10   2
Chromatin and chromosomes 5 7 0
Transcription 5 3 4
Cell cycle control/morphogenesis 4 6 6
Transport 4 3 3
Signal transduction 3 2 4
Cell polarity/cytoskeleton 3 1 2
Oxido-reduction processes 6 2 2
Protein modification/folding 2 1 4
Adhesion 1 0 0
Stress response 1 2 2
RNA processing and biogenesis 1 0 0
Pathogenesis 0 0 1
Class 2 
RNA processing and biogenesis 21 2 6
Unknown function 11 16 31
Transport 5 5 9
Metabolism and energy 3 6 16
Transcription 3 3 8
Protein modification/folding 2 4 3
Cell wall/surface 1 2 2
Oxido-reduction processes 1 1 6
Adhesion 1 0 3
Signal transduction 0 0 2
Stress response 0 2 2
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 Table 2. Selected genes modulated in the PHR1 null mutant ordered into different biological processes. 
Functional  
category 
Systematic 
name 
Locus 
name 
S.cerevisiae 
best hit 
1h
RF
3h
RF
5h
RF
Description 
CLASS 1     
Cell wall/surface orf19.3740 PGA23 - 21.5 22.2 65.6 GPI protein  
 orf19.750     6.4 11.1 36.0 In vitro substrate of Kex2p 
  orf19.535 RBR1 -    2.4 6.7 GPI protein  
 orf19.5384 CHS8 CHS1   2.2   2.0 4.3 Chitin synthase  
 orf19.6420 PGA13 -   4.1 3.7 GPI protein 
 orf19.2706 CRH11 CRH1   4.7   4.2 3.3 GPI transglycosylase  
 orf19.4225 ECM331 PST1   2.3   5.2 5.3 GPI protein 
 orf19.4765 PGA6 CCW12   2.8   6.8 3.4 GPI protein 
 orf19.2685 PGA54 -   2.0   3.5 GPI protein 
 orf19.1690 TOS1 TOS1   2.5 Putative (1,3)-glucanase 
 orf19.6594 PLB3 PLB1   2.3 GPI anchored phospholipase B 
 orf19.7298 CHS2 CHS1   2.4   2.0 Chitin synthase 
 orf19.2952    EXG2 EXG2   2.2  GPI-anchored exo--1,3-glucosidase cell wall protein 
 orf19.2990 XOG1 EXG1   2.3  5.9 Exo-β(1,3)-glucanase 
 orf19.3893 SCW11 SCW11 2.8 Cell wall protein similar to glucanases 
 orf19.5305 RHD3     3.4  n.a. Yeast associated  GPI-protein 
 orf19.675    6 Cell wall protein 
 orf19.7214  YBR056W  2.4 Glucan 1,3--glucosidase 
  orf19.6202 RBT4 PRY3  2.2   10 8.9 PRY family protein 
Protein folding 
modification  orf19.1665 MNT1 KTR1 2.4 Golgi (1,2)-mannosyltransferase 
 orf19.6864       2.5 3.5 Protein ubiquitylation 
 orf19.2444 CHS7 CHS7 n.a. n.a. 2.4 Export Chs3p from ER 
 orf19.6029 ROT1 ROT1   2.8 2.3 ER chaperone- (1,6)-glucan synthesis 
 orf19.3682 CWH8  2 Dol-P-P) phosphatase 
Metabolism orf19.9186 GFA1 GFA1  2.8    2.1 2.3 Glucosamine-6P synthase 
 orf19.979 FAS1 FAS1  2.9    2.0 β-subunit of fatty acid synthase 
 orf19.7466 ACC1 ACC1  2.6    2.0 Acetyl-coenzyme-A carboxylase 
 orf19.5949 FAS2 FAS2  2.5     2.0  α-subunit of fatty acid synthase 
 orf19.6459 DPP3  DPP1  3.1  DGPP phosphatase; farnesol synthesis 
 orf19.837 GNA1 GNA1  2.1  Glucosamine-6P acetyltransferase 
 orf19.24 RTA2 RSB1  4.8    3.3 3.9 Flippase for sphingolipid release 
Stress response  orf19.4082 DDR48 DDR48  4.5 3.4 Immunogenic stress-associated protein 
 orf19.2125     2.1 3.1 2.4 CipC-like ant biotic response protein 
Signal transduction orf19.4866 CPP1 MSG5 5.2 MAPK phosphatase  
 orf19.3775 SSK2 SSK2 2.1 4.7 MAPKKK 
 orf19.3216   2.5 3.0 3.6 Rab GTPase activatorr 
 orf19.5797 PLC2  5.3 3.0 PI-PLC 
 Orf19.7504  RST3 2.6 Phosphatase type 2A complex 
DNA 
replication/repair orf19.4616 POL30 POL30 2.6 2.6 PCNA 
 orf19.5182 POL3 POL3 2.2 Catalytic subunit of DNA pol delta 
 orf19.3752 RAD51 RAD51 3.3 Homologous recombination and repair 
 orf19.3322 DUT1 DUT1 2.3 3.2 dTTP de novo biosynthesis 
 orf19.4945 MSH6 MSH6 3.1 Mismatch repair 
 orf19.2267 RFA2 RFA2 2.4 Putative DNA replication factor A 
 orf19.2093 RFA1 RFA1 2.2 2.1 Putative DNA replication factor A 
 orf19.7425   UNG1 2 Base-excision repair 
 orf19.2796   POL12 3.5 n.a. n.a. DNA replication initiation 
 orf19.5873 POL1 POL1 3.2 n.a. n.a. DNA polymerase α 
 orf19.3761 CDC54 MCM4 2.4 Pre-replication complex helicase subunit
 orf19.5779 RNR1 RNR1 2 3.4 Subunit of r bonucleotide reductase 
 orf19.926 EXO1 EXO1 3.2 Exodeoxyr bonuclease 
 orf19.4030  PRI1 2.7 Orthologs have DNA primase activity 
 orf19.5487 CDC46 MCM5 2.6 2.5 MCM helicase complex subunit 
 orf19.2611 MCM6 MCM6 2 2.3 MCM replication initiation complex subunit 
Chromatin orf19.1854 HHF22 HHF2 2.2 2.6 Putative histone H4 
 orf19.1052  HTB1 3.2 Putative histone H2B 
 orf19.1059 HHF1 HHF1 3.2 Putative histone H4 
 orf19.6924 HTA1 HTA1 2.1 2.9 Histone H2A 
 orf19.1051 HTA2 HTA1 2.4 Putative histone H2A 
 orf19.6925 HTB1 HTB1 2.2 Histone H2B 
 orf19.7232 IRR1 IRR1 2.3 Putative cohesin complex subunit 
 orf19.3715 ASF1 ASF1 2.2 Chromatin assembly complex 
 orf19.6568 SMC6 SMC6 2.0 SMC protein 
 orf19.4664 NAT4 NAT4 2.6 n.a. Putative histone acetyl transferase 
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RF is the ratio between the expression ratio of each gene in the phr1 mutant and in the control 
CLASS 1: RF ≥ 2 refer to transcripts that are at least 2 times more abundant in the mutant than in the wild type and that 
passed the statistical criteria (see Table S1 and Material and methods).  Among the genes of Table S1, only genes that 
were upregulated by two-fold in the mutant (expression ratio ≥ 2) are shown. 
 
CLASS 2: RF ≤ 0.5 indicate transcripts that are less abundant in the mutant than in the wild type (see Table S2). 
The lack of value indicates that RF is present but does not pass the cut-off. 
n.a.: value not available because the expression ratio is statistically not significant or technically incomplete (less than 
three replicates) in either one of the strains or both.  
   
 
 
 
CLASS 2 
          
Adhesion orf19.1097 ALS2 SAG1   0.2 GPI protein; Adhesin 
  orf19.4555 ALS4 SAG1  n.a. 0.4 GPI protein; Adhesin 
 orf19.5267   0.4 n.a. Putative adhesion-like protein 
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Table 3. Candida albicans strains used in this work 
 
 
Strain Parental Strain Genotype* Source or reference 
CAF2-1 SC5314 URA3/ura3::imm434 [Fonzi &Irwin, 1993] 
CAI4  CAF2-1 ura3 ::imm434/ura3:: imm434 [Fonzi &Irwin, 1993] 
CAF3-1 CAF2-1 ura3 ::imm434/ura3:: imm434 [Fonzi &Irwin, 1993] 
CAS8 CAF3-1 phr1∆::hisG/phr1∆ [Saporito-Irwin et al., 1995] 
CAI10 CAF3-1 URA3/ura3 ::imm434 [Fonzi &Irwin, 1993] 
CAS10 CAS8 phr1∆::hisG/phr1∆ URA3/ura3 ::imm434 [Saporito-Irwin et al., 1995] 
C155 CAI4 chs2∆::hisG/chs2∆::hisG  [Walker et al., 2008] 
FP155-14-21 C155 phr1∆::hisG-URA3-hisG/phr1∆::NAT1                                 chs2∆::hisG/chs2∆::hisG  This work 
FP155-19-21 C155 phr1∆::hisG-URA3-hisG/phr1∆::NAT1                                       chs2∆::hisG/chs2∆::hisG  This work 
Myco3 CAI4 chs3∆::hisG/chs3∆::hisG  [ Walker et al., 2008] 
FP3-19-211 Myco3 phr1∆::hisG-URA3-hisG/phr1∆::NAT1                                chs3∆:: hisG/chs3∆::hisG  This work 
FP3-118-25 Myco3 phr1∆::hisG-URA3-hisG/phr1∆::NAT1                                  chs3∆:: hisG/chs3∆::hisG  This work 
NGY128 CAI4 chs8∆::hisG/chs8∆::hisG  [Walker et al., 2008] 
FP128-19-21 NGY128 phr1∆::hisG-URA3-hisG/phr1∆::NAT1                                chs8∆::hisG/chs8∆::hisG  This work 
FP128-111-21 NGY128 phr1∆::hisG-URA3-hisG/phr1∆::NAT1                                chs8∆:: hisG/chs8∆::hisG This work 
NGY138 CAI4 chs2∆::hisG/chs2∆::hisG chs8∆:: hisG/chs8∆::hisG [Walker et al., 2008] 
FP138-16-22 NGY138 phr1∆::hisG-URA3-hisG/phr1∆::NAT1                                       chs2∆::hisG/chs2∆::hisGchs8∆::hisG/chs8∆::hisG This work 
FP138-114-21 NGY138 phr1∆::hisG-URA3-hisG/phr1∆::NAT1                                       chs2∆::hisG/chs2∆::hisGchs8∆::hisG/chs8∆::hisG This work 
*all strains apart from CAF2-1, CAI10 and CAS10 are homozygous for the ura3 ::imm434 mutation [Fonzi & Irwin, 1993] 
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Table S3. Comparison of data from microarray and qRT-PCR analyses. 
 a and b Expression ratio of each gene at the indicated time 
compared to time zero in the same strain. 
c RF, Relation Factor, ratio of the expression ratios or fold-change 
MUT/WT 
d and e Fold-change of the transcript level of each gene at the 
indicated time with respect to time zero. 
Gene Time DNA Microarray qRT-PCR 
3 hr WTa phr1b RFc WT fold-changed phr1 fold-changee RF 
CRH11  1.2 5.1 4.2 2.5 ± 0.3 7.2 ± 0.2 2.8 ± 0.1 
GFA1 2.3 4.8 2.1 1.4 ± 0.5 3.7 ± 0.8 2.8 ± 0.4 
CHS8  3.0 5.9 2.0 2.1 ± 0.3 7.2 ± 0.1 3.5 ± 0.2 
PGA23  0.2 4.2 22.2 0.2 ± 0.01 5.6 ± 0.5 29.2 ± 0.1
5 hr
CRH11  2.3 7.6 3.3 2.1 ± 0.2 6.6 ± 2.7 3.1 ± 0.4 
GFA1 3.3 7.6 2.3 0.6 ± 0.4 2.1 ± 0.5 3.3 ± 0.6 
CHS8  2.6 11.1 4.3 1.6 ± 0.2 4.5 ± 0.9 2.9 ± 0.2 
PGA23  0.2 10.2 65.6 0.1 ± 0.01 7.3 ± 0.4 93.1 ± 0.1
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Table S4. Oligonucleotides used in this work 
 
Primer Sequence 
Primers for strain construction  
PHR1-N7  5’-CCATGGCCTCCTTAGATCAAATCATTCC-3’ 
hisG3'P  5’-GCCAAGCGCTTTCAGTTTCTC-3’ 
hisG-forward  5’-CCTCATATCCGCACCTCCTC-3’ 
PHR1rev(+1840) 5’-CACCAATTGAGAAACTTAGGGAT-3’ 
NAT1_5’link_rev  5-GAGCCGTAATTTTTGCTTCG-3’ 
NAT1-3'link_fwd  5’-TGGTCGCTATACTGCTGTCG-3’ 
Primers for Q-RT-PCR  
CRH11-F 5'-CTACCGTTACCAGTTCTTCG-3' 
CRH11-R 5'-CAGTGGAGGCAGTACTTGAA-3' 
GFA1-F 5'-ATCTGCTGGGGAATCTACTG-3' 
GFA1-R 5'-GCAGAATCTGGTTGTTCG-3' 
CHS8-F 5'-GGTAGTGGTGGAATACATGC-3' 
CHS8-R 5'-ATCTCTTCACCAGTGTCCAG-3' 
TDH3-F 5'-GGTTTCGGTAGAATCGGTAG-3' 
TDH3-R 5'-CACCCTTGTATCTACCGTGA-3' 
PGA23-F 5'-GGAAGCTTAGTTGGTGGTCT-3' 
PGA23-R 5'-TCTAGATCCTGAACCACTGC-3' 
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